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ABSTRACT 
 
G protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that 
perform transmembrane signal transduction. Due to their pivotal role in a wide range of 
essential physiological functions GPCRs represent a high proportion of all drug targets. 
High resolution X-ray structures of GPCRs are however underrepresented in the Protein 
Data Bank. This is due to their instability in detergent, low expression levels and the 
presence of misfolded receptors in many heterologous expression systems. 
 
The objective of this project was to engineer the angiotensin II type 1 receptor (AT1R), a 
human GPCR, to make it suitable for structural studies. It was determined that detergent-
solubilised AT1R was thermostable with antagonist bound with an apparent Tm of ~45°C, 
which was sufficiently stable for purification without further thermostabilisation by rational 
mutagenesis. Two expression systems were then evaluated for large-scale production of 
AT1R, namely baculovirus-mediated expression in insect cells and mammalian expression in 
HEK293 cells. Radioligand binding assays showed that only the mammalian system 
produced sufficient quantities of active AT1R for structural studies. Expression in the 
mammalian system was further optimised to approximately 6 mg/L. An AT1R-GFP fusion 
was created to examine membrane localisation using confocal laser scanning microscopy, to 
assay expression levels, to select highly expressing monoclonal cell lines using fluorescence 
activated flow cytometry and to develop a fluorescence size-exclusion chromatography-
based assay to examine the suitability of 12 different ligands for co-crystallization. AT1R 
was also engineered to facilitate crystallisation, including C-terminal truncations to remove 
predicted disordered regions and bacteriophage T4-lysozyme being added to the third 
intracellular loop to provide additional points of contact for crystallisation, which increased 
the apparent Tm by approximately 10°C. All modified versions of AT1R were assessed for 
expression, stability and monodispersity. Additionally a rapid western blotting based assay 
was developed for the detection of unfolded membrane proteins, which will have wide 
applicability in the field.   
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CHAPTER 1 INTRODUCTION 
 
1.1 Introduction to GPCRs 
 
 
 GPCR function and diversity 
 
G protein-coupled receptors (GPCRs) are a class of integral membrane proteins which act as 
signal transducers, responding to stimuli as diverse as hormones and light. Encoded by more 
than 800 genes 1, GPCRs encompass the largest and most diverse family of proteins in the 
human body 2. Multiple complex intracellular signalling pathways are modulated by GPCRs, 
including responses to the majority of neurotransmitters and hormones; they are also key 
components of vision, olfaction and taste 3. Characteristically, GPCRs span the plasma 
membrane with seven -helices and bind heterotrimeric G proteins to elicit their signal 
transduction pathway, although they are also known to signal independently from their 
eponymous pathway, mainly through coupling with the scaffold protein arrestin 3, 4. 
 
Within the human genome, GPCR sequences have been categorised into four major families 
based on sequence identity within the transmembrane domain (TMD) regions 5, 6. The four 
families are comprised of the rhodopsin family (class A), the secretin and adhesion family 
(class B), the glutamate family (class C) 5 and the smoothened and frizzled family (class F) 
6. In the human genome, class A is the largest group with 714 members 7 and binds the most 
varied set of ligands, ranging in size from small molecules to glycoproteins 8. Class A 
receptors are involved in diverse physiological processes such as vision, olfaction and 
immune response regulation, whereas some of the functions of class B and C receptors 
include blood glucose maintenance and synaptic transmission 9. In humans, class F consists 
of 10 frizzled receptors which control Wnt signalling and one smoothened receptor which 
controls the hedgehog pathway 6. Most class A receptors differ typically from others classes 
by having a relatively short N-terminus as compared to the long, heavily glycosylated N-
terminus generally seen in class B, C and F receptors 8. Class B receptors consist primarily 
of orphan receptors and characteristically have twopairs of -sheets and three disulphide 
bridges on their N-terminus, whereas class C receptors contain a ‘Venus fly trap’ domain on 
their N-terminus and class F receptors contain a cysteine rich domain on their N-terminus 6, 
8. Orthosteric ligand binding in class A occurs in the TMD bundle, whereas for class B 
receptors it extends from the TMD to the N-terminus, whilst for family C receptors the 
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evidence suggests that the agonist binds the Venus fly trap domain, which indirectly 
activates the TMD site 8. For class F GPCRs, it is thought that the cysteine rich domain on 
the N-terminus of the receptors is involved in ligand binding 6. 
 
 GPCRs as pharmaceutical drug targets  
 
Given the role of GPCRs in a diverse array of cellular processes, it is not surprising that they 
comprise one of the largest families in the druggable genome and thus form a major class of 
targets for experimental drugs 10. GPCRs exist in an equilibrium between an inactive 
conformation (R) and active conformation (R*), and the binding of a ligand can shift the 
balance towards one or other of these states 11. Ligand efficiency defines the biological 
response of a receptor to the binding of a ligand 11, 12 (Figure 1.1). Ligands that act on 
GPCRs fall into two main categories, agonists and antagonists, which respectively either 
activate the receptor or block binding of the agonist 11, 13. Agonists can be further classified 
as full, partial or weak depending on the level of biological response observed 13. 
Additionally, basal activity, or activity in the absence of agonist, can be supressed by an 
inverse agonist 12, 13 whereas neutral agonists neither activate nor suppress basal activity of 
the receptors 13.  
 
Figure 1.1 GPCR ligand efficiency 
The five main classes of GPCR ligands based on ligand efficiency. Agonists activate the receptor to varying 
degrees (full, partial or weak). Antagonists block the binding of agonists and fall into two major groups; neutral 
antagonists which neither activate nor suppress basal activity of the receptors and inverse agonists which 
reduce basal activity. Figure adapted from 13. 
 
GPCR signalling can be further influenced through allosteric modulators which bind to sites 
on the receptor separate from the natural binding pocket 4, 11. Allosteric modulators can act 
by either changing the signalling pathway or altering the binding affinity of the endogenous 
ligand 11. For example, it was observed both pharmacologically and structurally that 
intramembrane Na+ ions act as an allosteric modulator of the adenosine A2A receptor (A2AR) 
by decreasing the affinity for the agonist with increasing Na+ concentration 14, 15, 16, 17. 
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Agonist binding can activate receptors in two main ways. Firstly, it is possible for an agonist 
to physically displace stabilising interactions, which in turn causes a conformational change 
that is stabilised by a new set of interactions. Secondly, agonists can act as a bridge, which 
creates new opportunities for interactions between TMDs that could, for example, stabilise 
the active conformation. For larger ligands such as peptides, there is also the possibility that 
a combination of mechanisms might apply 12. Coupling of cognate G proteins to a receptor 
can increase its binding affinity through allosteric effects. For example binding of Gs to 
2AR increases its affinity for the agonist isoproterenol a hundred-fold 18.  
 
1.2 Crystallisation and structure determination of GPCRs 
 
 Milestones in GPCR structure determination 
 
In an effort to understand GPCR function it is important to have a number of high-resolution 
structures of the receptors. The first three-dimensional GPCR crystal structure obtained was 
bovine rhodopsin at 2.8 Å 19. Rhodopsin was the first GPCR to yield crystals due to its 
abundance from natural sources, stability in harsh detergents and the ability to control its 
conformational state 20. The first high-resolution rhodopsin structure had a P41 space group 
and the crystal contacts were formed between the hydrophilic domains of the receptor 19. 
Subsequent rhodopsin structures have formed crystal contacts between extracellular loops 
(ECLs) and cytoplasmic loops (CLs), which had a P31 space group and possibly showed a 
more native configuration of CL3, since it closely matched that seen in electron diffraction 
structures of 2-dimensional crystals (Gebhard Schertler, personal communication) 21. Other 
rhodopsin structures have been further refined to 2.2 Å 22. The next high-resolution GPCR 
structures were of the human 2 adrenergic receptor (2AR) 23, 24, the avian 1 adrenergic 
receptor (1AR) 25 and the human A2AR 16. These three structures represented a leap forward 
in GPCR structure determination because they illustrated the utility of newly developed 
protein engineering and crystallisation techniques (Section 1.3). With the advent of generic 
methodologies to both stabilise GPCRs and to make them more amenable to 
crystallography, the number and diversity of GPCR structures has dramatically increased 
(Figure 1.2). To date there are over 25 unique GPCR structures in the protein data bank 
(PDB) representing both active and inactive conformations and bound to ligands as diverse 
as small molecules and peptides 9. A major milestone in GPCR structure determination was 
when the active state of 2AR in complex with its cognate G protein, Gs, was solved at 3.5 
Å resolution 26. Stabilisation of this complex required fusion of 2AR with bacteriophage T4 
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lysozyme (T4L) as well as the binding of a single-chain camelid antibody fragment 
(nanobody) to the heterotrimeric G protein 27 (Section 1.2.4). More recently, structures of 
GPCRs from classes other than class A have been determined (Figure 1.2). These include 
structures of class B receptors for corticotropin-releasing factor 128 and glucagon 29; class C 
receptors, metabotropic glutamate receptor 1 30 and metabotropic glutamate receptor 5 31; 
and a class F receptor for smoothened 32. However all of these structures lack their N-
terminal domains, which are essential for binding the native agonists. 
 
Figure 1.2 Time line and milestones of GPCR structure determination 
(A) Bar graph indicating the increase in the number of GPCR structures from 1993 to 2012. Figure adapted from 
33. (B) Milestones in GPCR structure determination 2013 to present. Shown are structures representing the 
smoothened receptor, corticotropin-releasing factor (CRF1), glucagon receptor (GCGR), metabotropic 
glutamate receptor 1 (mGluR1) and metabotropic glutamate receptor 5 (mGluR5). Figure adapted from 9.  
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 Common structural characteristics of GPCRs 
 
To compare common structural characteristics of class A GPCRs, an alignment of the high 
resolution structures of 1AR and the dopamine D3 receptor (D3R) is shown in Figure 1.3. 
All GPCRs contain seven -helical TMDs which are oriented approximately perpendicular 
to the membrane. The TMD helix bundle serves to transmit extracellular signals in the 
ligand binding pocket approximately 30 Å to the G protein coupling region 34. GPCRs 
contain an extracellular N-terminus and intracellular C-terminus and their TMDs are 
connected by a series of three cytoplasmic loops (CL1-3) and three extracellular loops 
(ECL1-3) 2, which form the most structurally variable regions of GPCRs 33. In class A 
receptors, the cavity of the ligand binding pocket is primarily located in the TMD bundle 
and usually only the side chains of the residues are involved in ligand binding 35. In the 
1AR and D3R structures, the ligands interact primarily with helix 3 (H3), H5 and H7 35. 
Located towards the centre of the TMD bundle, it is thought that H3 functions as the 
structural and functional hub since virtually every residue either forms contacts with another 
TMD or the cognate G protein 33. In inactive structures, Arg3.50 (Ballesteros Weinstein 
numbering 36 used in superscript throughout the document) in the the highly conserved 
D[E]RY sequence, frequently forms a salt bridge with Asp[Glu]3.49 37. Another key feature 
of H3 is a second salt bridge formed between Arg3.50 and Asp6.30 which creates an ionic lock 
that potentially holds together the intracellular ends of H3 and H6 37. The CWXP motif 
located near the bottom of the ligand binding pocket is thought to act as a toggle switch in 
some receptors, thus controlling receptor signalling through Trp6.48. Activation of the 
receptor through agonist binding is thought to cause a rotational change in Trp6.48 which sets 
in motion a series of alterations in residues which in turn extend to the bottom of the TMD 
bundle 35. A further highly conserved motif is NPXXY which is located on the intracellular 
end of H7 and it serves as another switch controlling activation of the receptor. In inactive 
GPCR structures it is commonly found that the side chain of Tyr7.53 is oriented towards H1, 
H2 or H7, whereas in active structures it orientates toward H7 and interacts with H3 and H6 
37. ECL2 often contains one or more disulphide bonds and it is sometimes involved in ligand 
binding, as observed for example in peptide receptors and A2AR. In rhodopsin structures, 
this region contains -sheets, whereas in many GPCRs, such as 1AR and 2AR, this region 
contains an -helix 35. CL2 along with H5 and H6 are involved in G protein coupling 26. 
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Figure 1.3 Common structural characteristics of class A GPCRs 
The structures of 1AR (green, 2VT4) and D3R (red, 3PBL) are shown as examples of class A high-resolution 
structures determined by X-ray crystallography. The seven helices are labelled using Roman numerals and are 
connected by a series of three CLs and three ECLs. Ligand binding involves the binding pocket in the TMD 
bundle, in particular to residues in H3, H5 and H7. The ionic lock is a salt bridge which holds together H3 and 
H6. In some receptors activation of the receptor causes a rotational change in Trp6.48 (toggle switch) which 
allows the receptor to transmit its signal to the bottom of the TMD bundle. For a full description of the key 
features of the structures see Section 1.2.2. Ballesteros Weinstein numbering is shown throughout 36. Adapted 
from 8. 
 
 Signal transduction in GPCRs 
 
Originally in the two-state model, GPCRs were thought of as simple bimodal switches that 
were either in an active or inactive state and, indeed, this model is accurate for describing 
rhodopsin activation 12. In the inactive state, rhodopsin is covalently bound to 11-cis-retinal 
19. Exposure to light isomerises 11-cis-retinal to all-trans-retinal which activates the receptor 
in milliseconds 38, 39. Basal activity varies greatly among receptors. Rhodopsin has virtually 
no basal activity, which is essential for its light-sensing function, whereas other receptors, 
such as the histamine H3 receptor, have much higher levels of basal activity 
40. Although 
rhodopsin has several characterised intermediate conformations, none of them have direct 
roles in interacting with signalling proteins 20. Therefore the two-state model holds true 
since absorption of a single photon of light causes maximal activation and coupling to 
transducin (Gt) 
12. However, this is not the case for 2AR which can bind and signal through 
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both Gs and Gi as well as -arrestin 
3. Even when saturated with a high affinity agonist, only 
a small portion of receptors manage to achieve the fully active state at any given time 20. The 
concept of 2AR being able to signal through several pathways is illustrated by the binding 
of the drug carvedilol, which acts as an inverse agonist for the Gs pathway, but as a partial 
agonist for the arrestin pathway 18. Figure 1.4 is a simplified diagram displaying the wide 
array of signalling pathways activated by 2AR. GPCRs are now thought to exist in a variety 
of discrete conformations which are influenced by a number of agents including ligands, 
regulatory proteins, ions, pH and lipids 20. 
 
 
Figure 1.4 Signal transduction in GPCRs 
A wide array of signalling pathways can be activated by 2AR. 2AR can bind to two different heterotrimeric G 
proteins, Gs and Gi, which differentially regulate adenylate cyclase and can in turn generate cyclic AMP (cAMP) 
leading to the activation of protein kinase A (PKA). PKA controls the activity of a number of proteins including L-
type Ca2+ channels and 2AR itself forming a feedback loop. cAMP is downregulated by phosphodiesterase 
(PDE). G-protein-coupled receptor kinases (GRKs) and protein kinase C (PKC) phosphorylate 2AR after 
agonist-induced activation, which in turn allows -arrestin coupling. -arrestin can then signal through 
extracellular signal-regulated kinases (ERKs) and promote the internalisation of 2AR through clathrin-coated 
pits. Adapted from 3. 
 
 Conformational changes in the activation of GPCRs 
 
Initially, all GPCR structures were of receptors in the inactive conformation, because this 
state was the most stable and therefore more amenable to crystallisation. Full activation of a 
GPCR usually requires binding of an agonist and often also of the cognate G protein. To 
CHAPTER 1 Introduction  
 Page 8  
 
date only three receptors have been crystallised in both inactive and fully active 
conformations, these include rhodopsin 19, 38, 39, 2AR 23, 26, 41, 42, and the M2 muscarinic 
receptor 43, 44. However only 2AR has been crystallised in complex with the heterotrimeric 
G protein, Gs, 
26 as well as a G protein mimetic, nanobody (Nb) 80 42 as agonist alone was 
not enough to fully stabilise 2AR in the active conformation 45. The 2AR structures allow 
for a direct comparison of inactive and active conformations with a G protein bound (Figure 
1.5). The most striking structural changes observed upon receptor activation are a 14 Å 
outward shift in the cytoplasmic end of H6; followed by the extension by two helical turns 
and an outward movement of the cytoplasmic end of H5; and finally more minor 
rearrangements in H7 26. Primarily, in this structure, it is the outward shift in H5 and H6 that 
forms a cavity which allows for G protein coupling. Small changes in the ligand binding 
pocket, largely through the formation of additional hydrogen bonds, are thought to set off a 
chain of rearrangements down the TMDs which ultimately lead to the large outward shift 
seen in H5 and H6 46. NMR studies of activated 2AR bound to Nb80 remain consistent with 
the movements shown upon activation 47. Additionally, in the structure of rhodopsin bound 
to a C-terminal Gt peptide, H6 shows a 6 Å outward displacement 
38, 39. Further validating 
this model of activation, double electron-electron resonance (DEER) spectroscopy of 
rhodopsin has shown a 5 Å outward displacement of H6 upon activation of the receptor, 
along with smaller movements in H7 48. By contrast, crystal structures of A2AR in the 
intermediate-active state reveal only a 3 Å outward displacement of H6 upon agonist 
binding, which is smaller than that observed in either 2AR or rhodopsin, presumably due to 
the lack of a bound G protein 49, 50. The 2AR-Nb80 complex shows striking similarity to the 
2AR-Gs complex with an overall root mean square deviation between the two structures of 
0.6 Å. The only major differences are that Arg131 interacts with the nanobody in the 2AR-
Nb80 structure whereas it packs against Gs in the 2AR-GS structure and H6 does not 
move as much in the 2AR-Nb80 structure 26, 42 (Figure 1.5). 
 
Until recently the mechanism for how GPCRs activate G proteins and release GDP from the 
G subunit was unknown 
51. With the structure of the 2AR-GS complex, it is now possible 
to understand this mechanism (Figure 1.6). G proteins are able to couple to the GPCR after 
it is activated by an agonist and the cellular domains of H5 and H6 form a large pocket to 
enable this binding to take place. 
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Figure 1.5 Comparison of active and inactive 2AR structures 
(A) Side and cytoplasmic views of the 2AR-GS structure (green) compared to the inactive carazolol (CZ)-bound 
2AR structure (blue). The largest changes in conformation are located in the intracellular end of H5 and H6 
(note Hs are annotated by TMs in the diagram), which allows the G protein to bind. H5 is extended by two 
helical turns whereas H6 is moved outward by 14 Å as measured at the -carbons of Glu268 (yellow arrow) in 
the two structures. (B) Comparison of 2AR-Gs (green) with nanobody-stabilised active state (2AR–Nb80) 
(orange). (C) The positions of residues in the E/DRY and NPXXY motifs and other key residues of the 2AR-GS 
and 2AR–Nb80 structures. All residues occupy very similar positions except Arg131 which in the 2AR–Nb80 
structure interacts with the nanobody. (D) Cytoplasmic view of residues shown in illustrating a 3 Å shift in H6 
(C). Adapted from 26. 
 
From the crystal structure of the 2AR-Gs complex, CL2, H5 and H6 of 2AR form a large 
interface with Gs 
26. The formation of the complex allows the exchange of GDP for GTP 
and subsequent activation of the ,  and subunits of the G protein. Eventually they are 
deactivated and recycled. One of the major challenges in crystallising the 2AR-GS complex 
was the variable position of the -helical domain of the Gs subunit as revealed by electron 
microscopy (Figure 1.6). This was resolved by binding Nb35 to the Gs subunit, which 
locked it into one position 26. 
 
CHAPTER 1 Introduction  
 Page 10  
 
 
Figure 1.6 Activation and G protein coupling for 2AR 
(A) Agonist binding of 2AR causes a rearrangement in the cytoplasmic ends of the TMDs which allows 
coupling of the receptor to the GS heterotrimer (,  and ). Formation of the 2AR-GS complex leads to the 
release of GDP which in turn allows for the binding of GTP which causes the ,  and subunits to disassociate 
from 2AR. The subunits are then free to activate their associated effector proteins (adenylate cyclase (AC) and 
calcium channels in this case). The Gs heterotrimer is then reassembled from the ,  and subunits after GTP 
is hydrolysed to GDP. (B) Detergent solubilised, nucleotide-free 2AR-GS complex, illustrating the complexity of 
working with a nucleotide free Gs. Two nucleotide binding subunits comprise Gs, the -helical domain (AH) 
and Ras domain (Ras). When nucleotides are removed, the AH domain position varies relative to the Ras. 
Adapted from 26. 
 
 Conformational changes in GPCR--arrestin coupling 
 
Significantly less is understood about the structural changes that occur in GPCRs when -
arrestin couples, compared to when G proteins bind. Structures of 1AR bound to biased 
agonists have not identified a clear mechanism for why some ligands are biased and why 
some are not 52. However, there is some evidence to suggest that the cytoplasmic end of H7 
alters conformation upon arrestin binding 53, which correlates with the importance of the 
phosphorylated state of the C-terminus in dictating the model of arrestin binding 54. Single 
particle electron microscopy has revealed that the C-terminus and H5 in 2AR are important 
for coupling with arrestin-1 55. However the resolution of the structure was only about 30 Å, 
thus insufficient detail was resolved to define the model of arrestin binding. A high 
resolution structure of an arrestin bound GPCR would help to explain the mechanism of 
arrestin coupling. 
 
1.3 Requirements for GPCR crystallisation and strategies 
developed to overcome impediments 
 
 Difficulties in crystallising GPCRs 
 
Despite the increase in the number of GPCR structures in the past five years, they remain 
challenging targets for crystallography. This is due to several reasons. GPCRs exist in 
equilibrium between two main conformations, a low energy inactive R state which is 
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favoured in the absence of ligand and a higher energy active R* state that binds G proteins 
56. This conformational heterogeneity is not conducive to crystallisation and therefore it is 
essential to lock the receptors into one state. GPCRs have a relatively low hydrophilic 
surface area which can be used to form crystals 46. Compounding this problem, GPCRs are 
inherently flexible and unstable 46 and the harsh short chain detergents, which are required to 
expose hydrophilic faces, act to further destabilise them. The majority of GPCRs are not 
present from natural sources in quantities sufficient for structure determination 57, 58. 
Therefore, structural projects depend upon using an overexpression system capable of 
producing milligram amounts of active receptor, but unfortunately, low expression levels are 
typically obtained for mammalian membrane proteins produced from recombinant sources 
59. In addition, post-translational modifications, such as N-glycosylation, are often required 
for efficient mammalian membrane protein expression, folding and targeting to the plasma 
membrane. As shown for the N-glycosylated membrane protein, the serotonin transporter 
(SERT), the expression of fully active eukaryotic proteins cannot always be accomplished in 
heterologous expression systems 60. Expression of GPCRs will be further discussed in 
Chapter 2. Finally, the stability of the GPCR needs to be sufficient for purification in the 
detergent-solubilised state and also for the days or weeks required for crystallisation. Thus, 
for each potential structural biology project on GPCRs, three problems need to be overcome 
to optimise the probability of success: (1) milligram amounts of functional receptor 
expressed in a heterologous system; (2) sufficient stability of either the receptor alone or in 
complex with a ligand to allow purification and crystallisation; (3) a method to lock the 
receptor in a single conformation. 
 
 Strategies for the crystallisation of GPCRs 
 
Different strategies have been developed to overcome issues with GPCR crystallisation. 
Two separate approaches are used to increase the hydrophilic surface area of membrane 
proteins, which in turn allows the use of milder detergents with larger micelles. 2AR was 
co-crystallised with a fragment antigen-binding (Fab) antibody which provided sufficient 
hydrophilic surface contacts to allow for crystallisation in bicelles, which are lipid rich and 
consequently much larger than the detergent micelles usually employed 23. However the 
resultant structure was at a resolution of 3.4 Å and thus insufficient to model side chains in 
the extracellular portion of the receptor or to delineate the ligand. Another example of a Fab 
being used to stabilise a GPCR was the co-crystallisation of a conformationally-specific Fab 
with A2AR 
61 (Figure 1.7), which yielded a structure at a resolution of 2.7 Å. The use of 
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antibodies to stabilise receptors took a leap forward with the use of nanobodies (Nbs). These 
are derived from antibodies found in camelids, which are comprised of a single domain 
fragment that maintains the antigen-binding capacity of traditional antibodies, but which are 
only 15 kDa in size 27. Nbs are thought to be more stable than traditional antibodies, 
including Fabs, and can be easily expressed in bacteria and yeast, however their production 
requires milligram quantities of the purified protein that they are to be raised against 27. The 
resulting Nbs then need to be screened to isolate ones which recognise a single conformation 
of the protein of interest 27. A structure of active-state 2AR in complex with Nb80 was 
solved at 3.5 Å, however this structure also required the use of a fusion protein, 
bacteriophage T4 lysozyme (T4L; discussed in more detail below), to further increase 
crystal contacts 42 (Figure 1.5). Interestingly, Nb80 increased the affinity of the agonist 
isoproterenol by a hundredfold, which was similar to the increase observed when GS binds 
to 2AR 27, indicating that Nb80 mimics some of the effects of the G protein. A further 
nanobody, Nb35, was raised against 2AR crosslinked to the GS heterotrimer 26 and was 
essential during crystallisation to prevent the 2AR-GS complex from dissociating 26. The 
resulting structure also employed T4L to increase crystal contacts and was solved at 3.2 Å 26 
(Figure 1.5). 
 
As mentioned above, another strategy for increasing the likelihood of crystal contacts 
forming is to create a fusion with a small soluble protein such as T4L. This approach was 
also used to crystallise 2AR bound to a high-affinity inverse agonist and resulted in a 2.4 Å 
resolution structure 24. The crystals were grown in lipidic cubic phase, because vapour 
diffusion crystal trials did not yield diffraction-quality crystals. While the addition of a 
fusion protein can introduce flexibility, the careful placement of T4L in CL3 was successful 
in reducing flexibility in this region, however this particular placement can also prevent G 
protein coupling 41. Instead T4L can be fused to the N-terminus to maintain the ability of the 
receptor to bind G proteins 26. Another example of a GPCR-T4L fusion is A2AR-T4L that 
was solved at 2.7 Å resolution 50 (Figure 1.7). Thusfar the use of T4L fusion has been 
employed to crystallise over eleven unique GPCRs 62. This technique has also been extended 
to include other small soluble proteins such as apocytochrome b562RIL (BRIL). A fusion of 
A2AR with BRIL inserted into CL3 also resulted in a 1.8 Å structure 
14. The technique of 
creating a fusion with a small soluble protein however relies on the availability of high-
affinity ligands with slow dissociation rates, which are essential to both make the receptor 
sufficiently stable to allow purification and crystallisation and to stabilise the receptor in a 
single conformation 13.  
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Figure 1.7 Comparison of three strategies used for the crystallisation of A2AR 
Ribbon diagram in rainbow colouration (N-terminus blue, C-terminus red) illustrating three different techniques 
used for structure determination of A2AR bound to endogenous and synthetic ligands. Strategies employed 
include increasing the hydrophilic area through the use of a Fab (A), creation of a fusion with T4 lysozyme in CL3 
(B) or conformational thermostabilisation (C, D). A cartoon version of the lipid bilayer is shown for perspective. 
Ligands are shown in space-filling representation (C, yellow; N, blue; O, red). Above the receptors, the portions 
of the ligands that are similar to adenosine are shown in blue. Detailed inserts show the binding pocket for 
caffeine and adenosine: part of H3 has been removed for clarity; red broken lines, hydrogen bonds; blue broken 
lines, polar interactions; red spheres, water molecules; interacting amino acid side chains (C, green; N, blue; O, 
red); ligands are shown in stick representation (C, yellow; N, blue; O, red). PDB codes: (A), A2AR bound to Fab 
(grey) 3VG9 61; (B), A2AR-T4L (T4L, grey) 3QAK 50; (C), theromostabilised A2AR bound to caffeine 63 3RFM; (D), 
theromostabilised A2AR bound to adenosine 49 2YDO. Adapted from 13. 
 
Another mechanism for enhancing the likelihood of crystal formation stems from the 
observation that point mutations can increase the stability of a detergent-solubilised 
membrane protein 64. This offers the opportunity to engineer proteins that are stable enough 
to allow the use of short chain detergents for crystallisation. While these detergents expose 
the greatest surface area of the membrane protein, they are by nature very destabilising and 
therefore denature many proteins. Thus the crystallisation of membrane proteins in 
detergents such as nonylglucoside or octylglucoside only works for thermally stable 
proteins. Conformational thermostabilisation consists of evolving proteins through 
mutagenesis to be thermally stable whilst simultaneously selecting for proteins locked 
preferentially in one conformation 17, 65, 66, 67, 68, 69. The choice of assay to measure an 
apparent Tm is discussed in Chapter 2. For 1AR, conformational thermostability was 
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achieved through selecting stable mutants in complex with the antagonist dihydroalprenolol 
in the inactive conformation 69. Thermostabilisation allowed the protein to be crystallised in 
the harsh detergent n-octyl β-D-thioglucopyranoside (OTG) with cyanopindolol bound 25. 
Conformational thermostabilisation of GPCRs has allowed several further crystal structures 
to be obtained, most recently a class C GPCR, the metabotropic glutamate receptor 5 31 and 
a class B GPCR, the corticotropin-releasing factor receptor 28. The same approach has also 
been used to determine the structures of several class A receptors including: the adenosine 
A2A in both an R*-like state 
49 (Figure 1.7) and an R state 63 (Figure 1.7); the neurotensin 
receptor in an R*-like state 70; and 1AR in the R state bound to agonists, partial agonists, 
weak partial agonists and biased agonists 25, 52, 71, 72, 73. The advantage of conformational 
thermostabilisation over the other techniques mentioned here is that it allows for the 
crystallisation of GPCRs with low-affinity ligands 13. 
 
1.4 The angiotensin II type 1 receptor 
 
 Control of the cardiovascular system by AT1R 
 
A highly potent hormone, recognised as a key regulator of blood pressure, was identified by 
two separate groups in the1940s. The substance was separately named hypertensin and 
angiotonin and as a compromise, the portmanteau angiotensin was adopted as the standard 
nomenclature 74. The precursor to angiotensin, angiotensinogen, is a 56 kDa glycoprotein 
that is released into the blood primarily from the liver. It is cleaved by the protease renin to 
ten amino acids, which are then further cleaved by angiotensin converting enzyme (ACE) to 
create the biologically active octapeptide angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) 
75 (Figure 1.8). Angiotensin II is the endogenous ligand for the angiotensin II type 1 receptor 
(AT1R) which is a member of the class A (rhodopsin) family of GPCRs 
76. AT1R is involved 
in homeostasis of the cardiovascular system. It is expressed in a variety of tissues including 
vascular smooth muscle, adrenal glands, the kidneys and the brain 76. Binding of the 
endogenous agonist angiotensin II causes activation of Gq-mediated phospholipase C, which 
in turn stimulates inositol phosphate responses, Ca2+ signal generation and protein kinase C 
activation 77, 78 (Figure 1.8). Agonist activation of AT1R also elicits several intercellular 
signalling pathways including Ras and JAK/STAT 75. Cellular responses to angiotensin II 
binding are tissue specific and include vasoconstriction, sodium re-absorption, increased 
thirst and ventricular hypertrophy 76. 
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Independent of the eponymous G protein pathway, AT1R can signal through binding of the 
scaffold protein -arrestin. As part of GPCR desensitization, Ser and Thr residues on the C-
terminus of AT1R are phosphorylated by a variety of kinases, which then allows -arrestin 
to bind 78, 79 (Figure 1.8). Even after AT1R is targeted to endocytic vesicles, it can signal via 
-arrestin, since unlike most GPCRs such as 2AR, the complex is stable and not readily 
dephosphorylated 80. From the perspective of -arrestin binding, AT1R is categorised as a 
class B receptor, which means that AT1R is internalised along with -arrestin and can still 
activate numerous intercellular signalling pathways including, Src, ERK and JNK3 81, 82 
(Figure 1.8). These pathways in turn regulate cellular processes such as proliferation and 
apoptosis 82.  
 
Figure 1.8 Agonist activation and desensitisation of AT1R 
A wide array of signalling pathways can be activated by AT1R and a simplified version is shown here. Upon 
agonist binding, AT1R binds primarily to the heterotrimeric G protein, Gq which in turn activates PLC 
(phospholipase C), which then initiates IP (inositol phosphate) responses including IP3, Ca2+ signal generation 
and PKC (protein kinase C) activation. PKC controls the activity of a number of proteins including AT1R itself, 
forming a feedback loop. Activation of AT1R also mediates several intracellular signalling pathways including 
Ras and JAK/STAT. G-protein-coupled receptor kinases and PKC phosphorylate AT1R after agonist-induced 
activation, which in turn allows -arrestin coupling. -arrestin can then signal through Ras (rat sarcoma 
GTPase), JAK/STAT (janus kinase/signal transducer and activator of transcription), Src (sarcoma tyrosine 
kinase), ERK (extracellular signal-regulated kinase and JNK3 (c-Jun-N-terminal kinase 3) and it promotes the 
internalisation of AT1R through clathrin-coated pits, where it can still signal. Adapted from 3. 
 
 Analysis of the primary structure of AT1R 
 
Expression cloning was first used to isolate AT1R cDNA from bovine adrenal cells and rat 
aortic vascular smooth muscle cells which were both abundant sources of the receptor and in 
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subsequent years AT1R cDNA was obtained from several other vertebrates 
75. An amino 
acid sequence alignment of AT1R between the human receptor and that of other vertebrate 
species shows an extremely high level of conservation (Appendix 1). An additional 
alignment of human AT1R with GPCRs of known structure (Appendix 1) allows for the 
postulation of the location of the transmembrane domains. Sequence homology between 
AT1 receptors is greatest in the transmembrane domains and three intracellular loops and is 
least within the 4 extracellular regions and the C-terminus. There are potentially two highly 
conserved disulphide bonds present in AT1R. As seen in many GPCR structures, there is the 
possibility of a disulphide bond between ECL1 and ECL2. AT1R also contains an additional 
pair of cysteine residues putatively located in the N-terminal region and ECL3, whereas the 
other cysteine residues are most likely located in transmembrane domains. These disulphide 
bonds could impart a level of stability to the receptor 83. As an example, a disulphide bond 
was engineered to connect the N-terminus and ECL3 of rhodopsin, increasing its 
thermostability by 10°C 84. AT1R possesses three highly conserved N-linked glycosylation 
consensus sequences (Asn-X-Ser/Thr, where X is not Pro) in extracellular segments. Asn4 is 
at the N-terminus of the receptor while Asn176 and Asn188 are in ECL2. This source of 
heterogeneity could pose a problem for crystallisation. N-linked glycosylation of AT1R will 
be further discussed in Chapter 2. 
 
AT1R has been shown to be held in an inactive conformation and agonist binding is thought 
to destabilise these interactions. Specifically, Asn1113.35 interacts with Asn2957.46 to produce 
a locking mechanism 85. Mutation of Asn1113.35 to alanine produces a constitutively active 
receptor 86 and Asn1113.35 has been shown to interact with Tyr4 of angiotensin II 87. 
Therefore it is logical to postulate that agonist binding might destabilise the interactions 
between Asn1113.35 and Asn2957.46 12. AT1R possesses the highly conserved DRY motif and 
mutation of this sequence prevents G protein coupling after agonist binding, however it does 
not diminish receptor phosphorylation, internalisation or recruitment of -arrestin 88. 
 
 Pharmacology of AT1R 
 
As the gatekeeper of the cardiovascular system, AT1R has generated considerable 
pharmacological interest over many years 76 and a number of ligands have been designed 
which block it. Initial attempts at designing AT1R antagonists were complicated by the need 
to work with peptide analogues of angiotensin II. As such, the first AT1R antagonist, 
saralasin (Sar1-Val5-Ala8 angiotensin II), had to be administered intravenously and even 
CHAPTER 1 Introduction  
 Page 17  
 
presented partial agonist action in some patients 76, 89. The first non-peptide AT1R antagonist 
to reach clinical trials was losartan, followed shortly by a large number of derivative 
compounds, such as valsartan and candesartan 76. Unlike the peptide analogues, these 
compounds showed oral bioavailability and were effective at reducing blood pressure 89. 
Further development of non-peptide AT1R antagonists was aided by cloning of the Xenopus 
laevis AT1R DNA sequence. The amphibian receptor bound angiotensin II with a similar 
affinity to its mammalian counterpart, but it did not recognise losartan 90. Mutation of non-
conserved amino acids in the rat AT1R to those of the amphibian version obliterated losartan 
binding, whereas only small changes in the affinities for angiotensin II and the peptide 
antagonist Sar1-Ile8 angiotensin II (Sar1) were observed. Residues Val1083.32, Ala1634.60, 
Thr1985.41, Ser2526.47, Leu3007.51 and Phe3017.52 were shown to be of particular importance 
for non-peptide antagonist binding to AT1R and all were postulated to be located in 
transmembrane domains 90. The non-peptide agonist, L-162,313 has a physiological effect 
similar to the endogenous agonist 91. The most recent AT1R blocker to gain FDA approval, 
azilsartan, had a similar binding affinity to other non-peptide antagonists, but showed 
stronger inverse agonism, as determined by inositol phosphate production, and stayed bound 
to the receptor for a longer period of time 92. The structures of eleven AT1R ligands along 
with their binding affinities are shown in Chapter 4. 
 
AT1R ligands also include a number of biased agonists such as Sar
1-Ile4-Ile8 angiotensin II, 
which was the first ligand to be discovered that favoured signalling through -arrestin rather 
than Gq 
93, 94. Further compounds have since been developed that showed an even stronger 
bias towards -arrestin signalling, such as TRV120027, which exhibited a 30-fold increase 
towards -arrestin 2 recruitment over Sar1-Ile4-Ile8 angiotensin II 95, 96. This discovery of 
functional selectivity illustrated that the classical model of GPCR activation from the R to 
R* state was incomplete and multiple ligand-specific conformations (R*n) could exist, each 
of which could be capable of eliciting different downstream signalling 97. Although several 
AT1R biased agonists have been developed, there is currently no inverse agonist for both the 
G protein and -arrestin pathways. For example, although Sar1-Ile4-Ile8 angiotensin II was 
originally shown to be biased towards -arrestin signalling, additional assays which directly 
monitored the interactions between AT1R and the transducers (as opposed to assessing 
downstream signals such as cAMP or ERK1/2 phosphorylation) showed that it partially 
activated G proteins 98. 
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1.5 Aim of the research presented in this dissertation 
 
Although over 25 unique high-resolution GPCRs structures now exist, relatively little is 
known about the conformational dynamics of GPCRs, in particular the structural changes 
that occur after G proteins and arrestin bind. To date, there is only one structure of a GPCR 
bound to a G protein, 2AR in complex with Gs 
26. Since AT1R couples to Gq it presents an 
opportunity to understand G protein coupling with G proteins other than GS. Additionally, 
since AT1R forms a stable complex with arrestin and stays bound to arrestin longer than 
most GPCRs 80, it presents an opportunity to further understand GPCR-arrestin interactions. 
 
The aim of the work presented here was to develop an effective heterologous expression 
system for the production of milligram quantities of AT1R for structure determination. In 
addition, the effect of N-linked glycosylation on protein expression and stability had to be 
determined, as well as the best combination of ligand and detergent to produce an optimally 
stable receptor suitable for purification.
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CHAPTER 2 THE SUITABILITY OF AT1R AS A 
CANDIDATE FOR STRUCTURAL STUDIES 
 
2.1 Introduction 
 
Before structure determination of AT1R could proceed several potential obstacles needed to 
be assessed and, where necessary, overcome. The first aim was to examine the stability of 
detergent-solubilised AT1R. The second was to determine the expression levels of functional 
AT1R in heterologous systems and to determine the most efficient system for producing 
milligram quantities. 
 
Prior to the work presented here, the stability of detergent-solubilised AT1R was unknown.  
Several analytical methods exist for measuring protein stability with respect to temperature. 
These include sedimentation velocity 99, 100, circular dichroism spectroscopy 101, 102, 103, 
dynamic light scattering 99, 104 and the CPM unfolding assay 105. However, all these methods 
require purified protein and, in the case of the biophysical techniques, usually milligram 
quantities are necessary. In contrast, the CPM assay was developed to work on microgram 
quantities of membrane proteins. The CPM assay uses a maleimide fluorochrome which is 
nonfluorescent in its unbound state and fluoresces upon covalent attachment to accessible 
cysteine residues. A further benefit is that it is unaffected by the presence of detergent 105. 
Another method for determining protein stability is the use of green fluorescent protein 
(GFP) fusions coupled with fluorescence-detection size exclusion chromatography (FSEC) 
106, 107. The advantage of this method is that it uses unpurified material, however minor 
changes in stability are not easily measured by this technique. A further method to assess 
protein stability is the radioactive ligand-bound apparent thermostability (Tm) assay 
17, 65, 66, 
67, 68, 69. The Tm assay has the advantages of not requiring purified material, being rapid and 
easy to use on multiple samples, and requiring only a few nanograms of the target 
membrane protein. The apparent Tm of a protein is defined as the temperature at which 50% 
of the ligand remains bound after a 30 minute incubation. The Tm assay has been 
successfully used to evaluate thermostabilising mutations in GPCRs, which in turn has 
allowed several crystal structures to be obtained. These include: metabotropic glutamate 
receptor 5 31, corticotropin-releasing factor receptor 28 adenosine A2A in both an R*-like state 
49 and an R state 63, neurotensin receptor 70 and 1-adrenergic 25, 52, 71, 72, 73. Given these 
advantages, the Tm assay was selected to examine the stability of AT1R. 
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The turkey (Meleagris gallopavo) 1-adrenergic receptor was shown to have an apparent Tm 
that was 22°C higher in the detergent DDM than the orthologous human protein, this was 
despite having 76% sequence identity 108. This indicates that the amino acid sequence of a 
protein governs its thermostability, which therefore can be improved by alteration of the 
protein through making point mutations or by creating a fusion protein. The addition of a 
ligand can also increase the apparent Tm of a protein 
67, 68.  
 
Three methods for performing the thermostability assay were developed. In the [-] format, 
the detergent-solubilised receptor is heated before ligand is added and in the [+] format 
ligand is added to the solubilised receptor before heating. However, not all proteins are 
sufficiently stable to be measured in these conditions. Therefore the [Super +] format was 
developed, where ligand is added to the membrane preparation and allowed to bind to the 
receptor, the receptor is then solubilised in detergent and the mixture is finally heated 
(Figure 2.1).  
 
 
Figure 2.1 Schematic of the three methods for the thermostability assay. 
Figure adapted from 68. 
 
The apparent Tm derived from the [-] format is indicative of the overall stability of the 
ligand-free receptor, whereas the apparent Tm derived from the [+] and [Super +] formats is 
1 Receptor solubilised 
from membranes 
2 Receptor-ligand 
complex present 
during the heating step
1 Receptor solubilised 
from membranes 
2 Ligand-free receptor 
present during the 
heating step
[+]
Format
[-]
Format
Heat receptor for 30 
minutes
On ice, 5 minutes
Incubate 1 hour
Separate ligand bound to receptor 
from unbound ligand
Scintillation counting of ligand bound 
to receptor
1 Receptor-ligand 
complex solubilised 
from membranes
2 Receptor-ligand 
complex present 
during the heating step
[Super +]
Format
Solubilise
Add ligand
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Heat for 30 
minutes
On ice, 5 minutes
Unpurified AT1R fusion 
protein
Unpurified AT1R fusion 
protein
Solubilise
Incubate 1 hour
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descriptive of the stability of the ligand-bound receptor 68. Assessment of the apparent Tm of 
AT1R in all formats would give a good indication of the likelihood of crystal formation and 
suggest whether more work was needed to stabilise the receptor by mutagenesis. The next 
step would then be to produce sufficient quantities of AT1R for structural studies.  
 
If the apparent Tm of AT1R was deemed to be sufficiently high, focus would then shift to 
obtaining enough correctly folded AT1R to proceed with crystallisation trials. The majority 
of GPCRs are not present from natural sources in quantities sufficient for structure 
determination 57, 58. Therefore, structural projects depend on using an overexpression system 
capable of producing increased amounts of active receptor. In theory AT1R, could be 
overexpressed in Escherichia coli (E. coli) and yeasts, but these have had limited success in 
producing sufficient amounts of mammalian membrane proteins for structural biology, most 
likely because these systems have not evolved to fold mammalian membrane proteins 59, 109, 
110. To date only one GPCR, the neurotensin receptor, expressed recombinantly in E. coli 
has resulted in a crystal structure 111, whereas GPCRs expressed in yeast have produced two 
structures, the adenosine A2A receptor 
61 and H1 histamine receptor 
112. The first GPCR 
structure from recombinant sources utilised mammalian cells 84 (Table 2.1). However the 
most widely used system for the overexpression of GPCRs is recombinant baculovirus-
infected insect cells. This system has produced recombinant GPCRs that have resulted in 
over 100 X-ray crystal structures. In a survey of 17 unique GPCR high resolution structures, 
14 used the baculovirus expression system 113. One of the highest expression levels reported 
for the baculovirus system was the production of 360 pmol of the 1AR receptor per mg of 
solubilised membrane protein 114 which lead to a 2.7 Å resolution structure 25. Expression of 
AT1R in insect cells from recombinant baculovirus was reported to produce approximately 
30 pmol of receptor per mg of total membrane protein with an apparent KD for angiotensin II 
similar to that of the native receptor 115. These promising findings were a good starting point 
for the work described here, but the published results showed insufficient characterisation to 
fully understand the behaviour of AT1R. For example, the authors did not establish whether 
unfolded protein was present. Shukla et al. 115 also expressed AT1R in BHK cells using the 
Semliki Forest virus expression system to produce 32 pmol of receptor per mg of total 
membrane protein. These results however should be treated with caution since this system 
often produces protein which is misfolded and retained in the ER 110. Further attempts at 
high level expression of AT1R using mammalian cells have been limited to amounts 
sufficient for pharmacological study. AT1R has been expressed by transient transfection in 
COS-7 cells 116 and in CHO cells by both transient transfection and the construction of a 
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stable cell line which expressed AT1R constitutively from a human cytomegalovirus (CMV) 
promoter 117. The CHO cell line that stably expressed AT1R produced 12,000 molecules of 
AT1R per cell or 0.8 g per litre, assuming 1 million cells per ml. Strachan et al. 97 created a 
stable HEK293 cell line which also expressed AT1R constitutively from a CMV promoter. It 
produced 7.1 pmol of receptor per mg of membranes. While the receptor maintained its 
pharmacological characteristics in these expression systems, none produced amounts 
sufficient for structural studies. 
 
AT1R possesses three highly conserved N-linked glycosylation consensus sequences (Asn-
X-Ser/Thr, where X is not Pro) in its extracellular segments. Asn4 is at the N-terminus of 
the receptor while Asn176 and Asn188 are in extracellular loop two (ECL2; Appendix 1). A 
consideration for structural studies is whether to produce protein without post translational 
modification or to remove this source of heterogeneity during the purification process. It is 
therefore important to understand the role of N-linked glycosylation in terms of protein 
expression and integrity. Lanctôt et al. 116 reported that an AT1R mutant lacking all N-linked 
glycosylation sites showed five times lower expression than the wild type receptor while 
retaining the same affinity for the peptide antagonist Sar1. The glycosylation-deficient 
mutant was also present at higher concentrations in the endoplasmic reticulum-golgi 
apparatus complex than in the plasma membrane. Jayadev et al. 118 reported similar findings 
with a decrease in functional expression for the glycosylation-deficient AT1R mutant. In 
addition they found that ligand-binding affinities were unaffected. This suggests that 
glycosylation of AT1R is required for efficient cell surface expression. Baculovirus-driven 
expression in insect cells is known to be inefficient at producing protein with full N-linked 
glycosylation 57, 58, whereas mammalian cell overexpression systems have been shown to be 
effective at producing complex glycosylated membrane proteins for structural studies 60. 
Recombinant membrane protein produced using the mammalian system has resulted in nine 
membrane protein structures: bovine rhodopsin 38, 84, 119, the human ammonia transporter 
RhCG 120, the human GABAA receptor 3 71, the Drosophila melanogaster dopamine 
transporter 121, the human serotonin 5-HT3 receptor 
122, the Xenopus laevis NMDA receptor 
123 and the rat AMPA receptor 124. Most of these used the combination of a strong CMV 
promoter with a tetracycline-inducible system 125 (Table 2.1). This system has an advantage 
over constitutive expression systems when expressing proteins which might be toxic to the 
cell. After optimisation the inducible mammalian expression system produced 10 mg of 
opsin, the apo-form of rhodopsin, per litre of culture, assuming 10 million cells per ml of 
culture 126. The inducible mammalian system also produced 1.0 mg/L (assuming 1.2 million 
CHAPTER 2 The Suitability of AT1R as a Candidate for Structural Studies 
 Page 23  
 
cells per ml of culture) of the rat (Rattus norvegicus) neurotensin receptor (NTS1) and cell 
surface expression of NTS1 was nearly threefold higher in mammalian than insect cells 127. 
Together these results indicate that the tetracycline-inducible mammalian system under the 
control of a strong promoter is capable of producing sufficient authentically folded 
recombinant membrane protein for structural studies.  
 
Both the mammalian and baculovirus systems were worth investigating for the 
overexpression of AT1R. The baculovirus system is more established for the overexpression 
of GPCRs; however the near-native mammalian system appears to be better at expressing 
functional proteins with complete post translational modifications (Table 2.2). 
 
Table 2.1 X-ray diffraction structures of mammalian membrane proteins determined from protein 
overexpressed in mammalian cells  
Membrane protein Source Cells used for 
protein production † 
Resolution 
of structure 
Reference 
Rhodopsin N2C/D282C Bovine COS-7 3.4 Å 84 
Ammonia transporter RhCG Human HEK293S(TetR)-
GnTI— 
2.1 Å 120 
Rhodopsin N2C/D282C/D113Q Bovine HEK293S(TetR)-
GnTI— 
3.0 Å 38 
Rhodopsin N2C/D282C/M257Y Bovine HEK293S(TetR)-
GnTI— 
3.3 Å 119 
Dopamine transporter Drosophila HEK293S-GnTI— 3.0 Å 121 
GABAA receptor 3  Human HEK293S-GnTI— 3.0 Å 71 
Serotonin 5-HT3 receptor Mouse HEK293S(TetR) 3.5 Å 122 
NMDA receptor Xenopus laevis HEK293S-GnTI— 3.7 Å 123  
AMPA receptor Rat HEK293S-GnTI— 3.5 Å 124 
† TetR indicates the use of the tetracycline inducible system. Adapted from 110. 
 
Table 2.2 Comparison of baculovirus and mammalian expression systems for the production of 
recombinant membrane proteins 
 Expression in recombinant 
baculovirus-infected insect cells 
Inducible mammalian  
expression 
System maturity Established Emerging 
Expression levels Generally high Variable 
Quick investigation None 4 days (via transient transfections) 
Initiation period 1 month (via virus generation) 2-3 months (via stable cell lines) 
Large-scale production A few days A few weeks 
Advantages  Membranes contain cholesterol 
 Some post-translationational 
modification 
o Including limited glycosylation 
 Membranes contain cholesterol 
 Full post-translationational 
modification 
o Including full glycosylation 
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2.2 Materials and Methods 
 
 Materials  
 
The radiolabeled agonist [125I]-angiotensin II and antagonist [125I]-Sar1-Ile8-angiotensin II 
(Sar1) were purchased from Perkin Elmer. Unlabelled Sar1 was purchased from Source 
Biosciences. Unlabelled angiotensin II was purchased from Tocris Biosciences. The 
detergents n-dodecyl β-D-maltopyranoside (DDM), n-decyl β-D-maltopyranoside (DM), n-
nonyl β-D-glucopyranoside (NG), n-octyl β-D-glucopyranoside (OG) and lauryl maltose 
neopentyl glycol (LMNG) were purchased from Anatrace. Digitonin was purchased from 
Calbiochem. Cholesteryl hemisuccinate (CHS), sodium dodecyl sulphate (SDS) and sodium 
butyrate were purchased from Sigma. A tetracycline-inducible HEK293 cell line, T-REx™-
293, (iHEK) was purchased from Invitrogen. A tetracycline-inducible HEK293S cell line 
lacking N-acetylglucosaminyltransferase I (iGnTI—) was kindly provided by Philip J. 
Reeves (Massachusetts Institute of Technology) 126, 128. Anti-penta-histidine antibody 
conjugated to horseradish peroxidase (anti-pentaHis-HRP) was purchased from Qiagen. 
Peptide-N-glycosidase F (PNGase F), endoglycosidase H (Endo H), DpnI and all other 
restriction enzymes were purchased from New England Biolabs. 
 
 Mammalian and baculovirus expression construct design 
 
Expression of AT1R in mammalian cells was performed using derivatives of pcDNA4/TO 
(Invitrogen). The serotonin transporter (SERT) cDNA was inserted using EcoRV/NotI, 
followed by a cassette in the NotI/ApaI sites encoding enhanced green fluorescent protein 
(GFP) 129, 130 and a decahistidine (H10) tag (plasmid pJMA111, kindly provided by Juni 
Andréll, MRC Laboratory of Molecular Biology). The cDNA clone for human AT1R was 
obtained from the Missouri S&T cDNA Resource Center (www.cdna.org), amplified by 
polymerase chain reaction, flanked with EcoRV and NotI sites and cloned into the 
corresponding sites of pJMA111 to create plasmid pJAP2, which expressed AT1R-GFP-H10. 
For generating baculoviruses, AT1R was cloned into the BamHI/EcoRI sites of the transfer 
vector pBacPAK8 (Clonetech), creating plasmid pJAP15. Additionally, AT1R was cloned 
into the BamHI/EcoRI sites in plasmid pAcGP67-B (BD Biosciences) in order to utilise the 
acidic glycoprotein gp67 signal sequence (LS) preceding the N-terminus of AT1R, creating 
plasmid pJAP16, which expressed AT1R-LS-H10. All baculovirus sequences were 
engineered to contain a C-terminal tobacco etch virus (TEV) cleavage site and H10 tag. All 
constructs were verified by DNA sequencing at Source Biosciences, UK. 
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 Mutagenesis of AT1R 
 
Mutants were generated by PCR using pJAP2 as a template and the QuikChange II 
methodology (Stratagene); however KOD hot start polymerase (Novagen) was substituted 
for PfuUltra High-Fidelity DNA Polymerase. DpnI-digested PCR mixes were transformed 
into competent E. coli strain DH5, colonies were picked and grown in 5 ml Luria Bertani 
media containing 100 g/ml ampicillin with shaking overnight at 37°C. DNA was extracted 
using a Qiagen Miniprep kit. All constructs were verified by DNA sequencing at Source 
Biosciences, UK (Table 2.3).  
 
Table 2.3 AT1R N-linked glycosylation mutants for mammalian expression 
Putative N-linked glycosylation sites (Asn-X-Ser/Thr, where X is not Pro) were identified by aligning AT1R with 
other GPCRs of known structure to determine the position of the extracellular regions (Appendix 1). Alanine was 
substituted for asparagine in order to remove the glycosylation sites. 
Plasmid name Inserts and mutation(s) Vector backbone 
pJAP2 AT1R-GFP-H10 pJMA111 (pcDNA4/TO) 
pJAP6 AT1R(N4A)-GFP-H10 pJAP2 
pJAP7 AT1R(N176A)-GFP-H10 pJAP2 
pJAP8 AT1R(N188A)-GFP-H10 pJAP2 
pJAP11 AT1R(N4A+N176A+N188A)-GFP-H10 pJAP2 
pJAP12 AT1R(N176A+N188A)-GFP-H10 pJAP2 
pJAP13 AT1R(N4A+N176A)-GFP-H10 pJAP2 
pJAP14 AT1R(N4A+N188A)-GFP-H10 pJAP2 
 
 Transient transfection, generation of stable cell lines and protein 
expression 
 
Mammalian expression plasmids for the expression of AT1R and mutants were amplified in 
E. coli strain DH5, purified using a Maxi-prep kit (Qiagen) and transiently transfected 
(GeneJuice, Novagen) into adherent mammalian iHEK cells or iGnTI— cells following the 
manufacturer’s protocol. Cells were grown in Dulbecco's modified Eagle's media 
supplemented with 10% tetracycline-free foetal bovine serum (Invitrogen) and 5 g/ml 
Blasticidin (Invitrogen) and incubated at 37°C in an atmosphere containing 5% CO2. Cells 
were passaged every 3-4 days using standard tissue culture techniques. Expression of 
plasmids was induced by addition of 1 g/ml tetracycline and incubation at 37°C for 24 h. 
Stable cell lines were generated by selection with media containing 200 g/ml Zeocin 
(Invitrogen). After expression cells were washed twice in phosphate buffered saline (PBS), 
counted using the Countess Automated Cell Counter (Invitrogen), pelleted (1,200 × g for 5 
minutes) and resuspended at 10 million cells per ml in ice cold cell buffer (50 mM Tris pH 
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7.4, 150 mM NaCl supplemented with Complete EDTA-Free Protease Inhibitor Cocktail 
(Roche)). Cell suspensions were flash frozen in liquid nitrogen and stored at -80°C. 
 
 Baculovirus generation, protein expression and cell harvest 
 
Recombinant baculoviruses that expressed AT1R-H10 and AT1R-leader sequence (LS)-H10 
were made using the BaculoGold Baculovirus Expression System according to 
manufacturer’s protocol (BD Bioscience). Viruses were isolated by plaque purification 131 
and screened for expression by western blotting using an anti-pentaHis-HRP antibody. 
Recombinant baculoviruses were passaged two times in Sf9 cells to obtain high titre stocks. 
Viruses were used to infect either Sf9, Sf21 or Hi5 cells as indicated on the figure for either 
48 hours, or the time indicated for expression optimisation assays. After protein expression, 
cells were counted using the Countess Automated Cell Counter (Invitrogen), pelleted (1,200 
× g for 5 minutes), washed twice in PBS, and the cell pellet was resuspended at 10 million 
cells per ml in ice cold cell buffer (50 mM Tris pH 7.4, 150 mM NaCl supplemented with 
Complete EDTA-Free Protease Inhibitor Cocktail (Roche). Cell suspensions were flash 
frozen in liquid nitrogen and stored at -80°C. 
 
 Western blotting and deglycosylation 
 
Cell suspensions were sonicated briefly and the total protein concentration determined using 
the Bradford method 132. Samples were solubilised in the detergent DDM at 1% (w/v) final 
concentration at 4°C for 1 hour. Sodium dodecyl sulphate (SDS)-loading buffer was added 
to the supernatant (corresponding to approximately 150,000 cells), and samples were 
separated on a 4-20% tris glycine gel (Invitrogen) and transferred to nitrocellulose using 
standard techniques. Membranes were probed with anti-pentaHis-HRP at a dilution of 
1:1,000 and developed using enhanced chemiluminescence (GE Healthcare). Where 
indicated, 2 µl of PNGase F or Endo H was added to 15 l of the supernatant and incubated 
at 37°C for 1 hour prior to SDS-PAGE to remove N-linked glycosylation. 
 
 In-gel fluorescence 
 
The protocol for western blotting was followed except the gel was visualised with the 
Typhoon TRIO variable mode imager (GE Healthcare) using standard fluorescein amidite 
settings to detect GFP fluorescence. 
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 Laser scanning confocal microscopy 
 
For live cell imaging, cells were grown on 35 mm glass bottom culture dishes under 
standard conditions and visualised on an inverted LSM 710 Laser Scanning Microscope 
(Carl Zeiss Ltd, UK) with 63× oil-immersion objective and a 1.4 numerical aperture. The 
laser was set to an excitation wavelength of 488 nm for GFP visualisation.  
 
 Flow cytometry 
 
To perform fluorescence-activated cell sorting (FACS) analysis, cells were first washed with 
PBS and then harvested in PBS and analysed on a FACSCalibur II (Becton Dickinson). To 
examine GFP fluorescence the laser was set to an excitation wavelength of 488 nm and 
10,000 events were counted for each measurement using the FL-1 detector (530 nm). 
Results were evaluated with the programme FlowJo. To exclude dead cells from the 
population, cells were stained with propidium iodide (PI) (1 g/ml final concentration) and 
analysed as for GFP fluorescence, however the FL-2 detector (585 nm) was used. Cells were 
gated based on PI uptake, size (based on forward scatter) and optical homogeneity (based on 
side scatter) to only select whole live cells (G1) (Figure 2.2). Analysis was performed on the 
G1 population. G1 cell counts were normalised with the largest cell count set as 100%; Y-
axes of normalised graphs are accordingly labelled “% of Max”. GFP expression above 
background was established by measuring the maximum fluorescence intensity of non-
transfected parental cells and calculating the percent of the G1 population that was above 
this point (cells expressing GFP (%)). 
 
A 
 
B 
 
C 
 
Figure 2.2 FACS gating based on PI staining, cell size and optical homogeneity 
Colour density plots of iHEK cells stained with PI. (A) In order to exclude dead cells from the analysis, cells 
were stained with PI and fluorescence was detected using the FL-2 detector. The most intensely fluorescent 
cells which took up PI (pink ellipse) were predominantly below 200 on the forward scatter scale. Based on this, 
cell counts of below 200 on the forward scatter scale as well as the highest counts on the forward and side 
scatter scales were excluded from the population and only live, single cells were included in the analysis (pink 
quadrilateral) (B) resulting in population G1 (C). 
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 Thermostability assay of detergent-solubilised AT1R 
 
The cell suspension containing unpurified AT1R was sonicated briefly and diluted into 
buffer (50 mM Tris pH 7.4, 5 mM MgCl2, 1 mM EDTA, 0.1% (w/v) bovine serum albumin 
(BSA), 150 mM NaCl, 40 g/ml bacitracin). For agonist binding [125I]-angiotensin II and 
unlabelled angiotensin II were added to give final concentrations of 0.5 nM and 100 nM, 
respectively. For antagonist binding [125I]-Sar1 and unlabelled Sar1 were added to give final 
concentrations of 0.5 nM and 100 nM, respectively. AT1R present in the membrane was 
incubated for 1 hour at room temperature with either agonist or antagonist before chilling on 
ice and solubilising in 1% (w/v, final concentration) DDM, DM, NG, OG or 1% DDM with 
0.1% CHS as indicated for the [+] assay format. The samples were then heated at varying 
temperatures for 30 minutes and the [125I]-Sar1-bound receptor was separated from the free 
radioligand by gel filtration spin columns as described previously 67, 68, 69. For the [-] assay 
format, the cell suspension was solubilised in 1% (w/v, final concentration) DDM, LMNG, 
digitonin or 1% DDM with 0.1% CHS as indicated for 1 hour on ice before heating and 
adding ligand for 1 hour on ice. Background was determined by adding radioligand to non-
transfected parental mammalian cells or uninfected insect cells. Results were evaluated by 
nonlinear regression using GraphPad Prism. 
 
 Detergent-solubilised radioligand binding assays  
 
Cell suspensions were sonicated briefly and the total protein concentration determined using 
the Bradford method 132. Cells were diluted into buffer (150 mM NaCl, 50 mM Tris pH 7.4) 
and incubated with [125I]-Sar1 at the same concentration as for the Tm assay (1 h, 4°C), and 
then solubilised in a final concentration of 1% (w/v) DDM for 1 hour at 4°C. Bound and free 
radioligand were separated on gel filtration spin columns as per section 2.2.10. 
 
 Fluorescence-detection size exclusion chromatography and size 
exclusion chromatography detected by western blotting 
 
The void volume (8.16 ml) of the Superdex 200 10/300 (24 ml) (GE healthcare) was 
determined by running blue dextran through the column and observing where it eluted using 
A280. For fluorescence-detection size exclusion chromatography (FSEC), approximately 5 
million iHEK(AT1R-GFP-H10) cells were thawed on ice and sonicated briefly. Cells were 
incubated at room temperature for 1 hour with 40 nM Sar1 before chilling on ice and 
solubilising in 1% DDM (w/v, final concentration) followed by centrifugation at 280,000 × 
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g for 30 minutes at 4°C. The supernatant was then passed through a 0.22 m filter and 
injected onto a Superdex 200 10/300 column pre-equilibrated with running buffer (0.03% 
(w/v) DDM, 50 mM Tris pH 7.4, 150 mM NaCl and 1M Sar1). The fluorescence of eluent 
was detected by a Hitachi fluorometer (mV) set to an excitation of 488 nm and emission of 
525 nm. To detect AT1R-H10 produced in Sf9 cells, approximately 5 million cells were 
sonicated, incubated with ligand, solubilised and centrifuged as above. The eluent was 
detected by western blotting (Section 2.2.6) and bands corresponding to AT1R-H10 were 
quantified using ImageJ. 
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2.3 Results 
 
 Apparent thermostability of AT1R in detergent 
 
The apparent Tm of a protein is good indicator of the likelihood of the protein to form 
crystals in short chain detergents by vapour diffusion. For this reason, the apparent Tm was 
the first parameter considered in assessing the suitability of AT1R as a candidate for 
structural studies. To measure the apparent Tm of AT1R, it was expressed from the plasmid 
pJAP2 (expressing AT1R-GFP-H10) in the tetracycline-inducible cell line HEK293 (iHEK). 
Detergent-solubilised AT1R-GFP-H10 was assayed for its thermostability with the peptide 
agonist [125I]-angiotensin II and with the peptide antagonist [125I]-Sar1. Additionally, two 
different assay methods were used to test thermostability. In the [Super +] condition, the 
agonist angiotensin II or antagonist Sar1 was added to AT1R present in the membrane and 
allowed to bind for 1 hour before the receptor-ligand complex was solubilised in detergent; 
after heating for 30 minutes, the amount of ligand-bound receptor was determined. In the [-] 
condition, AT1R was first solubilised in detergent, then heated in the absence of ligand for 
30 minutes; radioligand was then added, allowed to bind, and the amount of ligand-bound 
receptor was determined. 
  
The thermostability of AT1R was first tested in the [-] format using [
125I]-Sar1, but no 
binding was detected after solubilising with either the detergent DDM alone or DDM with 
CHS (Figure 2.3 and Table 2.4). Consequently a sigmoidal dose response curve could not be 
fitted for these conditions. Although the detergent digitonin appeared to give the highest 
apparent Tm for the ligand-free condition, only a small proportion of AT1R was solubilised 
in a functional form and therefore digitonin was not a good choice of detergent. LMNG was 
the only detergent condition that gave a reliable apparent Tm of 25.3C ± 0.3 (n=3) and with 
a disintegrations per minute (dpm) count that was well above background in the [-] format. 
This suggests that AT1R is unstable in the absence of ligand and therefore subsequent assays 
were performed in the [Super +] format. Angiotensin II-bound AT1R had a low apparent Tm 
of 23.4C ± 1.5 (n=3) in the mild detergent DDM and also the amount of functional receptor 
was very low. In contrast Sar1-bound AT1R was shown to be more thermostable with an 
apparent Tm of 46.5C ± 0.3 (n=4) in DDM and 31.8C ± 0.3 (n=4) in the harsher detergent 
OG. In both detergents there was a similar amount of functional receptor with the antagonist 
bound. Unlike many receptors, CHS in combination with DDM gave a lower apparent Tm of 
26.3C ± 0.5 (n=3) than DDM alone, suggesting that CHS destabilised the receptor. Two 
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conclusions were drawn from the thermostability data. First, the large discrepancy in 
apparent Tm between the [Super +] and [-] format assays suggested that binding of the 
peptide antagonist Sar1 significantly enhances the stability of AT1R. Secondly, the apparent 
Tm of OG solubilised AT1R bound to the peptide antagonist Sar
1 was remarkably high for a 
GPCR and it was plausible that it could be purified and crystallised under these conditions, 
or crystallised in lipidic cubic phase (LCP). Therefore the next step was to determine the 
best expression system and the first step in this process was to determine the impact of N-
linked glycosylation on AT1R expression. 
 
 The role of N-linked glycosylation on AT1R expression and stability 
 
Since antagonist-bound AT1R was found to be thermostable with an apparent Tm of 46.5C 
in DDM the next step was to find a suitable expression system to produce enough 
recombinant protein for structural studies. AT1R has three putative N-linked glycosylation 
sites at Asn4, Asn176 and Asn188 (Appendix 1). N-linked glycosylation can be required for 
the expression and stability of a protein and therefore this can potentially limit the choice of 
expression system. Additionally, N-linked glycosylation causes heterogeneity in a protein, 
which reduces the likelihood of crystallisation, and therefore the ideal construct for the 
overexpression of AT1R would eliminate this. Before removal of N-linked glycosylation on 
AT1R could be achieved, the impact of N-linked glycosylation on trafficking to the cell 
surface, levels of expression and stability needed to be determined. To facilitate this 
investigation, three mutations were introduced to the putative N-linked glycosylation sites of 
AT1R-GFP-H10 (Table 2.3). The effects of these mutations were assessed by confocal 
microscopy, in-gel fluorescence, digestion with glycosidases and radioactive ligand binding 
assays. To ascertain whether AT1R was a glycoprotein when expressed in mammalian cells, 
two different enzymes, Endo H and PNGase F were tested for their ability to remove N-
glycans. AT1R-GFP-H10 was expressed by transient transfection in two mammalian cell 
lines, iHEK and a derivative cell line, which lacks N-acetylglucosaminyltransferase I 
activity (GnTI—) and expresses homogeneous N-glycans comprised of only seven sugars 
(Man5GlcNAc2) 
126, 128. As shown in the gel in Figure 2.4, two forms of N-linked 
glycosylated AT1R exist in the HEK cells, AT1R modified with high mannose N-glycans 
(Endo H sensitive) and AT1R modified with complex N-glycans (Endo H resistant and 
PNGase F sensitive). The iGnTI— cells produced only the high mannose form of AT1R. 
Both cell lines produced similar amounts of AT1R polypeptide and unglycosylated AT1R 
was not observed. 
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Figure 2.3 Thermostability of AT1R in detergent 
AT1R was expressed from plasmid pJAP2 in the mammalian cell line iHEK (expression of AT1R-GFP-H10) and 
induced for 24 hours with 1 g/ml tetracycline prior to being assayed. Graphs on the left side had the amount of 
specifically bound radioligand normalised to 100% at 4°C and 0% at 80°C to allow for comparison of the slopes 
of the curves. Graphs on the right are in dpm to emphasise differences in the total amount of functional 
detergent-solubilised AT1R. (A) Stability curve of Sar1-bound AT1R in the [-] condition with several detergents; 
LMNG (blue triangles), digitonin (green diamonds), DDM with CHS (yellow squares) and DDM (red circles). 
Dotted lines indicate that a sigmoidal dose response curve could not be accurately fitted. The results are from a 
single experiment performed in triplicate and plotted as a mean value ± SEM. (B) The stability of AT1R was 
measured in the [Super +] condition with the antagonist Sar1 (blue triangles) or agonist angiotensin II (red 
circles) bound. The results are from a single experiment performed in triplicate and plotted as a mean value ± 
SEM. (C) Stability curve of Sar1-bound AT1R in the [Super +] condition with several detergents; DM (blue 
triangles), DDM (green diamonds), OG (yellow squares) and NG (red circles). Results are from two independent 
experiments performed in duplicate and plotted as a mean value ± SEM. (D) Stability curve of Sar1-bound AT1R 
in the [Super +] condition; DDM (yellow squares) and DDM with CHS (black hexagons). The results are from a 
single experiment performed in triplicate and plotted as a mean value ± SEM. Results for all figures are 
summarised in Table 2.4. 
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Table 2.4 Apparent thermostability of AT1R under different assay conditions 
Ligand Assay format Detergent (w/v) Tm (C) SEM 
Sar1 [-] 1% LMNG 25.3 0.3 
Sar1 [-] 1% digitonin 29.5 † 1.3 
Sar1 [-] 1% DDM, 0.1% CHS Unable to fit curve — 
Sar1 [-] 1% DDM Unable to fit curve — 
Angiotensin II [Super +] 1% DDM 23.4 1.5 
Sar1 [Super +] 1% DDM 46.5 0.3 
Sar1 [Super +] 1% DM 36.4 1.0 
Sar1 [Super +] 1% NG 30.6 0.5 
Sar1 [Super +] 1% OG 31.8 0.3 
Sar1 [Super +] 1% DDM, 0.1% CHS 26.3 0.5 
† Digitonin has the highest apparent Tm for the [-] condition, however it had significantly lower amounts of 
functional detergent-solubilised AT1R in comparison to LMNG. 
 
These data indicate that AT1R is indeed heavily glycosylated and therefore attempts were 
made to reduce this by mutating the consensus N-glycosylation sequence from Asn-X-
Ser/Thr to Ala-X-Ser/Thr. In-gel fluorescence of an SDS-PAGE gel loaded with an equal 
amount of cells in each lane showed that the single mutations N176A and N188A appeared 
to give reasonable expression of AT1R but the N4A mutations significantly decreased 
expression levels. No AT1R was detected when all three N-linked glycosylation sites were 
mutated. Further experiments were therefore performed where combinations of two N-
glycosylation sites were mutated and analysed by confocal microscopy and ligand binding 
assays. The confocal microscopy data showed that any single deletion of an N-linked 
glycosylation site did not significantly impair trafficking to the cell surface (Figure 2.5). In 
contrast, of all the possible combinations of double mutants tested, only N4A+N188A and 
N4A+N176A gave significant amounts of cell surface expression, whereas the 
N176+N188A AT1R mutant was expressed predominantly within intracellular membranes. 
The triple mutant was also expressed mainly intracellularly. Transfected cells expressing 
either wild-type AT1R or one of the N-glycosylation mutants grew well, with the exceptions 
of the N176+N188A mutant and the triple mutant, both of which produced round detached 
cells in the confocal images. The double mutants N4A+N188A and N176A+N188A as well 
as the triple mutant had fewer cells positive for GFP expression in comparison to the wild 
type receptor and the other glycosylation mutants. It is difficult to ascertain expression 
levels from confocal images, so therefore the amount of DDM-solubilised AT1R mutants 
was determined using the [Super +] format assay described in section 2.2.11. 
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AT1R-GFP-H10 AT1R-GFP-H10 N-linked glycosylation mutations 
Figure 2.4 In-gel fluorescence analysis of N-linked glycosylation site mutations in AT1R 
Plasmid pJAP2 (expressing AT1R-GFP-H10) and N-glycosylation mutants of AT1R (Table 2.3) were transiently 
transfected into iHEK or iGnTI— cells and induced for 24 hours with 1 g/ml tetracycline for 24 hours prior to 
being assayed by SDS-PAGE and visualised by in-gel fluorescence. Removal of N-linked glycosylation was 
achieved by treatment of cell samples with either Endo H (+H), PNGase F (+F) or no enzyme (-). The different 
glycosylated forms of AT1R are indicated; complex N-glycans (CO), high mannose core N-glycans (HM) and 
unglycosylated (UG). An equal amount of cells was loaded in each lane. 
 
The radioligand binding assays showed that only three combinations of mutations gave 
expression levels similar to AT1R with all three N-glycosylation sites intact (Figure 2.6). 
Mutations of either Asn176 or Asn188 did not significantly decrease expression levels. In 
contrast N4A gave a seven-fold reduction in expression, but surprisingly, combinations of 
the mutations N4A and N188A gave a 70% increase in expression levels. All other 
combinations of mutations reduced expression levels relative to the fully N-glycosylated 
receptor with the lowest expression levels observed for the double mutant N4A+N176A and 
the triple mutant. Another important consideration is the stability of each of these mutants. 
The stability was tested for all of the mutants in a two-point thermostability assay (Figure 
2.6) and it appeared that removal of the N-glycosylation sites did not greatly affect stability 
for the N188A mutant or the double mutant N4A+N188A. The mutant N176A+N188A 
showed a slight decrease in stability, whereas the measurement for the mutant N176A had a 
large error and should be treated with caution. The lack of results for the other mutants 
containing the N4A mutation suggests that they did not express well in a functional form. 
 
In conclusion, these data suggest that the only mutant that may be worth considering for 
further structural studies is the N4A+N188A mutant, but this still indicates that expression 
of an N-glycosylated version of AT1R needed to be explored. This meant pursuing 
expression in either the baculovirus expression system or in mammalian cells. 
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Figure 2.5 Confocal microscopy analysis of N-linked glycosylation site mutations in AT1R 
Plasmid pJAP2 (expressing AT1R-GFP-H10) and N-glycosylation mutants of AT1R (Table 2.3) were transiently 
transfected into iHEK cells and induced for 24 hours with 1 g/ml tetracycline for 24 hours prior to being 
assayed. Confocal micrographs of iHEK cells expressing mutated forms of AT1R. Mutations of AT1R are 
indicated below each image. The gain and offset of the laser were set to be equal for all images. Scale bar 
represents 20 m. Non-transfected parental cells showed no fluorescence (data not shown).  
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Figure 2.6 Ligand binding analysis of N-linked glycosylation site mutations in AT1R 
Plasmid pJAP2 (expressing AT1R-GFP-H10) and N-glycosylation mutants of AT1R (Table 2.3) were transiently 
transfected into iHEK cells and induced for 24 hours with 1 g/ml tetracycline for 24 hours prior to being 
assayed. Antagonist [125I]-Sar1 binding was carried out on AT1R N-glycosylation mutants at 4°C (blue bars) and 
46.5°C (red bars). From these data, the percent of active AT1R remaining at 46.5°C was calculated (green 
bars). The results are from a single experiment performed in triplicate and plotted as a mean value ± SEM. 
 
 Baculovirus-mediated expression of AT1R in insect cells 
 
From the data presented here the extent of the role of N-linked glycosylation in determining 
the thermostability of AT1R is not clear, however it does affect expression levels. Given this, 
the choice of expression systems for the production of recombinant AT1R focused on two 
systems, baculovirus mediated expression in insect cells and mammalian expression using 
the iHEK cell line. Baculovirus mediated expression of recombinant GPCRs in insect cells 
has been utilised many times for the production of protein for crystallography, which has 
resulted in over a hundred GPCR structures. Given the success of this system, recombinant 
baculovirus expressing AT1R from the polyhedrin promoter were constructed. 
 
Two baculoviruses that expressed AT1R were created using the Baculo Gold method, 
referred to as bvAT1R-H10 and bvAT1R-LS-H10. The difference between the two AT1R 
constructs was that the leader sequence for acidic glycoprotein 67 from Autographa 
californica was inserted at the N-terminus of AT1R to make AT1R-LS-H10, since leader 
sequences have been shown to improve expression levels 58. To optimise expression three 
cell lines were tested (Sf9, Sf21 and Hi5) and cell samples were analysed at 24 hour 
intervals over 96 hours post infection. The presence of bvAT1R-H10 or bvAT1R-LS-H10 was 
detected by western blotting (Figure 2.7). Samples were deglycosylated using the enzyme 
Endo H and the amounts of glycosylated and unglycosylated AT1R were quantified using 
ImageJ (Figure 2.8). All conditions tested from 48 hours onwards showed the presence of a 
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large amount of unglycosylated AT1R, but only small amounts were observed at 24 hours 
post infection for bvAT1R-LS-H10 expressed in Sf9 cells. The expression levels of AT1R 
produced from either bvAT1R-H10 or bv-AT1R-LS-H10 in the three insect cell lines (Sf9, 
Sf21 and Hi5) were quantified by using the [Super +] assay format and measuring binding of 
the antagonist [125I]-Sar1 to DDM-solubilised AT1R (Figure 2.9). The best condition for 
expressing AT1R in insect cells was Hi5 cells infected with bvAT1R-LS-H10 for 48 hours. 
This produced approximately 1.8 million molecules of AT1R per cell (n=6), which, 
assuming 1 million cells per ml of culture, equates to 0.1 mg of AT1R per litre. Further 
analyses are presented in Section 2.3.5 where baculovirus expression is compared to 
mammalian expression. Given that glycosylation was shown to be important for cell surface 
expression, mammalian expression was also investigated since this system is able to achieve 
near native post translational modification. 
 
A 
 
  
B 
 
Figure 2.7 Optimisation of bvAT1R-H10 and bvAT1R-LS-H10 expressed in Sf9 cells 
Western blot of proteins from whole Sf9 cells expressing (A) bvAT1R-H10 or (B) bvAT1R-LS-H10. The blot was 
probed with an anti-pentaHis-HRP conjugated antibody. N-linked glycosylation was removed using Endo H 
where indicated (+). The high manose form of AT1R (HM), unglycosylated (UG) and putative degradation 
products (D) are indicated. Bands corresponding to HM and UG forms of AT1R were quantified using Image J 
(Figure 2.8). This assay was repeated for each cell line (Sf9, Sf21 and Hi5) and for each virus (bvAT1R-H10 and 
bvAT1R-LS-H10); Appendix 2. 
Endo H
kDa
U
n
in
fe
c
te
d
2
4
 h
o
u
rs
4
8
 h
o
u
rs
7
2
 h
o
u
rs
9
6
 h
o
u
rs
- + - + - + - + - +
64
250
148
98
50
36
22
16
UG
HM
D
Endo H
36
50
64
98
148
250
22
16
kDa
U
n
in
fe
c
te
d
2
4
 h
o
u
rs
4
8
 h
o
u
rs
7
2
 h
o
u
rs
9
6
 h
o
u
rs
- + - + - + - + - +
HM
UG
D
CHAPTER 2 The Suitability of AT1R as a Candidate for Structural Studies 
 Page 38  
 
 
Figure 2.8 Glycosylation of AT1R across four insect cell lines 
AT1R was expressed from recombinant baculoviruses bvAT1R-H10 or bvAT1R-LS-H10 in three insect cell lines 
(Sf9, Sf21 and Hi5) over 96 hours and analysed by western blotting. Bands on the western blot were quantified 
using ImageJ and correspond to either the high manose, glycosylated form of AT1R (blue bars) or 
unglycosylated AT1R (red bars). Western blot data are shown in Figure 2.7 and Appendix 2. 
 
 
 
Figure 2.9 Expression of AT1R in three insect cell lines 
AT1R was expressed from either the virus bvAT1R-H10 or bvAT1R-LS-H10 and used to infect the insect cell line 
indicated (Sf9, Sf21 or Hi5). Cells were harvested 48 hours post infection. The amount of functional AT1R in 
each insect cell line was determined by measuring specific binding of the antagonist [125I]-Sar1. After the 
addition of ligand, membranes were solubilised in DDM and non-bound ligand was separated from receptor-
ligand complex on gel filtration spin columns and measured by liquid scintillation counting. Each data point was 
determined in triplicate from two independent experiments and was plotted as mean ± SEM. 
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 Mammalian expression of AT1R  
 
Given the low levels of N-linked glycosylation of AT1R observed in insect cells, 
mammalian cell expression systems were investigated further, because they produce mostly 
proteins with full post translational modification. The mammalian expression plasmid 
pJAP2, based on pcDNA4/TO, was created to express AT1R-GFP-H10 under the control of a 
tetracycline-inducible CMV promoter. Transient transfection of plasmid pJAP2 into iHEK 
cells and induction with tetracycline gave low levels of expression of AT1R-GFP-H10, 
therefore a polyclonal cell line stably expressing AT1R was created. 24 hours post 
transfection, the cells were split into six populations containing 50 thousand to 500 thousand 
cells per well in a 6-well plate. Cells with a stable incorporation of plasmid pJAP2 were 
selected by adding Zeocin to the culture media, grown for 4-6 weeks until confluent in the 6-
well plate, then passaged twice before a subset was induced with tetracycline and screened 
for GFP expression by FACS analysis (Section 2.2.4). The most highly expressing 
polyclonal cell line, iHEK(AT1R-GFP-H10), showed a dramatic increase in expression of 
AT1R-GFP-H10 in comparison to transient transfection of plasmid pJAP2 and it produced 
high levels of AT1R-GFP-H10 even after the cells were passaged for 64 days (Figure 2.10). 
Confocal microscopy indicated that AT1R-GFP-H10 in the polyclonal cell line iHEK(AT1R-
GFP-H10) was expressed homogenously on the cell surface in comparison to transient 
transfection of plasmid pJAP2 (Figure 2.10). A 96-hour expression test of iHEK(AT1R-
GFP-H10) showed that the majority of AT1R was glycosylated (Figure 2.11) unlike the 
results seen for insect cells (Figure 2.8). Attempts to increase expression of AT1R in the 
stable cell line iHEK(AT1R-GFP-H10) by lengthening the induction time and the addition of 
agonist and antagonist ligands were not successful (Figure 2.12). However adding 5 mM 
sodium butyrate to the culture at the time of induction had a dramatic impact on expression 
levels as measured by FACS (Figure 2.12). This led to an increase in the elution of AT1R-
GFP-H10 from a size exclusion column, indicating that the protein remained correctly 
folded. However further increasing the amount of sodium butyrate in culture caused cell 
death, therefore 5 mM was selected to achieve a balance between increased expression and 
the health of cells. 
 
The majority of AT1R produced in the mammalian system was glycosylated. Expression in 
the mammalian system could be increased through creation of a stable cell line as well as 
including sodium butyrate in the media at the time of induction. A direct comparison of the 
amounts of functional AT1R between insect and mammalian systems was therefore required. 
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iHEK(AT1R-GFP-H10) 
Figure 2.10 Increased expression of AT1R-GFP-H10 in a stable cell line compared to transient 
transfection 
A stable cell line that expressed AT1R-GFP-H10 was created by selection for the integration of plasmid pJAP2 
into the genome of iHEK cells with Zeocin. For FACS analysis cells were harvested in PBS and analysed on the 
FACSCalibur II for GFP fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). 
(A) FACS analysis of iHEK cells. Non-transfected iHEK parental cells (red, median fluorescence 1.73), transient 
transfection of plasmid pJAP2 (expressing AT1R-GFP-H10) into iHEK cells and induced for 24 hours (green, 
median fluorescence 2.53) and stable polyclonal cell line iHEK(AT1R-GFP-H10) induced for 24 hours (blue, 
median fluorescence 267). (B) The expression levels of AT1R-GFP-H10 were compared in cells grown 
continuously for 64 days (blue line, median fluorescence 319) and freshly thawed cells (red line, median 
fluorescence 250). Both cell lines were induced for 24 hours with tetracycline before FACS analysis. (C) 
Confocal micrograph of AT1R-GFP-H10 expressed by transient transfection of plasmid pJAP2 into HEK cells and 
(D) the stable cell line iHEK(AT1R-GFP-H10). The laser was not set to be equal for both images. The scale bar 
represents 20 m. Cells were induced for 24 hours with tetracycline prior to imaging. 
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Figure 2.11 N-linked glycosylation of AT1R in a stable mammalian cell line 
(A) AT1R was expressed from the stable cell line iHEK(AT1R-GFP-H10) over 96 hours and analysed by western 
blotting. The blot was probed with an anti-pentaHis-HRP conjugated antibody. The different glycosylated forms 
of AT1R are indicated; complex N-glycans (CO), high mannose core N-glycans (HM) and unglycosylated (UG). 
Removal of N-linked glycosylation was achieved by treatment of cell samples with PNGase F (+F). A 
nonspecific band (NS) is indicated. An equal amount of cells was loaded in each lane. (B) Bands on the western 
blot from the expression assay corresponding to the complex glycosylated form of AT1R (blue bars) and 
unglycosylated AT1R (red bars, not visible for 48 and 96 hours) were quantified using ImageJ.  
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Figure 2.12 Optimisation of AT1R expression from the stable polyclonal cell line iHEK(AT1R-GFP-H10) 
(A) FACS analysis of GFP expression in the stable cell line iHEK(AT1R-GFP-H10) induced for 24 hours (red line, 
median fluorescence 250) and 48 hours (blue line, median fluorescence 319). (B) Induction of expression with 
ligands was tested; uninduced iHEK(AT1R-GFP-H10), (yellow line; median fluorescence 8); induction of 
iHEK(AT1R-GFP-H10) with tetracycline only, (blue line; median fluorescence 274); induction of iHEK(AT1R-GFP-
H10) with tetracycline and 1 M Sar1, (green line; median fluorescence 269); induction of iHEK(AT1R-GFP-H10) 
with tetracycline and 1 M angiotensin II, (red line; median fluorescence 271). (C) FACS analysis of GFP 
expression in the stable cell line iHEK(AT1R-GFP-H10) induced for 24 hours with either tetracycline (red line) or 
with tetracycline and 15 mM Na butyrate (blue line). (D) Median FACS fluorescence intensities are shown in the 
bar graph. (E) FSEC analysis of AT1R-GFP-H10. The cell line iHEK(AT1R-GFP-H10) was induced with 
tetracycline and the amount of Na butyrate indicated for 24 hours; tetracycline only (red), 1 mM Na butyrate 
(purple), 5 mM Na butyrate (yellow), 10 mM Na butyrate (green) and 15 mM Na butyrate (blue). 40 nM of Sar1 
was added to 5 million cells and allowed to bind for 1 hour at 23°C before being solubilised in 1% DDM. The 
elution of iHEK(AT1R-GFP-H10) was detected using GFP fluorescence (mV). The void (Vo) and total column 
volumes (VT) are indicated. 
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 Advantages of mammalian cell expression of AT1R compared 
baculovirus-mediated expression of AT1R in insect cells 
 
In order to determine the best overexpression system for AT1R, it was expressed in three 
different systems: baculovirus-mediated expression in insect cells (bvAT1R-H10) and 
expression in mammalian cells by either transient transfection of plasmid pJAP2 into iHEK 
cells or by the creation of the stable cell line iHEK(AT1R-GFP-H10). The apparent Tm of 
Sar1-bound AT1R solubilised in DDM produced from the three different systems was 
determined (Figure 2.13). The apparent Tm found in each case was similar within 
experimental error and the mean across the three systems was 46.6°C ± 0.6 (n=3). This 
suggested that the biophysical properties of AT1R expressed in all three systems were the 
same. 
 
Figure 2.13 Stability of DDM-solubilised AT1R expressed in three different systems bound to the 
antagonist [125I]-Sar1  
AT1R was expressed using three different expression systems: baculovirus bvAT1R-H10 in Sf9 cells (blue 
circles), transient transfection of plasmid pJAP2 into iHEK cells (expression of AT1R-GFP-H10) (green squares), 
stable clonal cell line iHEK(AT1R-GFP-H10) (red diamonds). The apparent Tm values of AT1R expressed in each 
system are: Sf9 cells, 46.4°C ± 0.8 (n=3); iHEK transient transfection, 47.7°C ± 0.5 (n=3); iHEK(AT1R-GFP-H10), 
45.7°C ± 0.7 (n=3). Each data point was determined in triplicate and was plotted as a mean value ± SEM. 
 
Quantification of the functional expression levels of AT1R produced in either mammalian or 
insect cells was performed using the [Super +] assay format and measuring binding of the 
antagonist [125I]-Sar1 to DDM-solubilised AT1R. There was a fivefold increase in functional 
expression of AT1R in the iHEK(AT1R-GFP-H10) cell line compared to the best expression 
in insect cells (Figure 2.14). The stable mammalian cell line produced 9.1 million molecules 
of AT1R per cell (n=6), which assuming 1 million cells per ml of culture equates to 0.6 mg 
of AT1R per litre. The best condition for expression in insect cells, Hi5 cells infected with 
bvAT1R-H10 for 48 hours, produced 1.8 million molecules of AT1R per cell (n=6), which 
equates to 0.1 mg of AT1R per litre. 
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Another important factor in choosing which expression system to use was the production of 
misfolded receptor which needs to be minimised. A western blot containing equal amounts 
of active material showed that there was a large amount of DDM-solubilised misfolded 
AT1R produced by the baculovirus system (Figure 2.15). However, when AT1R was 
solubilised and analysed by size exclusion chromatography (SEC), both the insect cell and 
mammalian cell systems produced AT1R of a similar size and homogeneity indicating that 
most of the unfolded AT1R in the insect system is removed during solubilisation, 
centrifugation and passage through the column pre-filter and the SEC resin (Figure 2.16). 
  
 
Figure 2.14 Five-fold higher functional expression of AT1R in mammalian cells compared to insect cells 
The amount of functional AT1R in each expression system was determined by measuring specific binding of the 
antagonist [125I]-Sar1. Mammalian expression was from the polyclonal cell line iHEK(AT1R-GFP-H10) (blue bar). 
Baculoviral expression was performed either in Sf9, Sf21 or Hi5 cells (red bars). After the addition of ligand, 
membranes were solubilised in DDM and non-bound ligand was separated from receptor-ligand complex on gel 
filtration spin columns and measured by liquid scintillation counting. Each data point was determined in triplicate 
from two independent experiments and was plotted as mean ± SEM. 
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Figure 2.15 DDM solubilises considerable amounts of inactive AT1R produced in the baculovirus 
expression system  
Western blot of DDM-solubilised AT1R, with equal amounts of active receptor per sample (lanes 2, 3, 5-10). The 
blot was probed with an anti-pentaHis-HRP conjugated antibody. Lane 1, iHEK parental cells; lanes 2 and 3, 
iHEK(AT1R-GFP-H10) stable clonal cell line (Chapter 3); lane 4, uninfected Sf9 cells; lanes 5-10, bvAT1R-H10 
infected insect cells. N-linked glycosylation was removed using PNGase F where indicated (+). AT1R was 
expressed either in the stable mammalian cell line iHEK(AT1R-GFP-H10) or by using the recombinant 
baculoviruses bvAT1R-H10 and bvAT1R-LS-H10 to infect Sf9, Sf21 and Hi5 cells as indicated. iHEK cell lines 
were induced with 1 g/ml tetracycline for 24 hours and insect cells were infected with recombinant baculovirus 
for 48 hours. The amount of functional AT1R was determined by measuring specific binding of the antagonist 
[125I]-Sar1 (Figure 2.14). 
 
 
Figure 2.16 Size exclusion chromatography of AT1R expressed in mammalian cells compared to insect 
cells 
Size exclusion chromatography was carried out using a Superdex 200 10/300 (24 ml) column. The elution of 
iHEK(AT1R-GFP-H10) was detected using GFP fluorescence (mV). The elution of bvAT1R-H10 was detected by 
western blotting and band quantification (ImageJ value). See Appendix 2 for western blot. iHEK(AT1R-GFP-H10) 
shows a symmetrical peak whereas bvAT1R-H10 shows two peaks however both systems show elution of a 
protein of a similar size and homogeneity. The void (Vo) and total column volumes (VT) are indicated.  
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2.4 Discussion 
 
Stability is an important factor for indicating the ability of membrane proteins to form 
crystals 133, 134, 135, 136, however there is no specific level of stability above which 
crystallisation is guaranteed. Several methods have been devised to measure stability and it 
is not always easy to compare the data since the techniques measure stability in different 
ways. A prevalent method for measuring stability is the CPM assay which utilises a thiol 
specific dye 105. When measured using the CPM assay, the nociception opioid peptide 
receptor (NOP) had an apparent Tm of 57°C in DDM and 69°C in DDM with CHS 
104. NOP 
was successfully crystallised in DDM with CHS resulting in a 3.0 Å structure, however 
apocytochrome b562RIL (BRIL) was fused to the N-terminus 
137, which might have raised 
the apparent Tm, but this was not recorded. Using the CPM assay on an A2A-T4 lysozyme 
fusion protein, which was bound to each of five different ligands, demonstrated that only the 
ligand with the highest apparent Tm resulted in a crystal structure (ZM 241385; 62°C) 
16. 
Another method for measuring thermostability is the radioactive ligand-bound apparent Tm 
assay. Using this assay, partly purified A2AR-GL26 solubilised in DM had an apparent Tm of 
44.5°C 67. Removal of an N-linked glycosylation site produced A2AR-GL31 which was 
crystallised in octylthioglucoside (Tm of 31°C) and resulted in a 3.0 Å resolution structure 
bound to adenosine and a 2.6 Å resolution structure bound to NECA 49. It is difficult to 
compare the stability of A2A between both assays because it was measured in different 
detergents and utilised different techniques. However both methods have been successfully 
employed to evaluate conditions which produced high resolution structures.  
 
For structure determination of AT1R to proceed the receptor needs to be sufficiently 
thermostable. The radioactive ligand-bound apparent Tm assay was chosen to measure the 
stability of AT1R since it has become a key parameter in GPCR structure determination and 
can be used on unpurified material. The apparent Tm of AT1R was first measured in the [-] 
format assay, where the detergent-solubilised receptor is heated before ligand is added. The 
only detergent condition that gave a reliable apparent Tm in the [-] format was LMNG 
(25.3°C). The instability of AT1R in the [-] format assay was indicated by the fact that no 
binding in DDM was observed coupled with the low apparent Tm in LMNG. Two other 
membrane proteins also shown to be unstable without ligand bound are a GPCR, A2AR-
GL26 67 and a transporter, rat (Rattus norvegicus) serotonin transporter (SERT) 65. Both of 
these membrane proteins had to be assayed using the [Super +] format apparent Tm assay, 
where ligand is added prior to solubilisation. Given that AT1R was unstable in the [-] format 
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assay all further assays were performed using the [Super +] format. Using this format the 
apparent thermostability of antagonist-bound AT1R was shown to be remarkably high in all 
detergents tested. In the mild detergent DDM the apparent Tm of AT1R was 0.5C higher 
than a thermostabilised version of DDM-solubilised SERT (SAH6) 65, which has resulted in 
crystals (Andréll, Edwards and Tate; unpublished). Additionally, the apparent Tm for A2AR-
GL26 solubilised in OG was 1.3°C less than the one obtained for AT1R in the same 
detergent. What this high apparent Tm showed is that antagonist-bound AT1R was a good 
candidate for structure determination by X-ray crystallography in its native form. 
Additionally, several GPCRs, which are presumed to have low stability, have been 
crystallised using alternative techniques. For example, 2AR was crystallised with 
bacteriophage T4 lysozyme (T4L) inserted into cellular loop 3 (CL3) and produced a 2.4 Å 
resolution structure 24, 41. The 2AR-T4L fusion was more resistant to proteases than the 
native receptor but its thermostability was not directly measured. If AT1R does not 
crystallise in its native form then alternatively a fusion of T4L into CL3 of AT1R might 
provide a path to crystallisation. 
 
Glycosylation can impart flexibility and heterogeneity to a protein 138; therefore it was 
important to examine the role of N-linked glycosylation in the expression and stability of 
AT1R and to establish whether the receptor could be expressed devoid of any glycosylation. 
Enzymatic deglycosylation of AT1R directly demonstrated the attachment of N-linked 
glycans to the receptor produced from both insect and mammalian systems. The 
glycosylation deficient iGnTI— cell line produced AT1R with only the core Man5GlcNAc2 in 
comparison to the heterogeneous glycosylation seen in the iHEK cell line. The iGnTI— cell 
line not only produced more homogeneous glycosylation, but it allowed different options 
during crystallisation. Complex glycosylation in iHEK cells must be removed with PNgase 
F which causes the Asn linked to the GlcNAc to be converted to Asp 138. In contrast the 
glycosylation produced in iGnTI— cells can be removed with either PNGase F or Endo H, 
the latter leaving one GlcNAc residue covalently bound to the protein, which can 
remarkably improve stability. Deletion of two N-linked glycosylation sites did not 
dramatically change expression levels but deletion of all three sites significantly reduced 
expression. These results however should be treated with caution since the experiments were 
carried out using transient transfection and therefore can give less reproducible results then 
those obtained from stable cell lines. Also it is worth examining amino acid substitutions 
other than Ala in the N-linked glycosylation sequence, for example Asn to Asp or Ser/Thr to 
hydrophilic amino acids, to explore whether this maintains the expression levels seen for the 
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wild type receptor. Additionally, fusion of BRIL to the N-terminus of NOP negated the need 
for three N-linked glycosylation sites 137 and might be a worthwhile approach for AT1R. 
What the results here suggested is that AT1R needs to have at least one N-linked 
glycosylation site intact for expression of the correctly folded receptor. Although this is 
unusual for the majority of GPCR structures obtained thus far, it is similar to what was seen 
for bovine rhodopsin. Rhodopsin has two N-linked glycosylation sites at Asn2 and Asn15. 
Removal of the N-glycosylation site at Asn2 had no effect, but removal of Asn15 reduced 
signal transduction and cell surface expression. Deletion of both of the N-linked 
glycosylation sites also reduced cell surface expression 139. All recombinant sources of 
bovine rhodopsin used for crystal structures thus far are confined to mammalian cells 113. 
These results are also similar to what has been shown for the mammalian transporter SERT. 
N-linked glycosylation has been established as a requirement for expression of correctly 
folded SERT or necessary for its stability since a SERT mutant lacking N-linked 
glycosylation showed 20-fold lower expression compared to the native transporter 140. 
Another example of a protein dependent on N-linked glycosylation for expression is the 
extracellular domain of the insulin receptor which was successfully expressed in CHO cells 
modified to produce limited N-linked glycosylation 141. An engineered monomer of the 
ectodomain of the insulin receptor, also produced in the modified CHO cells, contained 15 
N-linked glycans but could still be crystallised using two different Fab fragments, allowing 
structure determination at 3.8 Å resolution 142. The homopentameric GABAA receptor β3 
also had 15 N-linked glycosylation sites necessary for expression however these were 
cleaved prior to crystallisation with endoglycosidase F1 resulting in crystals that were used 
to determine a 3.0 Å resolution structure 71. A two-point thermostability assay showed that 
removal of the N-glycosylation sites did not greatly affect stability of AT1R, but even if 
removal does prove necessary, it has been shown that it is possible to crystallise GPCRs 
with glycosylation intact. Although this approach might be more difficult, the first rhodopsin 
crystal structure was purified from native sources and N-linked glycosylation was not 
removed 19. Additionally, a rhodopsin mutant lacking one glycosylation site (Asn2) was 
expressed in the iGnTI— system, which has restricted homogenous N-linked glycosylation, 
and this resulted in a structure where the core GlcNAc2-Man1 was ordered and formed 
crystal contacts 119. These results open up the possibility of producing and crystallising 
AT1R with N-linked glycosylation intact.    
 
Since a minimum of one N-linked glycosylation site is necessary for high levels of 
expression of AT1R, two overexpression systems were investigated thoroughly: expression 
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in insect cells by recombinant baculovirus and expression in mammalian cells. Also, the 
expression of functional eukaryotic membrane proteins has had significantly more success in 
eukaryotic rather than prokaryotic systems, possibly due to the slower rates of translation 
and folding seen in the later system 143. Expression of GPCRs in insect cells has proven to 
be successful, resulting in over a hundred crystal structures, however in a study of 16 related 
human GPCRs expressed in insect cells, yields of correctly folded material varied 
dramatically 57. Attempts at expressing each of the five muscarinic receptor subtypes under 
the same conditions in insect cells resulted in yields of between 0.6 and 16 pmol/mg 
however the three different opiod receptor subtypes all expressed at 1-2 pmol/mg 144. These 
data indicated that there is no reliable way to predict the yields of a particular expression 
system. Given that trial and error is the current best approach to determining optimal  
expression conditions, expression of AT1R in insect cells was optimised by examining 
different insect cell lines, different infection times and the inclusion of acidic glycoprotein 
67 leader sequence. However the only condition explored that had a measurable effect on 
expression levels was the inclusion of the leader sequence. The best insect cell expression 
condition was Hi5 cells infected with bvAT1R-LS-H10 for 48 hours (1.8 million molecules 
of AT1R per cell). Assuming 1 million cells per ml of culture this condition produced 
approximately 0.1 mg of AT1R per litre. The best condition in the absence of a leader 
sequence was also Hi5 cells infected with for 48 hours. This produced 0.05 mg of AT1R per 
litre. In addition to the low expression levels, the insect cell system also produced a large 
amount of unfolded AT1R peptide which would likely hinder crystallisation. This result was 
similar to what had been previously shown for rat SERT when expressed in insect cells 60. 
 
In contrast to the baculovirus system, nearly all of the AT1R produced in the mammalian 
system was glycosylated and localised at the cell surface. A tetracycline inducible system 
was chosen for expression of AT1R in mammalian cells since it has previously been shown 
that overexpression of some GPCRs is toxic to cells. For example, a constitutively active 
mutant of rhodopsin (E113Q+E134Q+M257Y) could not be successfully expressed in a 
constitutive mammalian system 126, but the tetracycline-inducible system 125 was successful 
for production of this constitutively active mutant of rhodopsin 128 as well as for the large 
scale production of NTS1 127 and SERT 145. Expression levels of AT1R from transient 
transfection were highly variable and too low to measure accurately. Based on FACS 
analysis of 10 thousand cells, generation of a cell line stably expressing AT1R-GFP-H10 
dramatically increased expression in comparison to transient transfection. The stable cell 
line, iHEK(AT1R-GFP-H10), also showed less variability in expression levels and was more 
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uniformly expressed on the cell surface in comparison to transient transfection. The cell line 
iHEK(AT1R-GFP-H10) produced 0.6 mg per litre of receptor when induced for 24 hours 
with tetracycline. Several methods were investigated to increase AT1R expression in the 
stable mammalian cell line including: lengthening the expression time; adding agonists and 
antagonists at the time of induction; and induction with sodium butyrate and tetracycline. 
The only condition that increased expression levels was the inclusion of sodium butyrate at 
the time of induction. Sodium butyrate has also been shown to increase GPCR expression in 
iHEK cell lines stably expressing rhodopsin 126, 128 and the neurotensin receptor 127. 
 
In conclusion, the Tm assay data suggested that AT1R bound to the high affinity peptide 
antagonist Sar1 is thermostable enough to consider purification and crystallisation in the 
wild type form. The mammalian system proved to be superior to the baculovirus system 
because of the higher levels of active material present in the former and the presence of 
unfolded material in the latter.
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CHAPTER 3 IMPROVING THE EXPRESSION OF AT1R IN 
MAMMALIAN CELLS 
 
3.1 Introduction 
 
AT1R presents a challenge to overexpress and crystallise because it is an integral membrane 
protein that contains three N-linked glycosylation sites in regions predicted to be on the 
extracellular surface of the cell. More than 50% of proteins encoded by the human genome 
are predicted to be glycosylated 146, however glycosylated proteins only represent around 
10% of all structures in the Protein Data Bank (PDB) 147. A common hindrance to the 
determination of glycoprotein structures is their requirements for expression of correctly 
folded material. In particular, they often need complex folding machinery and post-
translational modification, which are only found in mammalian cells 138. Human membrane 
proteins are frequently glycosylated and therefore they benefit from being expressed in 
mammalian systems. In addition, the near native lipid composition of mammalian cells is 
also advantageous for their overexpression 144, 148. It has become routine to use mammalian 
cells for functional studies, but protein obtained from mammalian hosts accounts for only 
~3% of unique structures in the PDB 149, although this figure has grown by 40% in the last 
two years 138. Despite their advantages, there has been a reluctance to use mammalian cells 
to overexpress membrane proteins, which is probably due to the expense of the system, the 
length of time involved in generating large volumes of cells and the low yields frequently 
obtained 144, 148, 150.  
 
If low expression levels of the target protein are obtained in mammalian cells, there are only 
a few published methods for increasing expression levels further. It might be reasonable to 
assume that increasing the stability of a protein could increase expression levels, however 
this was not the case for the expression of a thermostabilised version of SERT in HEK293 
cells 65, despite this expression system providing the highest amounts of functional protein 
out of seven expression systems examined 60. Chaudhary et al. 148 described a method for 
transiently transfecting multiple constructs tagged with GFP into HEK293 GnTI— cells, 
screening the solubilised protein for expression levels with western blotting and further 
analysing the recombinant protein with FSEC. While this method allows for a rapid 
assessment of the amounts of protein produced, expression levels are highly variable in 
transient transfection and often too low to be accurately measured by FSEC. Chaudhary et 
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al. further expanded upon this method as applied to deriving cell lines stably expressing the 
protein of interest. Since integration of the transfected plasmid into the genome of the host 
was a random event, the authors found that screening up to 24 polyclonal cell lines resulted 
in increased expression, presumably by finding a cell line which had the plasmid integrated 
into an area of high expression or which had been integrated more than once. While the use 
of stable cell lines might address the variability seen in transient transfection, this method is 
time consuming and relatively low-throughput. Another method developed to increase 
expression levels in mammalian cells used fluorescence activated cell sorting (FACS) 151 to 
select highly expressing polyclonal cell lines 150. This method used a constitutive CMV 
promoter to co-express the protein of interest and GFP, which served as a marker for 
expression, with the GFP downstream from an internal ribosome entry site (IRES) to allow 
independent translation. After incorporation of the bicistronic plasmid into the host’s 
genome, the resulting stable cell line was subjected to FACS and those cells that formed the 
top 0.1% of GFP fluorescence were selected (Figure 3.1). This process was repeated until 
sufficient expression levels were achieved and was used successfully on the rat serotonin 
receptor subtype 2c (5HT2c) to produce approximately 3 million molecules per cell (2.5 mg 
of receptor from 1-5 litres of culture) 150. The main disadvantage of this technique was that 
FACS was required every time cells were grown on a large scale in order for protein 
production to maintain high expression levels. A further way to increase expression of 
membrane proteins in mammalian cells is the use of sodium butyrate in the culture media at 
the time of induction. Sodium butyrate is thought to inhibit histone deacylation, thus 
increasing acetylation levels of histones, which in turn leads to less compact DNA packing 
that allows better access to the transcription machinery. Examples of the success of this 
approach include increased expression of rhodopsin 126, 128, the neurotensin receptor 127 and 
the human Rh C glycoprotein 120. Finally, protein engineering can be used to increase 
expression of the protein of interest. This will be discussed in more detail in Chapter 4. 
 
Recently, the FACS-based method of selecting highly expressing clonal cell lines 150 was 
refined in our lab for use with the T-REx™ tetracycline-inducible expression system 
(Andréll & Tate, unpublished). A polyclonal cell line was produced that stably expressed the 
protein of interest as a GFP-fusion under the control of the inducible CMV promoter. GFP 
served as a marker to select and assess highly expressing clonal cell lines by FACS (Figure 
3.1).  
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Figure 3.1 FACS based methods for increasing expression in mammalian cells 
Schematic of two separate methods for increasing expression in mammalian cells using GFP as a marker for 
expression. On the left is the method from 150 which utilises a constitutive expression system and an IRES 
sequence upstream of GFP. This method generates highly expressing polyclonal cell lines. On the right is the 
method from Andréll & Tate (unpublished). It utilises a tetracycline-inducible system and selects cells that have 
a high level of expression in the uninduced state. This method generates highly expressing clonal cell lines. 
Figure adapted from 150. 
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The cells which showed the highest levels of expression were selected in either the 
tetracycline-induced or uninduced state. The most successful approach so far was to select 
cells that showed a high level of expression in the uninduced state (Andréll & Tate, 
unpublished). Although this method also takes about two to three months to complete, it has 
the advantage of being high-throughput and not requiring multiple rounds of FACS.  
 
Limited options are currently available for increasing yields of recombinant protein from 
mammalian hosts. The work presented in this chapter further supports the FACS-based 
method for creating clonal stable cell lines which greatly increased expression levels in 
comparison to a traditional polyclonal cell line. 
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3.2 Methods 
 
 Generation of highly-expressing clonal cell lines using fluorescence 
activated cell sorting 
 
Highly-expressing clonal AT1R-GFP-H10 cell lines were selected from the uninduced 
polyclonal cell line iHEK-AT1R-GFP-H10 (Section 2.3.4) using a MoFlo High Speed Cell 
Sorter (Beckman Coulter) with the coherent sapphire laser set to 488 nm to excite GFP 
(Figure 3.2). Ten cells were deposited per well in a 96-well plate and allowed to grow until 
confluent under standard conditions. The cells were then transferred into 24-well plates. 
When the cells reached ~50% confluence they were induced for 24 hours with fresh media 
with 1 g/ml tetracycline. Both induced and uninduced samples were analysed on a 
FACSCalibur II (Becton Dickinson) (Section 2.2.9). The cell lines which showed the 
greatest increase in GFP expression were retained. 
 
 
Figure 3.2 Strategy for the selection of highly-expressing clonal cell lines  
FACS analysis of iHEK cells. Cells were harvested in PBS and analysed on the FACSCalibur II for GFP 
fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). iHEK parental cells (red), 
uninduced cell line stably expressing SERT-GFP (blue), induced cell line stably expressing SERT-GFP (green). 
Approximately 4% of the uninduced stable cell line shows high levels of basal expression. Isolating and 
screening individual cells from this population leads to the creation of highly-expressing clonal cell lines. Figure 
adapted from Juni Andréll, unpublished. 
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 Fixing and staining cells for analysis by confocal laser scanning 
microscopy 
 
To facilitate membrane staining, cells were grown on 35 mm glass bottom culture dishes, 
induced for 24 hours under standard conditions and fixed using 2% paraformaldehyde 60. 
After washing with PBS, membranes were selectively stained using a 10 g/ml solution of 
concanavalin A (conA)–Alexa Fluor 647 conjugate (Invitrogen) in PBS for 10 minutes at 
room temperature. After further washing with PBS, cells were stored in fresh PBS with 
0.02% Na azide at 4°C protected from light. Cells were visualised on a Leica TCS SP8 
STED inverted laser scanning microscope with 63× oil-immersion objective and a 1.4 
numerical aperture. The white light laser was set to a wavelength of 488 nm to excite GFP 
and to 633 nm for Alexa Fluor 647; the pinhole emission wavelength was set to 580 nm. 
 
 Large scale culture of mammalian cells 
 
For suspension cultures, cells were grown in FreeStyle™ 293 Expression Medium (Gibco) 
supplemented with 5% tetracycline-free foetal bovine serum at a density of one million cells 
per ml in 2-litre roller bottles (Corning) and incubated at 37°C and 200 r.p.m. Cells were 
induced at a density of 1-2 million cells per ml by adding 1 g/ml tetracycline and 
incubating at 37°C for 24 h. For growth in HYPERFlask™ (Corning) the manufacturer’s 
protocol was followed. 
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3.3 Results 
 
 Development of a novel strategy to increase AT1R expression in the 
mammalian system 
 
Although the stable polyclonal mammalian cell line, iHEK(AT1R-GFP-H10) was shown to 
have much higher expression of AT1R than any of the insect cell conditions investigated (0.6 
mg/L compared to 0.1 mg/L, assuming 1 million cells per ml of culture), this was below 
what was reported for the expression of other GPCRs in mammalian hosts, such as 10 mg of 
opsin, per litre of culture, assuming 10 million cells per ml of culture 126 and 1.0 mg of the 
NTS1 per litre of culture, assuming 1.2 million cells per ml of culture 127. Therefore another 
strategy was used to increase expression of AT1R in mammalian cells. This technique relied 
on creating an AT1R-GFP-fusion where GFP served as a marker for expression under the 
control of a tetracycline-inducible CMV promoter. A polyclonal cell line expressing AT1R-
GFP-H10 was created in iHEK cells through antibiotic selection (Section 2.3.4) and this 
served as the base from which clonal cell lines were created. Fluorescence activated cell 
sorting was used to select cells which showed high levels of GFP expression in the 
uninduced state and a separate selection was also performed for those cells which showed 
moderate levels of expression (Figure 3.2). From each of these two populations one cell was 
deposited per well in a 96-well plate, however only two cell lines survived from the first 
population and one from the second. To determine the minimum number of FACS-selected 
cells per well that are necessary to yield over 50% of the clonal cell lines surviving seven 
days after sorting, different numbers of cells per well were deposited into a 96-well plate 
and assessed for viability after seven days in culture (Figure 3.3). As a result of this 
optimisation ten cells were deposited per well for all further plates. 
 
Figure 3.3 Optimisation of the number of cells per well deposited for FACS 
In order to determine the minimum number of cells per well which led to at least 50% of wells containing viable 
cells, varying numbers of uninduced iHEK(AT1R-GFP-H10) cells were deposited per well in duplicate and the 
approximate number of cells surviving 7 days post sorting was assessed under a light microscope. 
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The clonal cell lines were allowed to grow until confluent in the 96-well plates and then 
transferred into 24-well plates in triplicate. When the cell lines reached ~50% confluence in 
the 24-well plates, one plate was induced for 24 hours with fresh media containing 1 g/ml 
tetracycline while the second plate was kept as an uninduced sample and a third plate was 
retained as a stock. In total 72 clonal cell lines in the induced and uninduced states were 
analysed for GFP expression using FACS analysis (Appendix 3). Of the total 72 clonal cell 
lines analysed, 24 were derived from the population with moderate basal expression and 48 
were derived from the population with high basal expression. The clonal cell lines which 
showed the most dramatic increase in expression in comparison to the polyclonal 
iHEK(AT1R-GFP-H10) cell line came from the population with a high basal level of 
expression (Figure 3.4).  
 
Figure 3.4 Isolation of clonal cell lines from a population with high basal expression leads to an 
increase in AT1R expression 
Frequency distribution histogram of FACS analysis data (Appendix 3). Clonal cell lines were isolated from two 
different populations of the polyclonal cell line iHEK(AT1R-GFP-H10): those with moderate basal expression (A 
and B) and those with high basal expression (C and D). The polyclonal cell line had a median fluorescence 
intensity of 276; represented by the dashed black line in the graphs (A) and (C) and 0% in the graphs (B) and 
(D). For the graphs (B) and (D) each bar represents an individual cell line and dashed lines are at ± 30% of the 
relative expression in the polyclonal cell line, which equated to ± 2 bins on the histograms (A and C). 
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13% of the clonal cell lines derived from the population with moderate basal expression 
showed a > 30% reduction in FACS median in comparison to the polyclonal cell line and 
only 4% showed a > 30% increase in FACS median (Figure 3.4). In contrast, 10% of the 
clonal cell lines derived from the population with high basal expression showed a > 30% 
reduction in FACS median in comparison to the polyclonal cell line and 10% showed a 
> 30% increase in FACS median (Figure 3.4). It was not possible to predict expression 
levels from the FACS median of uninduced cells because all of the cell lines tested had 
medians between 8-14 (iHEK parental cells, 6), whereas after induction the FACS median 
was 120-437 (Figure 3.5). This shift in FACS median between uninduced and induced states 
is clearly shown in (Figure 3.6). The clonal cell lines which showed the greatest increase in 
expression of AT1R-GFP-H10 were grown in culture for a further nine days and assessed for 
expression using FACS (Figure 3.7).  
 
A 
 
  
B 
 
Figure 3.5 Correlation of median FACS fluorescence intensity 
The median FACS fluorescence intensity data (Appendix 3) of the clonal cell lines in the induced state was 
correlated with that in the uninduced state. Linear regression was used to establish a line of best fit for cells 
derived from the population with moderate basal expression (A) and those derived from the population with high 
basal expression (B) from the original FACS sort (Figure 3.2). 
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Figure 3.6 Clonal cell lines show a high level of inducibility 
FACS analysis of iHEK cells. Cells were harvested in PBS and analysed on the FACSCalibur II for GFP 
fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). Light colours represent 
uninduced whereas dark colours represent cells induced with tetracycline for 24 hours. (A) Clonal iHEK319 cell 
line, derived from the population with moderate basal expression (orange). (B) Clonal iHEK415 cell line, derived 
from the population with high basal expression (blue). (C) Clonal iHEK420 cell line, derived from the population 
with high basal expression (green).   
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Figure 3.7 Increase in expression of AT1R-GFP-H10 in stable cell lines over time  
FACS analysis of iHEK cell lines was performed on cells harvested in PBS and analysed on the FACSCalibur II 
for GFP fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). (A) Polyclonal 
parental cell line, iHEK(AT1R-GFP-H10) after induction with tetracycline (red), clonal iHEK415 cell line after 
induction with tetracycline (blue). (B and C) Median FACS fluorescence intensity; uninduced (hatched bars), 
induced (solid bars), percentage of cells showing GFP fluorescence (diamonds).The expression levels of AT1R-
GFP-H10 from the initial analysis (B) were compared with cells grown continuously for further 9 days and then 
induced with tetracycline (C). 
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 Characterisation of AT1R expression in clonal mammalian cell lines 
 
As a verification of expression of AT1R, cell suspensions derived from the most highly 
expressing cell lines were equalised for total protein, separated by SDS-PAGE and 
visualised by in-gel fluorescence (Figure 3.8). The bands corresponding in size to AT1R-
GFP were quantified with ImageJ and this data was correlated to the median fluorescence 
intensity from FACS analysis of the samples prior to harvest (Figure 3.8). The strong 
association (R2 = 0.9, Figure 3.8) between the two sets of data suggests that GFP 
fluorescence as measured by FACS is a good indicator of AT1R expression due to the 
absence of GFP un-associated with AT1R (e.g. through proteolysis). The cell lines which 
showed the greatest increase in AT1R expression upon tetracycline-induction were also 
analysed by FSEC with the same number of cells in each sample (Section 2.2.12). All four 
cell lines produced a major peak at 11 ml retention volume that corresponded to AT1R-GFP-
H10. However the size of the peak varied markedly between the cell lines, with the largest 
peak produced from iHEK415 and the smallest peak from the polyclonal parental cell line 
iHEK(AT1R-GFP-H10). Intermediate-sized peaks were observed for the cell lines iHEK420 
and iHEK425. In addition, a second fluorescent product was observed at a retention volume 
of 17.5 ml in the iHEK425 cell line, which probably represented free GFP (Figure 3.9). The 
cell line iHEK415 was also examined by laser scanning confocal microscopy (Figure 3.10). 
The plasma membranes were stained with Alexa Fluor 647 conjugated to conA and co-
localisation of AT1R-GFP was shown on the cell surface indicating that AT1R-GFP was 
expressed predominantly on the plasma membrane in the iHEK415 cell line. As a final 
check for the presence of correctly folded material, the clonal cell lines which showed the 
greatest increase in AT1R expression were analysed by radioligand binding using the 
antagonist [125I]Sar1 (Section 2.2.11). In a one-point binding assay, the approximate number 
of functional AT1R molecules per cell was determined with 15 million copies per cell 
observed in cell lines iHEK415 and iHEK420. This compared to 9 million copies per cell in 
the polyclonal parental cell line and 2 million copies per cell in iHEK425 (Figure 3.11). The 
cell lines iHEK415 and iHEK420 showed only a modest reduction in expression levels of 
AT1R-GFP after induction when the cell lines had been cultured for over 20 days (Figure 
3.12). The combination of the FSEC data and the ligand binding data was used to determine 
which cell line was the best at producing AT1R for further studies. The low number of 
copies per cell and the presence of free GFP in FSEC suggested that AT1R-GFP-H10 
expressed in the cell line iHEK425 was being degraded. Cell lines iHEK420 and iHEK425 
apparently produced the most functional AT1R as assessed by ligand binding (15 million 
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copies per cell), but the FSEC peak for AT1R-GFP-H10 appeared to be considerably smaller 
for iHEK420 than that observed for iHEK415. This could be because AT1R-GFP-H10 
produced in iHEK420 was either poorly solubilised or more prone to aggregation than the 
AT1R-GFP-H10 produced in iHEK415, although the reason for this is unclear. Therefore, 
based on this analysis, iHEK415 was considered the best cell line for the production of 
AT1R-GFP-H10, which, based on the ligand binding data, equates to 1 mg per litre of cells 
assuming 1 million cells per ml. 
 
A 
 
  
B 
 
  
 
Figure 3.8 In-gel fluorescence shows an increase in expression of AT1R-GFP-H10 through the creation of 
clonal cell lines  
iHEK cells were transiently transfected with pJAP2 (expression of AT1R-GFP-H10) and polyclonal and clonal 
stable cell lines were generated as described before (Section 2.3.4 and Figure 3.2). All cells were induced for 24 
hours with 1 g/ml tetracycline prior to being assayed. An equal amount of cells was loaded in each lane. (A) In-
gel fluorescence of AT1R-GFP-H10 expression from transient transfection, polyclonal and clonal stable cell lines. 
(B) In-gel fluorescence of AT1R-GFP-H10 after removal of N-linked glycosylation by PNGase F. (C) Bands 
corresponding to deglycosylated AT1R-GFP-H10 were quantified with ImageJ (blue circles) and compared to 
their respective median FACS fluorescence intensity values (red squares). (D) Linear regression was used to 
establish a line of best fit. 
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Figure 3.9 FSEC analysis of AT1R-GFP-H10 produced from clonal cell lines 
The clonal cell lines derived from iHEK(AT1R-GFP-H10) were induced with tetracycline for 24 hours. 40 nM of 
Sar1 was added to 5 million cells and allowed to bind for 1 hour at 23°C before being solubilised in 1% DDM. 
Samples were then evaluated on a Superdex 200 10/300 GL column. Polyclonal cell line iHEK(AT1R-GFP-H10) 
(red); clonal cell lines: iHEK420 (green), iHEK425 (orange) and iHEK415 (blue). The elution of AT1R-GFP-H10 
was detected using GFP fluorescence (mV). The void (Vo) and total column volumes (VT) are indicated. 
 
 
Figure 3.10 AT1R produced in the clonal cell line iHEK415 is predominantly localised to the cell surface 
Confocal micrographs of the iHEK415 clonal cell line (expression AT1R-GFP-H10) after 24 hours induction with 
tetracycline. Cells were fixed using paraformaldehyde and the plasma membrane was defined by staining with 
Alexa Fluor 647-conjugated conA prior to visualisation. Unlabelled iHEK parental cells showed no fluorescence 
(not shown). The scale bar represents 10 m. 
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Cell line name iHEK(AT1R-GFP-H10)  Polyclonal 
Open reading frame 
schematic 
 
Parental cell line iHEK 
 
Master Gain 1107 
Median FACS 
fluorescence intensity 
265 Digital Gain 1.24 
Functional expression 
levels (copies/cell) 
9 million ± 0.5 (n=6) Digital Offset 0.00 
  
Cell line name iHEK415 Clonal 
Open reading frame 
schematic 
 
Parental cell line iHEK(AT1R-GFP-H10) 
 
Master Gain 696 
Median FACS 
fluorescence intensity 
846 Digital Gain 0.30 
Functional expression 
levels (copies/cell) 
15 million ± 0.4 (n=6) Digital Offset 2457.60 
  
Cell line name iHEK420 Clonal 
Open reading frame 
schematic 
 
Parental cell line iHEK(AT1R-GFP-H10) 
 
Master Gain 952 
Median FACS 
fluorescence intensity 
649 Digital Gain 1.00 
Functional expression 
levels (copies/cell) 
15 million ± 1.5 (n=6) Digital Offset 113.75 
  
Cell line name iHEK425 Clonal 
Open reading frame 
schematic 
 
Parental cell line iHEK(AT1R-GFP-H10) 
 
  
Median FACS 
fluorescence intensity 
418   
Functional expression 
levels (copies/cell) 
2 million ± 0.2 (n=6)   
Figure 3.11 Assessment of clonal cell lines derived from iHEK(AT1R-GFP-H10)  
FACS was used on the uninduced polyclonal cell line iHEK(AT1R-GFP-H10) to select clonal cell lines which 
showed the highest amount of GFP expression in the uninduced state. Assessment of the resulting clonal cell 
lines was based on confocal microscopy and the average counts for FACS analysis and [125I]-Sar1 binding. 
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Figure 3.12 Clonal cell lines show high levels of expression long term 
FACS analysis of iHEK cells. Cells were induced for 24 hours with tetracycline and harvested in PBS and 
analysed on the FACSCalibur II for GFP fluorescence using the FL-1 detector. Cell counts have been 
normalised (% of Max). (A) The expression levels of AT1R-GFP-H10 in the clonal cell line iHEK415 were 
compared in cells grown in culture for 26 days (dark blue line, FACS median 629) and freshly thawed cells (light 
blue line, FACS median 737). (C) The expression levels of AT1R-GFP-H10 in the clonal cell line iHEK420 were 
compared in cells grown in culture for 21 days (dark green line, FACS median 547) and freshly thawed cells 
(light green line, FACS median 649).  
 
 Dramatic increase in expression of AT1R in mammalian cells through a 
combination of FACS selection and use of sodium butyrate 
 
The process of selecting clonal cell lines on the basis of high basal expression of AT1R-GFP 
led to a 66% increase in expression in comparison to the polyclonal cell line based on the 
radioligand binding data. As it was previously noted that adding sodium butyrate at the time 
of induction increased active expression of AT1R in the polyclonal cell line (Section 2.3.4), 
the effect of 5 mM sodium butyrate added to the iHEK415 cell line was tested. FACS 
analysis showed a dramatic increase in expression and radioligand binding experiments 
demonstrated that functional levels of AT1R in the iHEK415 cell line increased to 
approximately 26 million receptors per cell or 1.8 mg of AT1R per litre of culture assuming 
1 million cells per ml (Figure 3.13). Sodium butyrate in combination with the generation of 
a clonal cell line produced a nearly a threefold increase in AT1R expression over the 
polyclonal cell line iHEK(AT1R-GFP-H10). A western blot loaded with equal amounts of 
active AT1R per lane indicated that the increase in expression was not at the expense of 
correct folding of the receptor since equal signal intensity was seen for all conditions (Figure 
3.14). As an additional check on the quality of the AT1R produced, an equal amount of cells 
transiently transfected with the plasmid pJAP2 (expressing AT1R-GFP-H10), the polyclonal 
cell line iHEK(AT1R-GFP-H10) or the clonal cell line iHEK415 were separated by SDS-
PAGE and visualised by in-gel fluorescence (Figure 3.15). Digestion of these samples with 
the glycosidase PNGase F indicated that AT1R was glycosylated in all of the conditions 
tested.    
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Figure 3.13 Significant increase in AT1R expression through a combination of FACS selection and the 
use of sodium butyrate 
FACS analysis of iHEK cells was performed on cells harvested in PBS and analysed on the FACSCalibur II for 
GFP fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). (A) Histogram of GFP 
fluorescence intensity. Non-transfected parental iHEK cells (red), transient transfection of pJAP2 (expressing 
AT1R-GFP-H10) (purple), polyclonal stable cell line iHEK(AT1R-GFP-H10) (green), clonal cell line iHEK415 
(orange), iHEK415 induced with 5 mM Na butyrate (blue). (B) Median FACS fluorescence intensity (blue bars) 
are compared with the number of cells positive for GFP expression (%) (red diamonds). (C) The amount of 
functional DDM-solubilised AT1R in each cell line was determined by measuring specific binding of the 
antagonist [125I]-Sar1 (blue bars). The results are from two independent experiments performed in triplicate and 
plotted as a mean value ± SEM. From these data, milligrams of AT1R per litre of cells, assuming 1 million cells 
per ml, were calculated (red diamonds). 
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Figure 3.14 Sodium butyrate does not significantly increase the amount of unfolded AT1R expressed 
Western blot of DDM-solubilised AT1R, with equal amounts of active receptor per sample (lanes 2-7). The blot 
was probed with an anti-pentaHis-HRP conjugated antibody. Lane 1, iHEK parental cells; lanes 2-5, 
iHEK(AT1R-GFP-H10) stable polyclonal cell line; lanes 6-7 clonal cell line, iHEK415. N-linked glycosylation was 
removed using PNGase F on all samples. Cells were induced with 1 g/ml tetracycline for 24 hours. The 
amount of functional AT1R was determined by measuring specific binding of the antagonist [125I]-Sar1. Two non-
specific bands are indicated (NS). 
 
 
 
Figure 3.15 Increasing levels of AT1R expression through FACS selection and induction with sodium 
butyrate  
In-gel fluorescence of AT1R-GFP-H10 expression from transient transfection, polyclonal and clonal stable cell 
lines. iHEK cells were transiently transfected with pJAP2 (expression of AT1R-GFP-H10). Polyclonal and clonal 
stable cell lines were generated as described before (Section 2.3.4 and Figure 3.2). All cells were induced for 24 
hours with 1 g/ml tetracycline or 1 g/ml tetracycline with 5 mM Na butyrate as indicated for 24 hours prior to 
being assayed. An equal amount of cells was loaded in each lane. 
  
kDa
36
22
50
64
98
148
250
iH
E
K
iH
E
K
(A
T
1
R
-G
F
P
-H
1
0
)
iH
E
K
(A
T
1
R
-G
F
P
-H
1
0
)
0
.5
 m
M
 N
a
 b
u
ty
ra
te
iH
E
K
(A
T
1
R
-G
F
P
-H
1
0
)
2
.5
 m
M
 N
a
 b
u
ty
ra
te
iH
E
K
(A
T
1
R
-G
F
P
-H
1
0
)
1
5
 m
M
 N
a
 b
u
ty
ra
te
iH
E
K
4
1
5
iH
E
K
4
1
5
5
 m
M
 N
a
 b
u
ty
ra
te
1 2 3 4 5 6 7
AT1R-
GFP-H10
NS
Transient 
transfection
+-+-+-+-
iHEK(AT1R-
GFP-H10)
iHEK415
iHEK415 + 
Na butyrate
23
33
41
65
100
155
kDa
PNGaseF
Mol.
Weight
CHAPTER 3 Improving the Expression of AT1R in Mammalian Cells  
 Page 69  
 
 Large scale growth of iHEK415 
 
The best clonal cell line for expressing AT1R was determined to be iHEK415. In order to 
obtain the milligram quantities required for purification and crystallisation of the receptor, 
the next step was to explore large scale growth. iHEK415 was grown adherently in T-175 
tissue culture flasks (172 cm2 surface area) and induced for 24 hours with tetracycline. Each 
flask yielded approximately 2.5 x 107 million cells. Assuming 1 million cells per ml, one 
litre of cells would yield 1 x 109 cells, therefore approximately 40 T-175 flasks would be 
required to obtain approximately 2 mg of AT1R. Growing the iHEK415 cell line in this 
fashion would require a large amount of time and resources, therefore suspension culture of 
iHEK415 was investigated. iHEK415 cells initially grown adherently were harvested and 
resuspended in Free Style media supplemented with 5% tetracycline-free foetal bovine 
serum at 1 million cells per ml in 2 litre roller bottles and placed into a shaking incubator at 
37°C. The suspension cultures of iHEK415 quickly aggregated onto the sides of the flasks, a 
result which was also observed when the cell concentration was diluted to 0.5 million cells 
per ml. The iHEK415 suspension cultures were checked every 24 hours and diluted as 
necessary. The cells were induced at 1.5 million cells per ml for 24 hours and analysed by 
FSEC (Figure 3.16). The cell line iHEK415 grown in suspension culture produced a peak at 
11 ml retention volume that corresponded to AT1R-GFP-H10. However a second larger 
fluorescent product was observed at a retention volume of 17.5 ml, which probably 
represented free GFP. Since suspension culture did not provide a favourable environment to 
grow iHEK415 in large scale, adherent cultures using roller bottles was next examined. This 
however also failed since the cells would not adhere to the sides of the bottles. The next 
method that was investigated was growth in Hyperflasks (1720 cm2 surface area per flask). 
These flasks proved to be technically challenging to use when changing the media for 
induction since iHEK cells are only loosely adherent and therefore large losses of cells 
occurred. From four Hyperflasks tested the average yield was 1.5 x 108 million cells per 
flask.  
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Figure 3.16 FSEC analysis of AT1R-GFP-H10 produced from iHEK415 grown in suspension 
The clonal cell line iHEK415 was grown in either suspension culture (blue line) or adherent culture (red line) and 
induced with tetracycline for 24 hours. 40 nM of Sar1 was added to 5 million cells and allowed to bind for 1 hour 
at 23°C before being solubilised in 1% DDM. Samples were then evaluated on a Superdex 200 10/300 GL 
column. The elution of AT1R-GFP-H10 was detected using GFP fluorescence (mV). The void (Vo) and total 
column volumes (VT) are indicated. 
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3.4 Discussion 
 
The main reason for creating a clonal cell line was to increase expression levels. The 
polyclonal cell line iHEK(AT1R-GFP-H10) had nine million molecules of AT1R per cell, 
whereas creation of a clonal cell line increased this number to 15 million molecules of AT1R 
per cells, representing nearly a two-fold increase. Functional yields of AT1R from the clonal 
cell line iHEK415 were further increased to 26 million molecules of AT1R per cells or 
approximately two mg of AT1R per litre of culture assuming one million cells per ml. 
Mancia et al. 150 described a FACS-based method for increasing expression levels of 
membrane proteins in human cells that expressed proteins constitutively from the strong 
CMV promoter. Optimisation of this system produced 3 million molecules per cell of the rat 
serotonin receptor subtype 2c (5HT2C) or 2.5 mg of receptor from 1-5 litres of culture, 
assuming 107 cells per ml. However this method required iterative rounds of FACS each 
time large volumes of cells were required for receptor purification 150. Nevertheless, the 
technique described by Mancia et al. 150, illustrated the value of FACS as a method for 
increasing expression levels. The method presented here used an inducible promoter to 
express the receptor, rather than a constitutive promoter; this approach had the advantage 
that cells grown in the uninduced state expressed very low levels of AT1R. Therefore the 
cells maintained a high level of expression after induction despite being in culture for over 
twenty days in the uninduced state. Thus a FACS sort was not required each time a large 
batch of cells was required, as observed for the constitutive expression system 150. 
 
Another example of a mammalian membrane protein highly over expressed in mammalian 
cells was the human 2 adrenergic receptor, which was expressed at 200 pmoles/mg in a 
stable CHO cell line 152. However, these levels decreased dramatically when the cells were 
left in culture for an extended period of time, possibly due to toxicity effects 109. A decrease 
in expression levels in mammalian stable cell lines upon extended culture under a 
constitutive promoter has been a common observation. Examples include, the 2 adrenergic 
receptor 153, the bradykinin 2 receptor 154, SERT 60 and rhodopsin 126, 128, 155. When 
comparative studies have been performed between inducible and constitutive mammalian 
expression systems, there has been a 4-12-fold increase in expression with the use of the 
tetracycline-inducible system 110. The decline in expression seen with a constitutive 
promoter could have been due to the excessive metabolic demands on the cell for protein 
biosynthesis, the intrinsic activity of the protein or there being insufficient amounts of 
specific molecular chaperones required for folding 110. Thus the main advantage of the 
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inducible mammalian system is the cells grow at a normal rate, unencumbered by the 
overproduction of recombinant proteins, until they reach the required density, at which point 
they can be induced to produce protein. That inducible expression in mammalian cells is far 
superior to the use of constitutive promoters is perhaps unsurprising given that this has been 
known in bacterial and yeast expression systems for several decades.  
 
The clonal cell line iHEK415 overexpressed AT1R to give a final yield of 2 mg of receptor 
per litre of culture, assuming 1 million cells per ml. However, whilst the clonal cell line 
iHEK415 showed little loss in expression upon prolonged growth on a small scale, it was 
not possible to adapt the cell line to suspension culture. Growing the cell line adherently for 
the production of AT1R for structural studies would have been very resource and labour 
intensive. Therefore a new stable cell line was required that could be grown on a large scale. 
As this would take 2-3 months to do it was decided to also engineer AT1R to improve the 
probability of crystallography, by removing N-linked glycosylation sites and removing 
flexible regions at the C-terminus, and also other potential improvements in expression 
levels were explored (Chapter 5).  
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CHAPTER 4 ASSESSMENT OF AT1R LIGANDS FOR 
STABILISATION 
 
4.1 Introduction 
 
As a key component of the cardiovascular system, AT1R has generated considerable 
pharmacological interest 76 and numerous ligands have been designed which block the 
receptor. The structures of several AT1R ligands are illustrated in Figure 4.1 and their 
respective binding affinities are shown in Table 4.1. For more background on AT1R 
pharmacology see Section 1.4.3. 
 
The choice of a ligand for stabilisation and co-crystallisation with a GPCR is crucial for 
obtaining well-diffracting crystals and there are several desirable characteristics of a ligand 
that are thought to correlate with its usefulness in GPCR crystalogenesis. For example, for 
wild type A2AR-T4L, out of eight ligands examined the only structures obtained were with 
ligands that gave the highest apparent Tms; UK-432097 
50 and ZM241385 16. Further 
structures of A2AR bound to ligands with a lower apparent Tm required the use of techniques 
to stabilise the receptor such as thermostabilisation 63, 49 or the use of antibodies 61. An ideal 
ligand should have a high binding affinity (pM to low nM), a slow off rate and it should 
stabilise the receptor in a single confirmation 13. Since there are multiple ligands with tight 
binding affinities for AT1R, FSEC was used to screen for the best candidates for stabilisation 
and co-crystallisation with AT1R.   
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Figure 4.1 Structure of AT1R agonists and antagonists 
Structures of selected AT1R agonists and antagonists, which are either peptides (the amino acid sequence is 
shown adjacent to the name) or non-peptide ligands. Figure adapted from the websites of the relevant 
manufacturers, see section 4.2.1. 
 
Table 4.1 Binding affinities of selected AT1R agonists and antagonists 
Ligand† Action† Binding affinity (nM) †  
(species) 
Reference† 
Angiotensin II Agonist 0.9 (human) 156 
L-162,313 Agonist 23.5 (rat) 157 
Sar1 Antagonist 0.2 (human) 158 
Valsartan Antagonist 1.4 (rat) 159 
Azilsartan Antagonist 3.1 (rat) 160 
Candesartan Antagonist 2.8 (human) 117 
EMD 66684 HCl Antagonist 0.7 (rat); IC50 161 
Olmesartan Antagonist 2.3 (rat) 162 
Losartan K Antagonist 6.7 (human) 117 
ZD 7155 HCL Antagonist 3.8 (guinea pig); IC50 163 
L-158,809 Antagonist 0.7 (rat) 164 
† Binding affinities are apparent KDs unless otherwise stated 
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4.2 Methods 
 
 Materials  
 
Sar1Ile8 angiotensin II (Sar1) was purchased from Source Biosciences and L-162,313 was 
purchased from Sigma. Angiotensin II, valsartan, azilsartan, candesartan, EMD 66684 
hydrochloride, olmesartan, losartan potassium and ZD 7155 hydrochloride were purchased 
from Tocris Biosciences. L-158,809 and Sar1Val5L-Br5Phe
8 were kindly provided by 
Emanuel Escher (Université, Sherbrooke). Molecular weight standards for SEC were 
purchased from Sigma and GE Healthcare.  
 
 Analytical FSEC 
 
The FSEC method described in section 2.2.12 was adapted for analytical use with the 
following alterations. To control for expression of AT1R-GFP, cells of the same passage 
number were induced, harvested, aliquoted and analysed together. Cells were incubated at 
room temperature with the ligand indicated for 1 hour prior to solubilisation on ice with the 
detergent indicated. In the condition where no ligand was used, cells were incubated at room 
temperature for 1 hour before being solubilised on ice with the detergent indicated. 
Approximately 5 million iHEK-AT1R-GFP cells at 10 million cells per ml (i.e. 500 l of cell 
suspension) were solubilised in the detergent indicated and loaded into a 200 l sample 
loop. 
 
 Gel filtration column calibration 
 
Molecular weight standards were separated on the Superdex 200 10/300 GL using a 200 l 
sample loop according to the manufacturer’s instructions. The partition coefficient (Kav) was 
calculated as per the equation below for each standard.  
 
Kav = (Ve – Vo) / (Vt –Vo) 
 
Ve = elution volume of the protein standard, Vo = void volume and Vt = total column volume. 
Vo was determined experimentally by measuring the Ve of blue dextran. Vt was obtained 
from the manufacturer. Linear regression was then used to establish a line of best fit relating 
the Kav and log10 of the molecular weights.  
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4.3 Results 
 
 Development of an analytical FSEC-based ligand screen 
 
Since AT1R is a medically relevant receptor, over twenty ligands that bind with nanomolar 
affinity have been developed. To determine which of these ligands was the best candidate 
for co-crystallisation with AT1R, an analytical FSEC-based ligand screen was developed. 
Points of optimisation for the assay included controlling the expression levels of AT1R in 
the iHEK415 clonal cell line, establishing the best storage condition for the harvested cells 
and determining the optimum size of the sample loop to use. Expression levels of AT1R in 
the clonal cell line iHEK415 varied by passage number and the frozen stock used (Figure 
4.2). This variation in expression level could have easily resulted in a change in peak height 
on FSEC. To prevent this, cells of the same stock and passage number were induced, 
harvested, stored in aliquots and analysed in parallel. 
 
Figure 4.2 Variation in expression of AT1R-GFP-H10 in the clonal cell line iHEK415 
FACS analysis of GFP expression in the stable cell line iHEK415 induced for 24 hours with tetracycline. Median 
fluorescence intensities are shown for cells grown continuously for either 4 passages (P4), 13 passages (P13) 
or 16 passages (P16). One set of cells was passaged 16 times (blue bars) and a separate set of cells was 
passaged 4 times (red bar). One passage is defined as when the cells have become confluent, are then 
resuspended and placed at a low dilution into new media, which normally occurs every 2-3 days. 
 
To establish the optimum storage temperature for cells expressing AT1R-GFP-H10, after 
induction and harvest cells were stored at either -20°C or -80°C for approximately 130 days 
before being analysed by FSEC. AT1R-GFP-H10 was found to be more stable when stored at 
-80°C in comparison to storage at -20°C, as indicated by both the reduction in fluorescence 
signal and a shift towards the void volume as measured by FSEC (Figure 4.3). Therefore all 
further cell suspensions were flash frozen in liquid nitrogen and stored at -80°C. Another 
point of optimisation was the size of the sample loop. In order to perform reproducible 
analytical gel filtration it was important that both the sample loop was overloaded (leaving 
no dead volume) and that the fluorescence intensity was not saturated so that the peak could 
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be evaluated in its entirety. It was found that a 200 l sample loop fulfilled both of these 
criteria better than the 500 l sample loop and therefore this was used for all further FSEC 
experiments (Figure 4.4).  
 
Figure 4.3 Optimisation of AT1R storage conditions 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours and stored 
at either -20°C (red line) or -80°C (blue line) for approximately 130 days before analysis by FSEC. The elution of 
iHEK(AT1R-GFP-H10) was detected using GFP fluorescence (mV). The void (Vo) and total column volumes (VT) 
are indicated. 
 
 
Figure 4.4 Optimisation of sample loop size for analytical FSEC 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours and 
analysed by FSEC using either a 200 l sample loop (red line) or a 500 l sample loop (blue line). The elution of 
iHEK(AT1R-GFP-H10) was detected using GFP fluorescence (mV). The void (Vo) and total column volumes (VT) 
are indicated. 
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 Results of FSEC-based ligand screen 
 
The analytical FSEC-based ligand screen was used to determine which ligands, when bound 
to AT1R, produced a monodispersed FSEC peak. To achieve this, ten ligands were evaluated 
and compared to the receptor in the absence of ligand (Figure 3.1). All ligands were added 
to the AT1R cell suspension at a concentration higher than their respective binding affinities 
(Table 4.1) and incubated for one hour at room temperature, then solubilised in DDM for 1 
hour. Insoluble material was removed by centrifugation and the samples were analysed by 
FSEC. AT1R in the absence of ligand gave a symmetrical peak on FSEC, but it was 
noticeable that none of the receptor-ligand complexes produced a peak of similar size or 
symmetry (Figure 4.5). The antagonist Sar1 was first tested since it is the same ligand that 
was used for the radioligand binding assays. This was used at a concentration of 40 nM, 
which was approximately 200 times apparent KD. The peak produced by this concentration 
maintained its symmetry although it showed a reduction in intensity and an increase in the 
void area, in comparison to the no ligand condition. It was previously thought that the more 
concentrated the ligand was in solution the more stable the receptor would be; therefore Sar1 
was tested at a concentration of 100 M. At this higher concentration, the peak shifted to the 
left, decreased in intensity and became less symmetrical in comparison to 40 nM Sar1, which 
are all indications that the receptor was less stable in 100 M Sar1 compared to 40 nM Sar1. 
Sar1 is known to exhibit partial agonist activity 76, therefore a ligand which exhibits only 
inverse agonism, azilsartan 92, 160, was tested at two concentrations, 40 nM and 100 M. 
Neither concentration of azilsartan gave a symmetrical peak as observed in the absence of 
ligand; however 100 M azilsartan gave an increase in peak height in comparison to 40 nM. 
The endogenous agonist angiotensin II, which was tested at a concentration of 40 nM, 
showed an increase in the void area in comparison to the no ligand condition as did the 
synthetic agonist L-162,313, which also showed a reduction in intensity in comparison to the 
no ligand condition. Since none of the ligands tested produced as symmetrical and intense a 
peak as the no ligand condition, six other antagonists were tested at the higher concentration, 
100 M. None of these additional ligands gave a peak as symmetrical as observed in the 
absence of ligand and showed varying amounts of aggregated receptor in the void volume. 
However, out of these ligands the peak produced from losartan-bound AT1R was the most 
symmetrical and had the greatest intensity. The shift in retention volume at the greatest peak 
height from the no ligand condition is further discussed in terms of the change in molecular 
weight in section 4.3.3. In order to determine whether the length of time that azilsartan had 
to bind to AT1R was affecting the results, AT1R was incubated at room temperature with 
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azilsartan for either 1 or 2 hours prior to solubilisation. Increasing the amount of time that 
azilsartan had to bind to AT1R did not seem to dramatically increase the signal intensity or 
result in a more symmetrical peak and incubation for 1.5 or 2 hours seemed to increase the 
amount of free GFP, possibly indicating that the AT1R-GFP fusion protein was being 
degraded (Figure 4.6). 
 
Since none of the ligands tested showed a peak as symmetrical and as intense as the no 
ligand condition, two experimental ligands, L-158,809 and Sar1Val5L-Br5 Phe
8 angiotensin 
II, were also screened by analytical FSEC. L-158,809 was chosen because it was an 
unsurmountable antagonist i.e. it showed slow dissociation from AT1R. The peptide 
antagonist Sar1Val5L-Br5 Phe
8 angiotensin II was chosen because it has neither Gq nor -
arrestin stimulation properties (E. Escher, personal communication). Both experimental 
ligands were insoluble at a final concentration of 100 M, therefore they were tested at 40 
nM and at 1 M. Both L-158,809 and Sar1Val5L-Br5 Phe8 angiotensin II gave a more 
symmetrical peak than azilsartan, however there was a reduction in signal in comparison to 
the no ligand condition which was more pronounced at a concentration of 1 M (Figure 
4.7).  
 
The data from the ligand screen were unusual from two perspectives. First, despite the high 
affinity of the ligands, adding a ligand did not improve the characteristic of the FSEC peak 
compared to when no ligand was bound, and in fact the quality usually got worse. Second, 
the high concentrations of ligands apparently led to a decrease in the ‘quality’ of the 
detergent-solubilised AT1R, as defined by peak height and peak symmetry. Subsequently, 
several concentrations of Sar1 from 2 nM to 100 M were analysed by FSEC (Figure 4.8) to 
identify if there was an ideal concentration of ligand to use. The Sar1 concentrations of 2 
nM, 10 nM and 100 nM gave a peak height similar to the no ligand condition, although there 
was a slight shift in the retention volume for the greatest peak height for ligand 
concentrations of 10 nM and 100 nM in comparison to the no ligand condition (Figure 4.8). 
The significance of these changes in peak height was assessed by a radioligand binding 
assay and it was found that DDM-solubilised AT1R in the presence of either 40 nM or 100 
nM Sar1 gave similar levels of specific binding (Figure 4.8). This suggested that either the 
differences in peak height in the FSEC experiments were not significant or that another 
parameter uncontrolled in the FSEC experiments was an important factor which needed to 
be considered. 
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Given the previous FSEC results, another parameter that could affect the FSEC result was 
tested i.e., the time during which the receptor was exposed to the ligand. AT1R in 
membranes was incubated with Sar1 for 1 hour at room temperature, then solubilised in 
DDM for approximately 16 hours, insoluble material was removed by centrifugation and the 
samples were analysed by FSEC. It was found that there was a dramatic reduction in signal 
for the condition which was solubilised with Sar1 overnight in comparison to the no ligand 
condition (Figure 4.9). However, what was striking was that once more the binding data did 
not change when measured over a 45 hour period (Figure 4.9).  
 
All of the above assays were performed using DDM to solubilise AT1R. The effect of using 
a different detergent, LMNG, was also examined. The combination of AT1R with LMNG 
seemed to produce aggregation (Figure 4.10). It appeared that the effects of azilsartan 
binding to AT1R were mitigated when the detergent LMNG was used, both with different 
concentrations and overnight incubations, however, without further study, it was impossible 
to tell whether the effects seen were because of the use of LMNG or azilsartan.  
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Figure 4.5 Analytical FSEC-based ligand screen 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours, incubated 
with the ligand at the concentration indicated (or no ligand was added), solubilised in DDM and evaluated by 
analytical FSEC using a 200 l sample loop. The elution of iHEK(AT1R-GFP-H10) was detected using GFP 
fluorescence (mV). Dashed lines indicate the middle of the ‘no ligand’ condition peak (green line). Agonists 
(purple lines) and antagonists (blue lines) are shown. Dark lines indicate that a higher concentration of 100 M 
was used. The void (Vo) and total column volumes (VT) are indicated. 
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Figure 4.6 Optimisation of azilsartan incubation time 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours and prior to 
analysis by FSEC, incubated with 1 mM azilsartan for 1 hour (green line), 1.5 hours (blue line) or 2 hours (red 
line) at room temperature. The elution of iHEK(AT1R-GFP-H10) was detected using GFP fluorescence (mV). The 
void (Vo) and total column volumes (VT) are indicated. 
 
 
Figure 4.7 Analytical FSEC-based ligand screen with experimental ligands 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours, incubated 
with the ligand at the concentration indicated (or no ligand was added), solubilised in DDM and evaluated by 
analytical FSEC using a 200 l sample loop. The elution of iHEK(AT1R-GFP-H10) was detected using GFP 
fluorescence (mV). Dashed lines indicate the middle of the ‘no ligand’ condition peak (green line). Antagonists 
are indicated (blue lines). Dark lines indicate that a higher concentration of 1 M was used. The void (Vo) and 
total column volumes (VT) are indicated. Sar1Val5L-Br5Phe8 Angiotensin II is abbreviated (Sar1Val5). 
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Figure 4.8 Analysis of AT1R with different concentrations of Sar1 
(A) The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours, 
incubated with Sar1 at the concentration indicated (or no ligand was added), solubilised in DDM and evaluated 
by analytical FSEC using a 200 l sample loop. The elution of iHEK(AT1R-GFP-H10) was detected using GFP 
fluorescence (mV). Dashed lines indicate the middle of the ‘no ligand’ condition peak (green line). Different 
concentrations of Sar1 (blue lines) are shown. The void (Vo) and total column volumes (VT) are indicated. (B) 
The amount of functional AT1R in each condition was determined by measuring specific binding of the 
antagonist [125I]-Sar1 (Section 2.2.11). After the addition of ligand, membranes were solubilised in DDM and 
non-bound ligand was separated from receptor-ligand complex on gel filtration spin columns and measured by 
liquid scintillation counting. An identical number of cells (55 thousand) was used for each assay. Each data point 
was determined in triplicate and was plotted as mean ± SEM.  
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Figure 4.9 Analysis of AT1R for different periods of time with Sar1  
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours, incubated 
with the ligand at the concentration indicated (or no ligand was added), solubilised in DDM and evaluated by 
analytical FSEC using a 200 l sample loop. The elution of iHEK(AT1R-GFP-H10) was detected using GFP 
fluorescence (mV). Dashed lines indicate the middle of the ‘no ligand’ condition peak (green line). The void (Vo) 
and total column volumes (VT) are indicated. (A) Different solubilisation times in DDM are shown: 1 hour (green 
line) and 16 hours (blue line). (B) Different solubilisation times are shown with DDM in the presence of Sar1: 1 
hour with no ligand (green line) and 16 hours with Sar1 (blue line). (C) The amount of functional AT1R in each 
condition was determined by measuring specific binding of the antagonist [125I]-Sar1. After the addition of ligand, 
membranes were solubilised in DDM and non-bound ligand was separated from receptor-ligand complex on gel 
filtration spin columns and measured by liquid scintillation counting. An identical number of cells (55 thousand) 
were used per assay. Each data point was determined in triplicate and was plotted as mean ± SEM. 
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Figure 4.10 Effects of azilsartan on AT1R is mitigated with the use of LMNG 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours, (A) 
incubated with no ligand (green line) or 100 M azilsartan (blue line), solubilised in LMNG and evaluated by 
analytical FSEC using a 200 l sample loop. (B) Overnight solubilisation in LMNG is shown without ligand 
(green line) and with 100 M azilsartan (blue line). 
 
 
 Change in apparent molecular weight of AT1R as determined by 
analytical FSEC 
 
In order to understand the change in retention volume at the highest point of the peak in 
terms of molecular weight, the column used for FSEC was calibrated with molecular weight 
standards (Figure 4.11). This enabled the estimation of the apparent molecular weight of 
AT1R under the various conditions tested (Table 4.2). Although the column used was the 
most appropriate one available for the size range that AT1R-GFP eluted, it did not separate 
proteins with good resolution in this range (Figure 4.11). From these data, the size of wild 
type AT1R-GFP, solubilised in DDM with no ligand bound (Table 4.2; numbers 1, 14, 19, 
20 and 33) varied from 490 kDa to 660 kDa with an average weight of 510 kDa. The 
molecular weight of AT1R-GFP solubilised in DDM with ligand bound (Table 4.2; numbers 
2-13, 15-18, 21 and 22) varied from 290 kDa to 650 kDa with an average weight of 460 
kDa, which within experimental error is similar to without ligand bound. From the amino 
acid sequence, the estimated molecular weight for wild type AT1R-GFP is 72 kDa (Table 
4.3). The DDM detergent micelle can add approximately 100 kDa of mass 100, 165. The mass 
of the three complex N-glycans was calculated by plotting the apparent mobility of 
glycosylated AT1R-GFP against the log molecular weight of the molecular weight standards 
on the gel from a western blot (Figure 2.11) and these were estimated to add 15-60 kDa. 
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Therefore the macromolecular weight of the protein plus the detergent micelle and the three 
complex N-glycans should be about 230 kDa, which is much less than the apparent 
molecular mass obtained from FSEC. There are a number of possibilities for explaining 
these observed discrepancies in apparent molecular weight and they are discussed in Section 
4.4. In contrast, AT1R-T4 lysozyme (T4L) fusion protein (produced from the cell line 
iGNTI42; Chapter 5) solubilised in DDM without ligand (Table 4.2; numbers 34-36) varied 
in apparent weight from 230 kDa to 280 kDa with an average molecular weight of 250 kDa 
without ligand, whereas the condition with ligand had an apparent molecular weight of 260 
(Table 4.2; number 38). Another observation from the data was that the apparent weight of 
AT1R-T4L-GFP in LMNG (Table 4.2; number 31) was lower than in DDM (190 kDa 
compared to 250 kDa) which was possibly due to LMNG having a smaller detergent 
micelle. LMNG also produced a smaller apparent molecular weight for wild type AT1R-GFP 
(Table 4.2; numbers 27 and 29; average 373 kDa).  
 
A 
 
  
B 
 
Figure 4.11 Calibration of Superdex 200 10/300 GL 
(A) The Superdex 200 10/300 GL was calibrated using molecular weight standards according to the 
manufacturer’s protocol. The retention volumes of each of the protein standards is as follows (molecular weights 
in parentheses (kDa)): blue dextran, 8.2 ml (2000); ferritin, 10.5 ml (440); -amylase, 12.1 ml (200); alcohol 
dehydrogenase, 13.0 ml (150); albumin, 13.9 ml (66); carbonic anhydrase, 15.8 ml (29); cytochrome C, 17.2 ml 
(12.4). (B) Linear regression was used to establish a line of best fit relating the partition coefficient (Kav) and 
log10 of the molecular weights (Section 4.2.3).  
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Table 4.2 Estimated molecular weight of AT1R-GFP-H10 
Cells expressing AT1R-GFP-H10 were solubilised in the detergent indicated and analysed by FSEC. The 
Superdex 200 10/300 GL was calibrated by running samples of known molecular weight (Figure 4.11). The 
ligand Sar1Val5L-Br5 Phe8 angiotensin II is abbreviated (Sar1Val5). The cell line iHEK415 expressed wild type 
AT1R-GFP-H10, whereas iGNTI25 expressed AT1R Del.K323-E359-GFP-ZZ (Chapter 5) and iGNTI42 
expressed LS-FLAG-AT1R(1-228)-T4L-AT1R(229-323)-TEV-AT1R(323-359)-GFP-H10 (Chapter 5); see Table 4.3 
for more information. Shading is used to group samples that were measured at the same time and are therefore 
directly comparable and fall into the following groups: Group 1, samples 1-13; Group 2, samples14-18; Group 3, 
samples 19-20; Group 4, samples 21-22; Group 5, samples 23-25; Group 6, sample 26; Group 7, samples, 27-
28; Group 8, 29-32; Group 9, samples 33-38.  
 
Index Cell line  
(Na butyrate) 
Ligand Detergent  
(solubilisation  
time) 
Peak  
height  
(mV) 
Peak height 
retention 
volume  
(ml) 
Estimated 
molecular 
weight  
(kDa) 
1 iHEK415 No ligand DDM (1 hour) 3.85 10.32 520 
2 iHEK415 40 nM Angiotensin II DDM (1 hour) 3.36 10.62 440 
3 iHEK415 100 μM L-162,313 DDM (1 hour) 2.05 10.62 440 
4 iHEK415 40 nM Sar1 DDM (1 hour) 3.31 10.59 450 
5 iHEK415 100 μM Sar1 DDM (1 hour) 1.29 10.02 610 
6 iHEK415 40 nM Azilsartan DDM (1 hour) 0.80 11.44 290 
7 iHEK415 100 μM Azilsartan DDM (1 hour) 1.86 11.23 320 
8 iHEK415 100 μM Candesartan DDM (1 hour) 1.54 10.77 410 
9 iHEK415 100 μM Valsartan DDM (1 hour) 1.94 10.64 440 
10 iHEK415 100 μM EMD 66684 DDM (1 hour) 1.85 10.88 390 
11 iHEK415 100 μM ZD 7155 HCl DDM (1 hour) 2.09 11.09 340 
12 iHEK415 100 μM Olmesartan DDM (1 hour) 1.56 10.85 390 
13 iHEK415 100 μM Losartan K DDM (1 hour) 2.18 10.75 410 
14 iHEK415 No ligand DDM (1 hour) 5.78 9.89 660 
15 iHEK415 40 nM Sar1Val5 DDM (1 hour) 5.15 10.03 610 
16 iHEK415 1 μM Sar1Val5 DDM (1 hour) 4.37 10.00 620 
17 iHEK415 40 nM L-158,809 DDM (1 hour) 5.36 10.14 570 
18 iHEK415 1 μM L-158,809 DDM (1 hour) 4.35 9.90 650 
19 iHEK415 No ligand DDM (1 hour) 7.28 10.45 490 
20 iHEK415 No ligand  DDM (overnight) 3.85 10.35 510 
21 iHEK415 100 nM Sar1 DDM (1 hour) 6.28 10.51 470 
22 iHEK415 100 nM Sar1 DDM (overnight) 0.95 10.93 380 
23 iGNTI25 40 nM Sar1 DDM (1 hour) 1.83 10.93 380 
24 iGNTI25 (1 mM)  40 nM Sar1 DDM (1 hour) 3.77 11.12 340 
25 iGNTI25 (5 mM)  40 nM Sar1 DDM (1 hour) 2.90 10.99 360 
26 iHEK(AT1R-GFP-H10) 10 μM Angiotensin II Digitonin (1 hour) 0.99 11.14 340 
27 iHEK415 No ligand LMNG (overnight) 3.90 10.69 430 
28 iHEK415 100 μM Azilsartan LMNG (overnight) 3.65 10.83 400 
29 iHEK415 No ligand LMNG (1 hour) 4.33 11.23 320 
30 iHEK415 100 μM Azilsartan LMNG (1 hour) 3.99 11.17 330 
31 iGNTI42 No ligand LMNG (1 hour) 0.74 12.16 190 
32 iGNTI42 100 μM Azilsartan LMNG (1 hour) 0.85 12.16 190 
33 iHEK415 No ligand DDM (1 hour) 5.66 10.83 400 
34 iGNTI42 No ligand DDM (1 hour) 0.38 11.49 280 
35 iGNTI42 (2.5 mM) No ligand DDM (1 hour) 0.62 11.83 230 
36 iGNTI42 (5 mM)  No ligand DDM (1 hour) 0.92 11.68 250 
37 iGNTI42 No ligand DDM + CHS (1 hour) 1.06 11.63 260 
38 iGNTI42 1 μM Sar1 DDM (1 hour) 0.41 11.60 260 
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Table 4.3 Molecular weights of proteins expressed from three cell lines 
Cell line 
name 
Recombinant protein expressed  Estimated molecular 
weight of the protein 
(kDa) 
N-linked glycosylation sites 
(type of sugars) 
iHEK415 * AT1R-GFP-H10 72 3 (complex glycosylation) 
iGNTI25 † AT1R(Del.K323-E359)-GFP-ZZ 86 3 (high mannose) 
iGNTI42 † LS-FLAG-AT1R(1-228)-T4L-AT1R(229-
323)-TEV-AT1R(324-359)-GFP-H10 
93 3 (high mannose) 
* The clonal cell line iHEK415 is discussed in detail in Chapter 3. † Cell lines iGNTI25 and iGNTI42 are 
discussed in detail in Chapter 5.  
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4.4 Discussion 
 
Given the availability of several ligands which tightly bind to AT1R, an FSEC-based ligand 
screen was performed to determine which of these would best stabilise the receptor. It was 
found that none of the receptor-ligand complexes tested had an FSEC peak as symmetrical 
and as intense as the condition with no ligand. One possibility was that while the ligands 
might be an inverse agonist for one pathway (such as G protein coupling) they may act as an 
agonist for another pathway (such as -arrestin coupling). In the active conformation that 
couples to either a G protein or -arrestin, GPCRs tend to be much less stable than when in 
the inactive conformation. Although none of the ligands tested here have been shown to be 
biased agonists in the literature, the effect of concentration might cause these ligands to act 
in such a fashion by increasing the amount of time a receptor is bound to a ligand and hence 
increasing the probability of a conformational change. Another possibility was that the 
ligands may be behaving in a manner analogous to protean agonism. This theory describes 
the potential for a ligand to change its activity from agonism to inverse agonism if the 
agonist produces a conformation that is of lower efficacy than the constitutively active 
conformation 166, 167, 168. This means that a ligand can activate receptors in the inactive state 
and act as an inverse agonist to receptors showing a constitutive level of activity. Protean 
agonism has thus far only been observed in systems with a high level of basal activity 169 
and AT1R had been thought to be held in an inactive conformation 
88. However it is difficult 
to determine what happens to receptors in detergent since both G protein and -arrestin 
coupling assays cannot be performed on detergent-solubilised receptors. Nevertheless, the 
theory of protean agonism suggests that the pharmacological characteristics of a receptor are 
dependent on its environment. This, combined with concentration effects, might explain the 
behaviour of AT1R shown here. Thermostabilisation of the receptor might enable AT1R to 
be locked in one conformation diminishing or entirely abolishing these effects. Another 
approach would be to use T4L to stabilise the receptor, however the only AT1R-T4L 
construct to be expressed at suitable levels proved to be unstable as assayed by FSEC 
(Chapter 5).  
 
From the amino acid sequence, the molecular weight of AT1R-GFP-H10 was predicted to be 
72 kDa, however, as determined by FSEC, the average observed molecular weight of AT1R-
GFP-H10 without ligand bound was 510 kDa. This discrepancy could potentially be 
explained by the increase in the Stokes radius of AT1R-GFP due to the presence of three 
complex N-glycans, which could appreciably affect the mobility of the protein on SEC and 
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therefore cause it to elute at a lower volume than expected. Interestingly, the cell line 
iGNTI25 (Chapter 5), which has all three glycosylation sites intact but only produced the 
mannose core, had an average molecular weight of 350 kDa with ligand bound. Since this 
weight was also much larger than what was predicted from the amino acid sequence, 
glycosylation alone does not explain the increase in weight. Another possibility for the 
increase in molecular weight was the detergent micelle. However, the detergent micelle 
from DDM only contributes approximately 100 kDa of mass 100, 165. Using a detergent assay 
170 on the purified protein would determine precisely how much weight the detergent micelle 
added. Similarly, repeating FSEC on the deglycosylated receptor could establish the 
contribution of N-glycans to the weight of AT1R, but using PNGase F on unpurified material 
is prohibitively expensive. If these assays confirm that AT1R is still much larger than 
predicted, two theories might explain this. First, AT1R might have either G proteins or -
arrestin still bound which could add over 100 kDa or 50 kDa respectively. A high salt wash 
(1 M or above) of the membranes prior to solubilisation would disrupt any protein-protein 
interactions and allow for this theory to be tested. Second, AT1R-T4L in DDM had an 
apparent molecular weight much closer to the estimated weight of AT1R-GFP in DDM with 
three complex N-glycans. Since the apparent molecular weight of AT1R-T4L was half that 
of AT1R without the T4L fusion, it is possible that AT1R exists in detergent solution as a 
dimer and T4L prohibits the formation of AT1R dimers. If AT1R is normally a dimer, this 
might also explain why the FSEC signal was very low for all of the AT1R-T4L-GFP 
conditions. This could be because detergent-solubilised AT1R might be significantly more 
stable in the dimeric form or it might prevent the binding of a G protein.  
 
In conclusion, the most symmetrical FSEC peak observed was with no ligand bound. Further 
assays needed to be performed on the purified material, therefore the next steps were to 
express AT1R in large scale and to purify the receptor. 
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CHAPTER 5 ENGINEERING AT1R FOR USE IN 
STRUCTURAL STUDIES 
 
5.1 Introduction 
 
The use of FACS to select highly expressing clonal stable cell lines increased the expression 
of AT1R two-fold in comparison to the stable polyclonal cell line. Although this increase in 
expression was substantial, it was not without its problems. For example, the FACS sort 
method takes 2-3 months to complete on top of the 2 months required to create the parental 
polyclonal stable cell line, therefore other methods of increasing expressing were 
investigated. Additionally, it was important to establish whether AT1R would benefit from 
further engineering in order to make it more amenable for crystallography. Specifically, it 
was unknown whether AT1R contained flexible regions which might hinder crystal 
formation and whether the strategy of adding a small soluble protein, such as bacteriophage 
T4 lysozyme (T4L), would improve the stability of AT1R and increase the likelihood of 
crystal contacts forming. 
 
It has been observed that there is a charge-bias in membrane proteins, with more positively 
charged residues in the cytoplasmic loops compared to the extracellular loops 171, 172. The 
positive-inside rule indicates that short protein segments (less than 70-80 residues long) 
containing Arg and Lys residues are translocated across the plasma membrane two to four 
times less frequently than segments not containing those residues 172. Therefore, insertion of 
GPCRs into the plasma membrane might be negatively impacted if positively charged 
residues were present on the N-terminus. Since AT1R contained four positively charged 
residues on its N-terminus (Lys12, Arg13, Lys20 and Arg23) this might explain why 
expression of AT1R was low. Another strategy to increase expression of membrane proteins 
with an extracellular N-terminus is the inclusion of a leader sequence (LS). LSs are short 
amino acid sequences which are generally non-conserved and are comprised of a 
hydrophobic core flanked by polar amino acids 173. During biosynthesis of a membrane 
protein, the ribosome is first targeted to the membrane where it docks to the heterotrimeric 
Sec61 complex which efficiently exports the C-terminal portion of a LS to the endoplasmic 
reticulum lumen, hence resulting in the translocation of the N-terminus of the GPCR 174. The 
use of a LS for the expression of AT1R in the baculovirus system doubled the amounts of 
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active AT1R (Section 2.4), therefore it was worth investigating its utility in the mammalian 
system.  
 
Flexible regions in a protein often present potential obstacles for crystallography. A 
common approach to removing flexible regions of a protein is the use of limited proteolysis 
on the purified protein, however this method is not always 100% reproducible and can lead 
to protein heterogeneity. Another method to remove flexible regions from a protein is the 
use of site-directed mutagenesis to produce suitable truncations. For GPCRs, non-conserved 
regions are potentially flexible and an alignment of the receptor of interest can be performed 
with GPCRs of known structure to determine these areas. In particular, regions in the N-
terminus, the C-terminus and CL3 are often flexible. For AT1R, both the N-terminus and 
CL3 are short, however it does contain a long non-conserved C-terminus (Appendix 1). 
Additionally, algorithms such as the regional order neural network (RONN) software 175 can 
be used to predict disordered regions. For the 1-adrenergic receptor truncations at the C-
terminus and CL3 were necessary in order to obtain well-diffracting crystals 165. Using CHO 
cell lines stably expressing C-terminal deletions of rat AT1R cells Conchon et al. 
176 showed 
that deletions of the C-terminus of AT1R up to residue 314 exhibited a similar affinity for 
angiotensin II as the wild type receptor and did not change expression levels. However, 
Gaèborik et al. 177 also examined the effect of C-terminal deletions on the rat AT1R up to 
residue 309 and found that, while binding affinities were unchanged, expression of the 
receptor decreased with increasing the length of the truncation and truncation at residue 309 
reduced expression to 4% of the wild type receptor. If AT1R is to be truncated to remove 
flexible regions, the impacts on expression and ligand binding need to be carefully 
monitored.  
 
A common strategy for increasing the hydrophilic area of GPCRs, as well as potentially 
stabilising them, is to create a fusion with a small soluble protein such as bacteriophage T4 
lysozyme (T4L). This method was successfully employed to crystallise the β2AR and 
resulted in a 2.4 Å resolution structure 24, 41. The crystals were grown in lipidic cubic phase 
(LCP), because vapour diffusion crystal trials did not result in the formation of well-
diffracting crystals. While the addition of a fusion protein can introduce flexibility, the 
specific placement of lysozyme in CL3 was successful in reducing flexibility in this region. 
T4L has since been used to successfully produce numerous high-resolution GPCR structures 
and it was therefore worthwhile investigating this strategy for the crystallisation of AT1R.  
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5.2 Materials and Methods 
 
 Materials 
 
IgG Sepharose 6 FastFlow and Q Sepharose were purchased from GE Healthcare. Anti-
FLAG M2 affinity gel and Concanavalin A resin were purchased from Sigma. 
 
 Further alterations of AT1R 
 
Site directed mutagenesis (Section 2.2.3) was used to remove positive residues from the N-
terminus of AT1R expressed from the plasmid pJAP2 (Section 2.2.3). A leader sequence 
(LS) based on the 5HT3A serotonin receptor (MRLCIPQVLLALFLSMLTGPGEGS) was 
inserted before the sequence of AT1R. In order to label AT1R the Snap tag sequence (New 
England Biolabs) was added to its N-terminus. A sequence encoding a tandem IgG binding 
domain (ZZ) based on S. aureus protein A 178 was added to the C-terminus of AT1R-GFP to 
enable affinity purification. The sortase sequence (LPETGGGRR) 179, 180, 181, 182 was added 
to the truncated C-terminus of AT1R to facilitate the attachment of peptides to AT1R. The 
tobacco etch virus (TEV) recognition sequence (ENLYFQG) was added to promote site 
specific proteolysis 183, 184. The nucleotide sequences for the inserts in plasmids pJAP24, 25 
and 32 were synthesised by IDT and cloned into the EcoRI/XbaI sites of pcDNA4/TO. 
Cysteine-free bacteriophage T4 lysozyme (N2-Y161 with the mutations C54T and C97A) 70 
was codon optimised for expression in mammalian cells and inserted between residues 
Ile228 and Gln229 of AT1R. See Table 5.1 for a full description of the plasmids used. 
 
 Large scale suspension culture of mammalian cells 
 
For large scale suspension culture of mammalian cells, 2 litres of cells at a density of 0.5-1 
million cells per ml were added to a 10-litre Cellbag (GE Healthcare), connected to a 
WAVE Bioreactor (GE Healthcare), incubated at 37°C with 5% CO2 and rocked at 20 r.p.m. 
with an angle of 6°. The cell density was checked daily and the culture was expanded by 
diluting it to 1 million cells per ml with fresh media when the cells reached a density over 
1.5 million cells per ml until the desired total volume was reached (i.e. 10 litres). The r.p.m. 
were gradually increased to 30 and the angle to 7° as the culture was expanded. Cells were 
induced at a density of 1-2 million cells per ml by adding tetracycline to a final 
concentration of 1 g/ml and incubating at 37°C for 24 h.   
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Table 5.1 AT1R alterations for mammalian expression 
Plasmid 
name 
Inserts and mutation(s) † Vector 
backbone 
pJAP4 LS-Snap tag- AT1R-GFP-H10 pcDNA4/TO 
pJAP17 AT1R(K12Q)-GFP-H10 pcDNA4/TO 
pJAP18 AT1R(R13Q)-GFP-H10 pcDNA4/TO 
pJAP19 AT1R(K20Q)-GFP-H10 pcDNA4/TO 
pJAP20 AT1R(R23Q)-GFP-H10 pcDNA4/TO 
pJAP22 LS-AT1R-GFP-H10 pcDNA4/TO 
pJAP24 LS-FLAG tag-TEV-AT1R(Del. P321-E359)-TEV-GFP-H10 pcDNA4/TO 
pJAP25 LS-FLAG tag-TEV-AT1R(Del. K323-E359)-Sortase-GFP-TEV-ZZ pcDNA4/TO 
pJAP26 LS- FLAG tag-TEV- AT1R(N4A+N188A+Del.P321-E359)-TEV-GFP-H10 pcDNA4/TO 
pJAP30 LS-FLAG tag-TEV- AT1R(Del. K323-E359)-TEV-GFP-H10 pcDNA4/TO 
pJAP32 LS-FLAG tag-TEV- AT1R(I228-Q229 CL3-T4L-Del. K323-E359)-TEV-GFP-H10 pcDNA4/TO 
pJAP40 LS-FLAG tag-TEV- AT1R(I228-Q229 CL3-T4L-Del. K323-E359)-TEV-GFP-ZZ-H10 pcDNA4/TO 
pJAP42 LS-FLAG tag-TEV- AT1R(I-228)-T4L-AT1R(229-323)-TEV-AT1R(324-359)-GFP-H10 pcDNA4/TO 
pJAP43 LS-FLAG tag-TEV- AT1R(Del. K323-E359)-TEV-GFP-ZZ-H10 pcDNA4/TO 
† The inclusion of a leader sequence (LS), the ZZ domain of protein A (ZZ) and bacteriophage T4 lysozyme 
(T4L) into cellular loop 3 (CL3) of AT1R are indicated. 
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5.3 Results 
 
 Effects of N-terminal alterations and inclusion of a leader sequence on 
AT1R expression in mammalian cells 
 
The positive-inside rule indicates that short protein segments containing Arg and Lys 
residues are translocated across the plasma membrane less efficiently than segments not 
containing those residues 171, 172. In order to test whether this had any impact on the 
expression of AT1R, the N-terminus of AT1R was mutated. AT1R contained four positively 
charged residues in its N-terminal region: Lys12, Arg13, Lys20 and Arg23. Therefore, 
expression of AT1R could potentially be reduced by the presence of these positively charged 
amino acids. To test this theory, each of the positively charged residues was mutated to the 
polar uncharged residue Gln (Table 5.1). The mutated plasmids were transiently transfected 
into iHEK cells and analysed by both FACS (Figure 5.1) and in-gel fluorescence (Figure 
5.2). There was a noticeable increase in expression of AT1R when the positive residues on 
the N-terminus were mutated to Gln. In particular mutations K12Q and R23Q appeared to 
have the greatest impact on increasing expression (Figure 5.1).  
 
A 
 
B 
 
Figure 5.1 Removal of positive charges on the N-terminus of AT1R increases expression 
For FACS analysis, iHEK cells were transiently transfected with plasmids expressing either AT1R-GFP-H10 or 
the mutations indicated and induced for 24 hours, harvested in PBS and analysed on the FACSCalibur II for 
GFP fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). (A) Histogram of GFP 
fluorescence intensity. AT1R-GFP-H10 (red), AT1R(K12Q)-GFP-H10 (blue), AT1R(R13Q)-GFP-H10 (green), 
AT1R(K20Q)-GFP-H10 (orange) and AT1R(R23Q)-GFP-H10 (purple). (B) Median FACS fluorescence intensity; 
uninduced (hatched bars), induced (solid bars) and cells positive for GFP expression (%) (diamonds).  
 
In-gel fluorescence of N-terminal positively charged AT1R mutants showed that despite the 
alterations, they were still glycosylated and the gel band intensity roughly correlated with 
the percentage of positive cells (Figure 5.2). Despite these positive findings, N-terminal 
residues had previously been found to be important for ligand binding in peptide receptor 
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structures, such as the neurotensin receptor 70. Disruption of the ligand binding pocket would 
not be a favourable outcome, therefore, other means for increasing AT1R expression were 
investigated.  
  
A 
 
B 
 
 
 
Figure 5.2 In-gel fluorescence analysis of N-terminus mutants 
N-terminal mutants of AT1R were transiently transfected into iHEK cells, induced for 24 hours with tetracycline 
and analysed by in-gel fluorescence. An equal amount of cells was loaded in each lane (A). N-linked 
glycosylation was removed by treatment with PNGase F (B). Bands corresponding to deglycosylated AT1R were 
quantified by using ImageJ (blue circles) and plotted against cells expressing GFP (red squares) (C). Linear 
regression was used to establish a line of best fit for the percentage of positive cells and the Image J values (D). 
 
The addition of a leader sequence (LS) in front of the AT1R sequence doubled its expression 
in the baculovirus system (Section 2.4) therefore the same approach was investigated for 
mammalian cells. A LS based on the 5HT3A serotonin receptor was added in front of the 
AT1R sequence (Table 5.1), the plasmid was transiently transfected into iHEK cells and 
these were analysed by FACS (Figure 5.3). Inclusion of a LS gave an increase in FACS 
median of 3 to 4. Additionally, an iHEK cell line stably expressing AT1R with a LS (iHEK4; 
Figure 5.4) showed a 50% increase in expression of AT1R-GFP as measured by FACS 
analysis (Figure 5.3). The inclusion of a LS was an ideal way to increase expression since it 
did not require the 2-3 months that FACS selection took (Chapter 3), nor was it likely to 
interfere with ligand binding, which N-terminal mutations could have done. 
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Figure 5.3 Inclusion of a leader sequence increases AT1R expression in mammalian cells 
Histogram of GFP fluorescence intensity. For FACS analysis cells were induced for 24 hours, harvested in PBS 
and analysed on the FACSCalibur II for GFP fluorescence using the FL-1 detector. Cell counts have been 
normalised (% of Max). (A) iHEK cells were transiently transfected with plasmids expressing either AT1R-GFP-
H10, (red line; median fluorescence intensity of 3) or AT1R-LS-GFP-H10, (blue line; median fluorescence intensity 
of 4). (B) FACS analysis of the stable polyclonal cell line iHEK(AT1R-GFP-H10) (green line; median fluorescence 
intensity of 293) and iHEK4 (expressing LS-Snap Tag-AT1R-GFP-H10) (see Figure 5.4 for construct information) 
(purple line; median fluorescence intensity of 425).  
 
 
Cell line name iHEK4 
Open reading frame 
schematic 
 
Parental cell line iHEK 
 
Master Gain 1107 
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  Digital Offset 0.00 
  
Figure 5.4 Assessment of cell line created to express AT1R-LS-GFP-H10 
Assessment of the iHEK4 polyclonal cell line was based on confocal microscopy and the average counts for 
FACS analysis. 
 
 The impact of AT1R C-terminal truncations on expression 
 
To determine whether AT1R had any disordered regions, which might hinder crystallisation, 
the amino acid sequence of human AT1R was analysed by regional order neural network 
(RONN) software 175 (Figure 5.5). This software used an algorithm to detect potentially 
disordered regions in AT1R. The N-terminus of AT1R was predicted to be ordered, but the 
C-terminus, starting from Ala324, was predicted to be disordered (Figure 5.5). 
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Figure 5.5 Human AT1R probability of disorder  
The amino acid sequence of human AT1R was entered into the RONN software algorithm 175 to detect natively 
disordered segments. A probability of 0.5 or greater suggests that the residue was likely to be disordered. 
Human AT1R was predicted to have a disordered C-terminus starting at alanine 324. 
 
To remove the potentially disordered C-terminus, AT1R was truncated in two different 
ways, either P321-E359 or K323-E359. Six new cell lines that stably expressed truncated 
versions of AT1R were created (Figure 5.6). From the FACS analysis and radioligand 
binding data only cell lines that contained P321-P322 showed favourable expression (Figure 
5.7). Cell lines iHEK25 and iGNTI25, which contained P321-P322, showed a 19-fold 
increase in molecules of AT1R per cell in comparison to cell lines iHEK24 and iHEK26, 
both of which did not contain the two proline residues. Additionally, when analysed by 
FSEC, the iGNTI25 cell line showed a peak around the volume expected for AT1R-GFP 
(approximately 11 ml) (Chapter 4), whereas the cell line iHEK26 only showed a peak at 
about 16 ml, which is the volume where GFP alone elutes, possibly indicating that AT1R in 
the iHEK26 cell had been degraded (Figure 5.8). The effects of C-terminal truncations on 
AT1R were unexpected since previously it had been shown that C-terminal truncation of the 
rat version of AT1R up to amino acid 314 did not alter its expression in CHO cells 
176. 
However the opposite was found to be true in a further study 177. One possible explanation 
for the decrease in expression was that the truncations were near to or located in helix 8. An 
alignment of AT1R with GPCRs of known structure (Appendix 1) indicated that H8 of AT1R 
might be located in this region. If the C-terminal truncations removed a portion of H8, then 
AT1R would be severely destabilised and rapidly degraded. This might explain the drop in 
expression. For further analysis of the iGNTI25 cell line see Section 5.3.4. 
 
After examination of the effects of N-linked glycosylation upon AT1R expression and 
stability, it was deemed that the only N-linked glycosylation mutant worth further exploring 
was AT1R(N4A+N188A) (Section 2.3.2). Therefore, two cell lines stably expressing AT1R 
N-linked glycosylation mutations (N4A and N188A) were created, one in iHEK cells 
324
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(iHEK26) and one in iGnTI— cells (iGNTI26) (Figure 5.6). Neither of these stable cell lines 
showed favourable levels of expression and therefore were not further investigated. 
However, unfortunately both contained C-terminal deletions that removed P321-P322, 
therefore it is unknown whether the reduction in AT1R expression was due to the lack of N-
glycosylation sites or the C-terminal truncation. 
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Figure 5.6 Assessment of cell lines created to express C-terminal truncations of AT1R 
Assessment of polyclonal cell lines was based on confocal microscopy and the average counts for FACS 
analysis and [125I]-Sar1 binding. 
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Figure 5.7 Truncation of AT1R at proline 321 decreases expression 
Six stable cell lines were created from three separate constructs and two different cell lines: three in iHEK cells 
and three in iGnTI— cells. See Figure 5.6 for construct information. For each of these cell lines, the process was 
repeated six times and the highest expressing population was retained. (A) Cells were harvested in PBS and 
analysed on the FACSCalibur II for GFP fluorescence using the FL-1 detector. (B) The amount of functional 
DDM-solubilised AT1R in each cell line was determined by measuring specific binding of the antagonist [125I]-
Sar1. The assay was performed in at least triplicate and plotted as a mean value ± SEM. 
 
 
 
Figure 5.8 FSEC analysis of AT1R-GFP expression from the iGNTI25 and iHEK26 stable cell line 
The cell lines iGNTI25 (expressing AT1R(Del. K323-E359)-GFP-H10) (red line) and iHEK26 (expressing 
AT1R(Del. P321-E359)-GFP-H10) (blue line) were induced with tetracycline for 24 hours and analysed by FSEC. 
The elution of AT1R-GFP-H10 was detected using GFP fluorescence (mV). The void (Vo) and total column 
volumes (VT) are indicated. 
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 Stability gained by the insertion of T4 lysozyme into intra-cellular loop 
three of AT1R 
 
In order to increase the likelihood of crystal contacts forming and to potentially increase the 
stability of AT1R, T4L was inserted into intracellular loop three (CL3) of AT1R. In order to 
determine where to place T4L, AT1R was aligned with other GPCR-T4L fusions (Appendix 
1). From this alignment the ideal area to place T4L in CL3 was determined to be between 
residues I228-Q229. Four separate cell lines stably expressing the AT1R-CL3-T4L fusion 
were created as well as two cell lines without the T4L fusion; the last two cell lines acted as 
a control to see whether the inclusion of T4L affected expression (Figure 5.9). The only cell 
line of this group that showed favourable expression was iGNTI42 which expressed 
approximately 3 million copies of AT1R-CL3-T4L per cell (Figure 5.9).  
 
As a way to measure the stability of the AT1R-CL3-T4L fusion, the apparent Tm of AT1R-
CL3-T4L expressed in the stable cell line iGNTI42 (expressing AT1R-T4L; Table 5.1) was 
measured (Section 2.2.10). From this assay, antagonist-bound AT1R-CL3-T4L fusion 
showed an 11°C increase in the apparent Tm in comparison to wild type receptor in the 
[Super +] format assay (Figure 5.10 and Table 5.2). Interestingly, the [-] format assay 
showed that antagonist-bound AT1R-CL3-T4L was 6°C less stable than the wild type 
receptor (Figure 5.10 and Table 5.2). Additionally, when examined by FSEC, the AT1R-
CL3-T4L fusion had a significantly lower signal than the wild type receptor, where an equal 
number of cells were examined, as well as a peak that was shifted to the right (Figure 5.11). 
The addition of the antagonist Sar1 and the use of CHS did not help to stabilise the AT1R-
CL3-T4L fusion (Figure 5.12), neither did the use of the mild detergent LMNG, nor addition 
of the antagonist azilsartan (Figure 5.13). 
 
Since the [Super +] format assay measures the stability of the ligand binding pocket and the 
[-] format assay is an indicator of the overall stability of a protein, a possible explanation for 
the reduction in signal seen in the FSEC analysis could be that while T4L stabilised the 
ligand binding pocket of AT1R, it destabilised the other regions of the receptor. Given this, it 
was decided to progress with the iGNTI25 cell line which did not contain T4L but contained 
a C-terminal truncation of AT1R, thus making it more suitable for crystallography than the 
wild type protein and which showed the highest level of AT1R expression of all of the C-
terminal truncations.  
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Figure 5.9 Assessment of cell lines created to express AT1R-T4L and C-terminal truncations of AT1R 
Assessment of polyclonal cell lines was based on confocal microscopy and the average counts for FACS 
analysis and [125I]-Sar1 binding. 
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Figure 5.10 Tm assay of AT1R-T4L fusion 
(A) Stability of DDM-solubilised AT1R bound to the antagonist [125I]-Sar1 performed in the [Super +] format. 
AT1R was expressed from the stable cell line iHEK415 (expressing AT1R-GFP-H10), green diamonds, and 
iGNTI42 (expressing AT1R-T4L-GFP-H10), blue triangles. (B) Stability of LMNG-solubilised AT1R bound to the 
antagonist [125I]-Sar1 performed in the [-] format. AT1R was expressed from the stable cell line iHEK415 
(expressing AT1R-GFP-H10), green diamonds, and iGNTI42 (expressing AT1R-T4L-GFP-H10), blue triangles. 
Each data point was determined in triplicate and was plotted as a mean value ± SEM. Results are summarised 
in Table 5.2. 
 
 
Table 5.2 Thermostability of AT1R-T4L fusion  
CL3 Fusion Assay Format Detergent (w/v) Tm (C) SEM 
None [Super +] 1% DDM 43.5 0.7 
T4L [Super +] 1% DDM 54.2 0.8 
None [-] 1% LMNG 27.4 1.1 
T4L [-] 1% LMNG 21.8 1.4 
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Figure 5.11 FSEC analysis of AT1R expression from the iGNTI42 stable cell line 
The cell line iGNTI42 (expressing AT1R-T4L-GFP-H10) was induced with tetracycline only (green line), 
tetracycline with 2.5 mM Na butyrate (red line) or tetracycline with 5 mM Na butyrate (blue line) for 24 hours and 
analysed by FSEC. The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline only 
for 24 hours (grey line). An equal amount of cells was analysed for each run. The elution of AT1R-GFP was 
detected using GFP fluorescence (mV). The void (Vo) and total column volumes (VT) are indicated. 
 
 
 
Figure 5.12 The addition of antagonist and the use of CHS did not stabilise AT1R expressed from the 
stable cell line iGNTI42 
The cell line iGNTI42 (expressing AT1R-T4L-GFP-H10) was induced with tetracycline only for 24 hours and 
analysed by FSEC. 1 M of Sar1 was added to 5 million iGNTI42 cells and allowed to bind for 1 hour at 23°C 
before being solubilised in 1% DDM (red line) or no ligand was added prior to solubilisation (green line). 
Additionally, 5 million iGNTI42 cells were solubilised in 1% DDM with CHS without ligand (blue line). The clonal 
cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours and analysed by 
FSEC. 5 million iHEK415 cells were solubilised in 1% DDM without ligand (grey line). An equal amount of cells 
was analysed for each run. The elution of AT1R-GFP was detected using GFP fluorescence (mV). The void (Vo) 
and total column volumes (VT) are indicated. 
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Figure 5.13 The use of LMNG did not stabilise AT1R-CL3-T4L  
The cell line iGNTI42 (expressing AT1R-T4L-GFP-H10) was induced with tetracycline for 24 hours and analysed 
by FSEC. 100 M of azilsartan was added to 5 million iGNTI42 cells and allowed to bind for 1 hour at 23°C 
before being solubilised in 1% LMNG (orange line) or no ligand was added prior to solubilisation (green line). 
The clonal cell line iHEK415 (expressing AT1R-GFP-H10) was induced with tetracycline for 24 hours and 
analysed by FSEC. 100 M of azilsartan was added to 5 million iHEK415 cells and allowed to bind for 1 hour at 
23°C before being solubilised in 1% LMNG (blue line) or no ligand was added prior to solubilisation (red line). 
An equal amount of cells was analysed for each run. The elution of AT1R-GFP was detected using GFP 
fluorescence (mV). The void (Vo) and total column volumes (VT) are indicated. 
 
 Analysis of the stable cell line iGNTI25 
 
The stable cell line iGNTI25 (truncation of K323 to E359) showed the highest level 
expression of AT1R in comparison to all C-terminal truncations of AT1R (6 million copies 
of AT1R per cell compared to less than 0.4 million copies for all other AT1R truncations; 
Figure 5.6) therefore this cell line was further investigated. It was unknown whether C-
terminal truncations of AT1R affected the stability of the receptor, therefore the stability of 
AT1R(Del. K323-E359) produced from the iGNTI25 cell line was measured using the 
apparent Tm assay (Section 2.2.10). The apparent Tm of antagonist-bound AT1R expressed in 
the iGNTI25 cell line (45.2°C ± 0.8; Figure 5.14) was similar to the apparent Tm of the wild 
type protein (46.5°C ± 0.3; Section 2.3.1) in DDM. 
 
The next step was to optimise expression of AT1R in the iGNTI25 cell line. As shown 
previously (Sections 2.3.4 and 3.3.3), the addition of sodium butyrate to the culture media at 
the time of induction can increase the amount of AT1R produced, and therefore this was 
tested in the stable cell line iGNTI25. As measured by FACS analysis, the addition of 1 mM 
sodium butyrate to the culture media increased expression of AT1R by twofold in 
comparison to no sodium butyrate, whereas the addition of 5 mM sodium butyrate increased 
expression of AT1R by threefold (Figure 5.15). 
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Figure 5.14 Tm assay of AT1R produced from the stable cell line iGNTI25  
Stability of DDM-solubilised AT1R expressed from the stable cell line iGNTI25 bound to the antagonist [125I]-
Sar1.The apparent Tm value of AT1R expressed from iGNTI25 is 45.2°C ± 0.8. Each data point was determined 
in triplicate and was plotted as a mean value ± SEM. 
 
However, the addition of 5 mM sodium butyrate did not increase the in-gel fluorescence 
signal (Figure 5.15). Also, FSEC analysis showed a reduction in signal with the use of 5 mM 
sodium butyrate in comparison to the addition of 1 mM sodium butyrate (Figure 5.16). A 
possible explanation for this was AT1R reached a limit of expression with the inclusion of a 
LS and 1 mM sodium butyrate. Therefore 1 mM sodium butyrate was used for all further 
iGNTI25 cultures.  
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A 
 
B 
 
C 
 
 
 
Figure 5.15 Optimisation of AT1R(Del. K323-E359)-GFP expression in the stable cell line iGNTI25 
FACS analysis of iGNTI25 cells. Cells were harvested in PBS and analysed on the FACSCalibur II for GFP 
fluorescence using the FL-1 detector. Cell counts have been normalised (% of Max). (A) Histogram of GFP 
fluorescence intensity. Uninduced (red), induced with 1 g/ml tetracycline (orange), induced with 1 g/ml 
tetracycline and 1 mM Na butyrate (blue) and induced with 1 g/ml tetracycline and 5 mM Na butyrate (green). 
(B) Median FACS fluorescence intensity. Colours as in (A). (C) In-gel fluorescence of AT1R-GFP expression 
from the iGNTi25 stable cell line. An equal amount of cells was loaded in each lane. N-linked glycans were 
removed using Endo H where indicated (+). (D) Bands corresponding to deglycosylated AT1R were quantified 
using ImageJ (blue circles) and plotted against the median FACS fluorescence intensity (red squares). (E) 
Linear regression was used to establish a line of best fit for the median FACS fluorescence intensity and the 
Image J values. 
 
%
 o
f 
M
a
x
 
Fluorescence Intensity (Arbitrary Units)
FL1
kDa
41
65
155
100
33
M
o
l.
 W
t.
(E
m
p
ty
)
T
e
tr
a
c
y
c
li
n
e
T
e
tr
a
c
y
c
li
n
e
T
e
tr
a
c
y
c
li
n
e
+
 1
 m
M
 N
a
 b
u
ty
ra
te
T
e
tr
a
c
y
c
li
n
e
+
 1
 m
M
 N
a
 b
u
ty
ra
te
T
e
tr
a
c
y
c
li
n
e
+
 5
 m
M
 N
a
 b
u
ty
ra
te
T
e
tr
a
c
y
c
li
n
e
+
 5
 m
M
 N
a
 b
u
ty
ra
te
- - - + - + - + Endo H
CHAPTER 5 Engineering AT1R for Use in Structural Studies 
 Page 110  
 
 
Figure 5.16 FSEC analysis of AT1R(Del. K323-E359)-GFP expression in the iGNTi25 stable cell line 
The iGNTI25 cell line was induced with tetracycline (orange), tetracycline and 1 mM Na butyrate (blue) and 
tetracycline and 5 mM Na butyrate (green) for 24 hours. 40 nM of Sar1 was added to 5 million cells and allowed 
to bind for 1 hour at 23°C before being solubilised in 1% DDM. An equal number of cells was analysed for each 
run. The elution of AT1R-GFP-H10 was detected using GFP fluorescence (mV). The void (Vo) and total column 
volumes (VT) are indicated. 
 
 
 Large scale growth of mammalian cells 
 
After optimising expression of AT1R in the iGNTI25 cell line, the next step was to grow 
iGNTI25 in large scale in order to obtain the amounts of AT1R required for crystallisation 
trials. Previous attempts to express wild type AT1R in the polyclonal cell line iHEK(AT1R-
GFP-H10) using a Wave Bioreactor system, led to the degradation of AT1R, which was 
demonstrated by the presence of free GFP in in-gel fluorescence (Figure 5.17). The cell line 
iHEK(AT1R-GFP-H10) when adapted to suspension culture tended to form clumps and could 
not be grown above a density of 1.5 x 106 cells per ml without a large increase in the number 
of dead cells. The cell line iHEK(AT1R-GFP-H10) when grown in a Wave Bioreactor system 
produced ten litres of culture with 1.3 x 106 cells per ml at time of harvest and had a median 
FACS fluorescence intensity of 227. 
 
In contrast, the polyclonal cell line iGNTI25 did not form clumps and was able to be grown 
at a density of 3.4 x 106 cells per ml in the Wave Bioreactor system. Propidium iodide (PI) 
staining of this population indicated that the cell line iGNTI25 showed minimal cell death 
(2.3% of the total population) (Figure 5.18). The cell line iGNTI25 was induced with 
tetracycline and 1 mM Na butyrate when the density reached approximately 1.5 x 106 cells 
per ml. Ten litres of iGNTI25 cells at 3.4 x 106 cells per ml were harvested and they had a 
median FACS fluorescence intensity of 1407. The clonal cell line iHEK415 induced with 
tetracycline and 5 mM sodium butyrate has a similar median FACS fluorescence intensity of 
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1400 and, using a radioligand binding assay, this cell line was determined to contain 
approximately 26 million molecules of AT1R per cell (Section 3.3.3). Based on this, it was 
estimated that there was approximately 6 mg of AT1R per litre of culture, assuming 3.4 x 
106 cells per ml. 
 
 
Figure 5.17 Degradation of AT1R-GFP produced from the polyclonal cell line iHEK(AT1R-GFP-H10) when 
grown in suspension culture 
In-gel fluorescence of AT1R-GFP expression from the iHEK(AT1R-GFP-H10) stable cell line grown adherently or 
in suspension as indicated. An equal amount of cells was loaded in each lane. N-linked glycans were removed 
using Endo H (+ H) or PNGase F (+ F) where indicated. 
 
 
 
Figure 5.18 FACS analysis of iGNTI25 grown in large scale 
Colour density plots of iHEK cells stained with propidium iodide (PI). The cell line iGNTI25 was grown in a Wave 
Bioreactor. For FACS analysis, a sample of cells was stained with PI (Section 2.2.9) and analysed using the FL-
2 detector to detect fluorescence. Numbers inside the pink rectangles represent the percentage of cells falling 
within the relevant rectangle. 
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 Purification of AT1R 
 
Two stable mammalian cell lines produced sufficient material for the purification of AT1R, 
the monoclonal cell line iHEK415 and the polyclonal cell line iGNTI25. Only iGNTI25 
could be grown in large scale suspension culture (Section 5.3.5), therefore efforts to purify 
AT1R focused on this cell line. Recently a mammalian dynein complex was purified from 
the baculovirus system using a two-step purification consisting of the recombinant protein 
binding to IgG Sepharose and then being directly cleaved from the resin with the use of 
TEV protease, resulting in a homogenous product 185. Since the mammalian dynein complex 
was expressed at a level similar to AT1R (2 mg of dynein complex from 1 litre of culture, 
assuming 1-2 x 106 cells per ml) 185 it was reasonable to assume that this purification process 
would work well with AT1R. However this was not the case. AT1R did not adhere to the IgG 
Sepharose and ended up mostly in the flowthrough (Table 5.3). One possible explanation for 
this was that the binding of AT1R to the resin was hindered due to the presence of 1% 
detergent (final concentration), which was not required for the purification of dynein (a 
soluble protein). However, reducing the amount of detergent used during the solubilisation 
step to 0.5% (final concentration) did not reduce the loss in the flow through. Therefore, an 
Anti-FLAG M2 affinity gel was investigated. Despite optimising the salt concentration and 
examining the use of other detergents, this resin also resulted in major losses of AT1R in the 
flow through (Table 5.3).  
 
One potential explanation for this is that negatively charged DNA present in the cell lysate 
was adhering to the resin and preventing AT1R from binding. As a method to remove DNA, 
a negative purification of AT1R was attempted with Q Sepharose (Table 5.3). Some of the 
DNA was retained on the resin, however the resulting AT1R in the flow through still did not 
bind to the FLAG resin, indicating that either insufficient amounts of DNA were removed or 
some other factor was influencing the binding of AT1R such as the presence of detergent. 
Another possibility was that the resin had a very low binding capacity. A potential way to 
alleviate this problem would be to produce anti-FLAG antibodies and attach them to a resin. 
Finally, Concanavalin A resin, which binds glycoproteins, was used. This had the opposite 
effect to that observed with the other resins. Once AT1R was bound it could not be removed 
from the resin (Table 5.3) however, a glucose gradient was used for elution whereas elution 
with methyl -D-mannopyranoside might have been more effective. 
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Table 5.3 AT1R purifications attempted 
Tag / binding recognition Resin Optimisations Result 
Protein A  IgG Sepharose  1 and 0.5% final 
detergent concentration 
for solubilisation 
 Major loss of protein in 
the flow through 
FLAG tag  Anti-FLAG M2  
affinity gel 
 High and low salt 
 DDM, DDM + CHS and 
LMNG 
 ~80% loss of protein in 
the flow through 
Negatively charged 
substances 
Q Sepharose  Gradient of NaCl for 
binding  
 Negative purification to 
remove contaminating 
DNA 
 Major loss of protein in 
the flow through 
 Some DNA bound 
Glycoproteins Concanavalin A  Elution with a glucose 
gradient 
 AT1R would not elute 
from column 
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5.4 Discussion 
 
Protein engineering is often a requirement for obtaining well-diffracting crystals. It can be 
used to increase expression of the target protein, to remove N-linked glycosylation sites and 
flexible regions and to stabilise the protein. The FACS sort method used to create clonal cell 
lines (Chapter 3) was effective at increasing AT1R expression, however it was a time 
consuming process. It has been observed that there is a charge-bias among proteins inserted 
into the plasma membrane, in particular residues with positively charged amino acids are 
more likely to be located in the cytoplasm 171, 172. Since the N-terminus of AT1R contained 
four positively charged residues, removal of one or more of them appeared to be a promising 
means for increasing expression. This proved to be the case for the expression of N-terminal 
mutants of AT1R transiently transfected into iHEK cells, however each positively charged 
amino acid was examined in isolation. It would be interesting to see whether removal of 
more than one positively charged residue further increased expression and also whether this 
increase was seen in stable cell lines created from N-terminal mutants. Additionally, 
examining the effects of using amino acids other than Gln might be valuable. Ultimately this 
technique was not further investigated since it was unknown whether N-terminal alterations 
of AT1R might negatively impact ligand binding. Instead the use of a leader sequence (LS) 
was examined as a means to increase expression of AT1R in mammalian cells. This 
approach had previously been successfully employed in the baculovirus system (Chapter 2) 
and therefore using it in the mammalian system was a logical extension. The addition of a 
LS to AT1R expressed in the mammalian system, in combination with the use of sodium 
butyrate at the time of induction, removed the need to use the FACS sort method because 
expression levels were comparable (both induced cell lines iHEK415 and iGNTI25 gave a 
median FACS fluorescence intensity of approximately 1400). 
 
The use of RONN software 175 in combination with an alignment of AT1R with other 
GPCRs of known structure, predicted that the C-terminus was flexible and might prohibit 
well-diffracting crystals from forming. There was conflicting information available about 
the impact of C-terminal truncations on the expression of AT1R. Both rat and human AT1R 
consist of 359 residues and share 95% sequence identity (Appendix 1). CHO cell lines stably 
expressing C-terminal deletions of rat AT1R up to residue 314 showed that neither the 
binding affinity nor the expression levels of AT1R were impacted 
176. However, C-terminal 
deletions of the rat AT1R up to residue 309, expressed by transient transfection in COS-7 
cells, showed that, despite binding affinities remaining unchanged, expression of AT1R 
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decreased with increasing the length of the truncation 177. It was therefore necessary to 
establish whether it was possible to remove the putatively disordered C-terminus of AT1R 
without negatively impacting expression. To facilitate this, mammalian cell lines stably 
expressing two different truncations of AT1R were examined; P321-E359 and K323-E359. 
Only cell lines containing P321 and P322 showed high levels of expression of AT1R 
possibly indicating that truncation of AT1R beyond K323 destabilised the receptor. The 
apparent Tm of antagonist-bound AT1R(Del. K323-E359) solubilised in DDM was similar to 
that of the wild type receptor, demonstrating that the stability of the altered protein was not 
negatively impacted by the truncation.     
 
The addition of T4L to increase the hydrophilic area of a GPCR, particularly in combination 
with the use of LCP, has become a routine method for the crystallization of GPCRs. A 
2AR-CL3-T4L fusion has previously been carefully engineered with the intention of 
stabilising the receptor rather than introducing further flexibility and resulted in a high-
resolution structure 24, 41. Since then numerous high-resolution GPCR structures have been 
obtained using this method, therefore the creation of an AT1R-T4L fusion appeared to be 
worthwhile. Using the [Super +] format apparent Tm assay, antagonist-bound AT1R-CL3-
T4L showed an 11°C increase in apparent Tm in comparison to the wild type receptor. 
However using the [-] format assay, AT1R-CL3-T4L showed a 6°C reduction in apparent Tm 
in comparison to the wild type receptor. Additionally, FSEC analysis of AT1R-CL3-T4L 
demonstrated a dramatic reduction in signal intensity in comparison to the wild type 
receptor, which persisted despite optimisation. A possible explanation for this effect was 
that while T4L stabilised the binding pocket, the other domains of the receptor were 
destabilised. Another possibility was that the introduction of T4L caused an increase in the 
flexibility of CL3, thus destabilising the receptor. A method for determining whether this 
was happening would be to introduce rigid linkers at the AT1R-T4L junction, or other 
placements of T4L. Finally AT1R might exist as a dimer and the addition of T4L might 
inhibit the formation of dimers, which could also destabilise the receptor (Chapter 4). 
 
Given the inconsistent behaviour of AT1R-CL3-T4L, it was decided to proceed with a 
version of AT1R that did not contain T4L but had a C-terminal truncation which did not 
affect expression. The cell line iGNTI25, which expressed AT1R(Del. K323-E359) grew 
well in the Wave Bioreactor system and it was estimated that there was approximately 6 mg 
of AT1R per litre of culture, assuming 3.4 x 10
6 cells per ml. Unfortunately, it was not 
possible to purify the receptor derived from this cell line. It is likely that the antibody based 
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purification of AT1R was unsuccessful because of the presence of detergent in the 
solubilisate. One potential way to alleviate this problem would be to use a tag such as H10. 
The binding of H10 to IMAC resin is not known to be affected by detergent and it should be 
sufficiently long that it would not be occluded by the detergent micelle. However the only 
cell line which was successfully grown in suspension, iGNTI25, did not express AT1R with 
a H10 tag. Therefore, a new stable cell line would need to be generated. Alternatively, the 
genome of iGNTI25 could be edited to contain the H10 tag using the clustered regularly 
interspaced short palindromic repeats (CRISPR) / CRISPR-associated protein-9 nuclease 
(Cas9) system from Streptococcus pyogenes 186. 
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CHAPTER 6 DETECTION OF UNFOLDED RECOMBINANT 
MEMBRANE PROTEINS IN EUKARYOTIC 
CELLS 
 
6.1 Introduction 
 
One of the most important aspects of membrane protein overexpression is knowing both 
how much of the target protein is folded correctly and how much is misfolded. However, 
detecting the presence of misfolded recombinant membrane proteins is often very difficult. 
For E. coli a method was devised that relies upon the creation of a C-terminal GPF-fusion 
protein; if the target membrane protein is correctly folded, GFP is fluorescent, but if the 
membrane protein misfolds, it forms aggregates within the cell and the GFP does not 
fluoresce 183, 187. On SDS-PAGE, the fluorescent GFP fusion protein is observed by in-gel 
fluorescence. A western blot of the same gel probed with anti-GFP antibody identifies both 
folded and misfolded fusion protein. It is usually the case that the functional GFP fusion 
protein migrates further than the misfolded GFP fusion protein. This system has been 
adapted to work in yeast expression systems 188. However, for eukaryotic expression 
systems, GFP often remains fluorescent despite being fused to misfolded proteins 189, 190. 
Prior to the work described in this thesis detection of misfolded eukaryotic membrane 
proteins relied upon either radioligand binding experiments 60 or examination of the void 
area produced from an FSEC trace 148. 
 
It has been observed previously that SERT expressed using the baculovirus system showed 
differential amounts of peptide on a western blot depending on the ‘harshness’ of the 
detergent used (Tate, unpublished data). This was consistent with the observation that most 
of SERT expressed in insect cells was misfolded, whereas subsequent work showed that the 
majority of SERT expressed in a mammalian cell line was correctly folded 60. However, in 
most baculovirus expression trials it is not possible to compare western blots because either 
a radioligand is not available for the target or a stable mammalian cell line is not available 
for comparison. This means that a simple assay would be of great utility in detecting 
whether misfolded protein was expressed in any expression system. To address this, the 
observation of differential solubility of misfolded and correctly folded membrane protein in 
detergent of different ‘harshness’ was used to develop an assay. In order to assess the 
efficacy of this assay targets were chosen that had been expressed in both mammalian cells 
and insect cells, and which also had a radioligand binding assay. The assay was used to 
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determine how much functional membrane protein was solubilised in two mild detergents 
(digitonin or DDM). The amount of detergent-solubilised target protein was then determined 
on a western blot and compared between different types of detergents i.e. the harsh 
detergents SDS and FC12 and the mild detergents digitonin and DDM. It was anticipated 
that if all the target protein was correctly folded then the western blot signal should be 
identical in all four samples. If there was misfolded protein present, then this would be 
observed by an increase in the amount of target protein seen in the samples solubilised in 
either SDS or FC12.   
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6.2 Materials and Methods 
 
 Materials 
 
All radiolabelled ligands were purchased from PerkinElmer: [3H]-dihydroalprenolol ([3H]-
DHA), [3H]-dipropylcyclopentylxanthine ([3H]-DPCPX) and [125I]-2-carbomethoxy-3-(4-
iodophenyl)tropane ([125I]RTI-55). The detergent fos-choline-12 (FC12) was purchased 
from Anatrace.  
 
 Constructs 
 
Expression in mammalian cells was performed using derivatives of pcDNA4/TO 
(Invitrogen) (Section 2.2.2 for a description of mammalian expression vectors for SERT and 
AT1R). The cDNA for the human adenosine A1 receptor (A1R) (Missouri S&T cDNA 
Resource Center) was cloned into the EcoRV/NotI sites of pJMA111 (Section 2.2.2) to 
create plasmid pJAP34, which expressed A1R-GFP-H10. In an effort to create a thermostable 
A1R receptor, 4 mutations that stabilised the adenosine A2A receptor (A2AR) in the active 
state (L48A, A54L, T65A, Q89A 67 were transferred to A1R (mutations L51A, A57L, L68A, 
Q92A). In addition, the mutations N148G and N159G were included to remove the putative 
N-linked glycosylation sites. To remove flexible regions, the N-terminus was truncated 
between Pro2 and Ile5, the C-terminus was truncated at Phe307 and the sequence 
VLRQQEPFKAA was added to the C-terminus, thus generating A1R-GL26. A synthetic 
cDNA encoding A1R-GL26 (Life Technologies) was cloned into the EcoRV/NotI sites in 
pJMA111 creating pJAP37, which expressed A1R-GL26-GFP-H10. For generating 
baculoviruses, A1R was cloned into the XhoI/EcoRI sites of the transfer vector pBacPAK8 
(Clonetech), and A1R-GL26 was cloned into the EcoRI/EagI sites of the same vector, 
creating plasmids pJAP44 and pJAP33 respectively (see Section 2.2.2 for AT1R baculovirus 
transfer vector creation). All baculovirus sequences were engineered to contain a C-terminal 
tobacco etch virus (TEV) cleavage site and H10 tag. All constructs were verified by DNA 
sequencing (Source Biosciences, UK). 
 
 Transient transfection, generation of stable cell lines and protein 
expression 
 
Mammalian expression plasmids for the expression of A1R (pJAP34) and A1R-GL26 
(pJAP37) were amplified, transiently transfected into adherent mammalian iHEK cells or 
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iGnTI— cells, grown in culture and induced with tetracycline as described previously 
(Section 2.2.4). Stable cell lines were generated by selection with media containing Zeocin 
(Section 2.2.4). An iGnTI— stable cell line expressing a thermostable mutant of SERT, 
SERT-SAH9 65, iGnTI— (SERT-SAH9-GFP-H10), was kindly provided by J. Andréll. Cells 
were induced and harvested as described previously (Section 2.2.4). 
 
 Recombinant baculovirus generation and protein expression 
 
Recombinant baculoviruses that expressed either A1R or A1R-GL26 were generated, isolated 
and screened for expression as described previously (Section 2.2.5). Recombinant 
baculovirus that expressed SERT with a H10 tag at its C-terminus was created as previously 
reported 131, 140. Recombinant baculovirus that expressed β1AR with a H10 tag at its C-
terminus was kindly provided by R. Nehme (MRC Laboratory of Molecular Biology) and a 
thermostable 1AR fused to thioredoxin (ts1AR) was kindly provided by T. Warne (MRC 
Laboratory of Molecular Biology). Recombinant baculoviruses were passaged twice in Sf9 
cells to obtain high titre stocks. Viruses were used to infect either Sf9, Sf21 or Hi5 cells for 
48 or 72 hours as indicated. Cells were harvested as described previously (Section 2.2.5). 
 
 Differential solubility western blotting 
 
Cell suspensions were sonicated briefly and the total protein concentration determined using 
the Bradford assay 132. Samples were then solubilised in the detergent indicated (SDS, FC12, 
DDM or digitonin; all at 1% (w/v) final concentration) at either 4°C (FC12, DDM, 
digitonin) or 20°C (SDS) for 1 hour. The solubilisate was centrifuged at 280,000 × g for 30 
minutes at 4°C to remove the insoluble fraction. SDS-loading buffer was added to the 
supernatant (corresponding to approximately 150,000 cells) and samples were separated on 
a 4-20% tris glycine gel and transferred to nitrocellulose using standard techniques. 
Membranes were probed with anti-pentaHis-HRP (Section 2.2.6). Where indicated, PNGase 
F was added to the supernatant prior to SDS-PAGE (Section 2.2.6). 
 
 Detergent-solubilised and membrane bound radioligand binding assays  
 
Detergent solubilised radioligand assays were performed as described previously (Section 
2.2.11) with the following additions: [3H]-DHA was used at a final concentration of 200 nM 
and [3H]-DPCPX at 39 nM in 150 mM NaCl, 50 mM Tris pH 7.4. [125I]-RTI-55 was used at 
a concentration of 1 nM in PBS. Binding of [3H]-DHA, [3H]-DPCPX and [125I]-RTI-55 was 
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on ice for 1 hour. To determine the amount of SERT, AT1R, 1AR or A1R present in cell 
membranes, binding assays were performed without the samples being solubilised. 
Separation of receptor-bound and free radioligand was achieved by filtration through 96-
well glass fibre filter plates (Millipore) pre-treated with 0.1% polyethyleneimine 65 except 
for [125I]-Sar1 where no polyethyleneimine was used. Background for both assays was 
determined by adding radioligand to non-transfected parental mammalian cells or uninfected 
insect cells. 
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6.3 Results 
 
 Development of an assay to detect unfolded recombinant membrane 
proteins in eukaryotic cells 
 
The first step in purifying any membrane protein is its extraction from the lipid bilayer using 
a detergent, therefore the ability of four detergents to solubilise AT1R was examined. It was 
observed that AT1R produced in the baculovirus system gave a considerably stronger signal 
on a western blot when harsher detergents (SDS and FC12) were used in comparison to 
when milder detergents (DDM and digitonin) were used, indicating that SDS and FC12 were 
solubilising more AT1R peptide than DDM and digitonin (Figure 6.1). This finding 
contrasted with the equal signal seen across all detergent conditions for AT1R produced in 
the mammalian system (Figure 6.1). Combined with the knowledge that the baculovirus 
system produced large quantities of unfolded AT1R, whereas the mammalian system did not 
(Section 2.3.5), these findings were further investigated using radioligand binding 
experiments.  
 
For AT1R produced by both the mammalian and baculovirus system [
125I]Sar1-bound AT1R 
was only detected using the mild detergents DDM and digitonin (Figure 6.1). Across both 
systems, only a small amount of binding was observed when FC12 was used and no binding 
was detected when SDS was used. In order to compare the radioligand binding data across 
both systems, the data in Figure 6.1 were normalised. However it should be noted that the 
stable mammalian cell line expressed 20 times more functional AT1R than was observed in 
Sf9 cells. In addition, there was twice as much [125I]Sar1-bound AT1R detected when the 
receptor was solubilised with DDM than when the receptor was bound to membranes 
(Figure 6.1). Since freeze-thawed membranes were used for this assay, the lower signal seen 
in membranes could be due to the membrane-impermeant peptide [125I]-Sar1 not being able 
to access inside-out vesicles which were present along with rightside-out vesicles. Given 
that no [125I]Sar1-bound AT1R was detected for the SDS condition, it was conceivable that 
the signal seen on the western blot for this detergent condition represented misfolded AT1R 
protein. Conversely, given the high levels of radioligand binding seen for the DDM 
condition, an assumption can be made that DDM solubilised only active AT1R. Therefore a 
discrepancy in signal on the western blots between harsh and mild detergents could indicate 
the presence of misfolded material. It was next important to establish whether this remained 
the case for other membrane proteins. 
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Figure 6.1 Misfolded AT1R produced by the baculovirus expression system is poorly solubilised by 
either DDM or digitonin 
(A) Western blot of AT1R solubilised from whole cells using four different detergents (SDS, FC12, DDM or 
digitonin) and probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of 
total protein and N-linked glycosylation was removed from all samples using PNGaseF prior to SDS-PAGE. 
AT1R was expressed either in the stable mammalian cell line iHEK(AT1R-GFP-H10) or by using the recombinant 
baculovirus bvAT1R-H10 to infect Sf9 cells. The iHEK cell line was induced with 1 g/ml tetracycline for 24 hours 
and Sf9 cells were infected for 48 hours. The western blot insert is a 7 times longer exposure. (B) The amount 
of functional detergent-solubilised AT1R was determined by measuring specific binding of the antagonist [125I]-
Sar1. After the addition of ligand, membranes were solubilised in the detergent indicated and non-bound ligand 
was separated from receptor-ligand complex on gel filtration spin columns and measured by liquid scintillation 
counting: filled red bars, AT1R expressed in Sf9 cells; filled blue bars, AT1R expressed in iHEK cells. The 
amount of AT1R in membranes (non-solubilised) was determined by separation of receptor-bound and free 
radioligand by filtration through glass fibre plates: hatched red bars, AT1R expressed in Sf9 cells; hatched blue 
bars, AT1R expressed in iHEK cells. For ease of comparison, binding data have been normalised with respect to 
AT1R in membranes (100%), which is equivalent to 1,400 ± 240 dpm (n=2; 380 fmoles/million cells) for 
baculovirus-infected Sf9 cells and 12,000 ± 300 dpm (n=2; 8.8 pmoles/million cells) for iHEK(AT1R-GFP-H10) 
cells. Absolute levels of AT1R therefore cannot be compared meaningfully between the two expression systems 
using this bar graph. Binding assays for AT1R contained either 150,000 Sf9 cells or 55,000 iHEK cells. Each 
data point was determined in duplicate or triplicate from a single experiment and was plotted as mean ± SEM. 
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 Expression of A1R in insect and mammalian cells 
 
The next membrane protein to be investigated was the adenosine A1 receptor (A1R). 
Although structures of A2AR in inactive 
16, 61, 63 and active-like 49, 50 conformations have 
been determined, no structures of A1R had been published to date, therefore this presented 
an opportunity for further study. Human A1R contains two N-linked glycosylated sites in 
EL2 (Asn148 and Asn159). For the same reasons previously described in this thesis for 
AT1R (Chapter 2) two expression systems for the production of recombinant A1R were 
chosen, baculovirus mediated expression in insect cells and mammalian expression using the 
iGNTI— cell line. A baculovirus that expressed A1R from the polyhedrin promoter (bvA1R-
H10) was created using the Baculo Gold method and used to infect Sf9 cells for 72 hours. 
Additionally a cell line stably expressing A1R-GFP-H10 was created using iGNTI
— cells. 
Cells were induced for 24 hours with tetracycline prior to harvest. Interestingly, in the 
uninduced state the cell line A1R-GFP-H10 grew significantly slower (over two weeks to 
reach confluency in a T-75 flask) than the parental cells or cell lines stably expressing 
AT1R-GFP-H10, presumably due to high basal activity of the receptor. In an attempt to 
diminish these effects, the inverse agonist DPCPX was added to the culture medium at final 
concentrations of 1 M, 10 M and 100 M, but none of the conditions increased the 
growth rate of the cells.  
 
When A1R was expressed in the cell line iGNTI
— (A1R-GFP-H10) there was a reduction in 
apparent molecular weight when the enzyme PNGase F was used (Figure 6.2), presumably 
due to the removal of N-linked glycosylation. This was not seen for A1R produced in insect 
cells (Figure 6.2). As measured by [3H]-DPCPX binding, similar amounts of A1R was 
produced in mammalian cells compared to insect cells (Figure 6.2). However, a western blot 
containing equal amounts of active material showed that the baculovirus produced a 
significant amount of unfolded receptor whereas the mammalian system produced none 
(Figure 6.2). 
 
A western blot of A1R using four different detergent conditions produced a similar pattern to 
that seen for AT1R. Specifically, A1R expressed in insect cells showed a much stronger 
signal in harsh detergents (SDS and FC12) in comparison to mild detergents (DDM and 
digitonin) whereas an equal signal was seen across all conditions when A1R was expressed 
in mammalian cells (Figure 6.3). A1R-[
3H]-DPCPX binding was noticeably less for all 
detergent solubilised conditions in comparison to binding in membranes (Figure 6.3), 
presumably due to the instability of the detergent-solubilised receptor.  
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Figure 6.2 Expression of A1R in mammalian cells compared to insect cells 
(A) Western blot of whole cells expressing A1R solubilised in SDS. Lanes 1 and 3, iGnTI— parental cells; lanes 2 
and 4, iGnTI—(A1R-GFP-H10) stable cell line; lanes 5 and 7, uninfected Sf9 cells; lanes 6 and 8, bvA1R-H10 
infected Sf9 cells. N-linked glycosylation was removed using PNGaseF where indicated (+). Bands 
corresponding to A1R-GFP-H10 in mammalian cells are indicated with a yellow asterisk (*). The iGnTI— cell line 
was induced with 1 g/ml tetracycline for 24 hours and insect cells were infected with recombinant baculovirus 
for 72 hours. The blot was probed with an anti-pentaHis-HRP conjugated antibody. (B) The amount of functional 
A1R in each expression system was determined by measuring specific binding of the antagonist [3H]-DPCPX. 
After the addition of ligand, membranes were solubilised in DDM and non-bound ligand was separated from 
receptor-ligand complex on gel filtration spin columns and measured by liquid scintillation counting. Each data 
point was determined in duplicate and was plotted as mean ± SEM. (C) Western blot of DDM-solubilised A1R, 
with equal amounts of active receptor per sample (lanes 2, 3, 5, 6). The blot was probed with an anti-pentaHis-
HRP conjugated antibody. Lane 1, iGnTI— parental cells; lanes 2 and 3, iGnTI—(A1R-GFP-H10) stable cell line; 
lane 4, uninfected Sf9 cells; lanes 5-6, bvAT1R-H10 infected Sf9 cells. N-linked glycosylation was removed using 
PNGase F where indicated (+). A1R was expressed either in the stable mammalian cell line iGnTI—(A1R-GFP-
H10) or by using the recombinant baculovirus bvA1R-H10 to infect Sf9 cells. Bands corresponding to A1R-GFP-
H10 in mammalian cells are indicated with a yellow asterisk (*). The iGnTI— cell line was induced with 1 g/ml 
tetracycline for 24 hours and insect cells were infected with recombinant baculovirus for 72 hours. The amount 
of functional A1R was determined by measuring specific binding of the antagonist [3H]-DPCPX. 
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Figure 6.3 Misfolded A1R produced by the baculovirus expression system is poorly solubilised by either 
DDM or digitonin 
(A) Western blot of A1R solubilised from whole cells using four different detergents (SDS, FC12, DDM or 
digitonin) and probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of 
total protein and N-linked glycosylation was removed from all samples using PNGase F prior to SDS-PAGE. 
A1R was expressed either in the stable mammalian cell line iGnTI—(A1R-GFP-H10) or by using the recombinant 
baculovirus bvA1R-H10 to infect Sf9 cells. The iGnTI— cell line was induced with 1 g/ml tetracycline for 24 hours 
and Sf9 cells were infected for 72 hours. (B) The amount of functional detergent-solubilised A1R was 
determined by measuring specific binding of the antagonist [3H]-DPCPX. After the addition of ligand, 
membranes were solubilised in the detergent indicated and non-bound ligand was separated from receptor-
ligand complex on gel filtration spin columns and measured by liquid scintillation counting: filled red bars, A1R 
expressed in Sf9 cells; filled blue bars, A1R expressed in iGnTI— cells. The amount of A1R in membranes (non-
solubilised) was determined by separation of receptor-bound and free radioligand by filtration through glass fibre 
plates: hatched red bars, A1R expressed in Sf9 cells; hatched blue bars, A1R expressed in iGnTI— cells. For 
ease of comparison, binding data have been normalised with respect to A1R in membranes (100%), which is 
equivalent to 120,000 ± 2000 dpm (n=3; 2.9 pmoles/million cells) for baculovirus-infected Sf9 cells and 7,500 ± 
250 dpm (n=3; 3.8 pmoles/million cells) for iGnTI—(A1R-GFP-H10) cells. Absolute levels of A1R therefore cannot 
be compared meaningfully between the two expression systems using this bar graph. Binding assays for A1R 
contained either 150,000 Sf9 cells or 7,500 iGnTI— cells. Each data point was determined in duplicate or 
triplicate from a single experiment and was plotted as mean ± SEM.  
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 Generation of a thermostable version of A1R 
 
Thermostabilising mutations in turkey 1AR have been successfully transferred to both 
human 1AR and human 2AR 108. An alignment of transmembrane regions of adenosine 
receptors showed that A1R had a 51% identity with A2AR (Table 6.1). Therefore, in an effort 
to thermostabilise A1R, 4 mutations that stabilised the A2AR in the active state (L48A, 
A54L, T65A, Q89A 67 were transferred to A1R (mutations L51A, A57L, L68A, Q92A) thus 
generating A1R-GL26. A baculovirus that expressed A1R-GL26 from the polyhedrin 
promoter (bvA1R-GL26-H10) was created using the Baculo Gold method and used to infect 
Sf9 cells for 72 hours. Additionally, a cell line stably expressing A1R-GL26-GFP-H10 was 
created using iGNTI— cells. Cells were induced for 24 hours with tetracycline prior to 
harvest. Confocal microscopy of the cell line iGNTI—(A1R-GL26-GFP-H10) showed that the 
vast majority of A1R-GL26 was internalised and presumably unfolded (Figure 6.4). This 
was in contrast to wild type A1R produced in mammalian cells which was predominantly 
localised to the cell surface (Figure 6.4). A western blot using different detergents showed 
that there was a significantly stronger signal observed for the harsh detergents SDS and 
FC12 when A1R-GL26 was expressed in either mammalian or insect cells (Figure 6.4). [
3H]-
DPCPX binding showed that, similar to A1R binding, the signal was highest for membrane-
bound A1R-GL26 and only a weak signal was detected for receptor solubilised with the mild 
detergents DDM and digitonin (Figure 6.5). When combined with the radioligand binding 
assays, the differential signal intensity seen in the western blot when harsh detergents were 
used indicated that the majority of the receptor was unfolded in both expression systems.  
 
Table 6.1 Percentage identity of transmembrane regions of human adenosine receptors 
 A1R A2AR A2BR A3R 
A1R  51 48 50 
A2AR 51  63 42 
A2BR 48 63  40 
A3R 50 42 40  
Table generated using ClustalW2 191. 
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Figure 6.4 A1R-GL26 is misfolded when expressed in mammalian cells 
(A-C) Confocal micrographs of the iGnTI—(A1R-GFP-H10) cell line after 24 hours induction with tetracycline. 
Cells were fixed using paraformaldehyde and the plasma membrane was defined by staining with Alexa Fluor 
647-conjugated con A prior to visualisation. Unlabelled iGnTI— parental cells showed no fluorescence (not 
shown). The scale bar represents 10 m. (D-F) Confocal micrographs of the iGnTI—(A1R-GL26-GFP-H10) cell 
line after 24 hours induction with tetracycline. Cells were fixed using paraformaldehyde and the plasma 
membrane was defined by staining with Alexa Fluor 647-conjugated con A prior to visualisation. Unlabelled 
iGnTI— parental cells showed no fluorescence (not shown). The scale bar represents 10 m.  
  
CHAPTER 6 Detection Of Unfolded Membrane Proteins 
 Page 129  
 
 
Figure 6.5 Misfolded A1R-GL26 is poorly solubilised by either DDM or digitonin 
(A) Western blot of A1R-GL26 solubilised from whole cells using four different detergents (SDS, FC12, DDM or 
digitonin) and probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of 
total protein. A1R was expressed either in the stable mammalian cell line, iGnTI—(A1R-GL26-GFP-H10), or by 
using the recombinant baculovirus bvA1R-GL26-H10 to infect Sf9 cells. The iGnTI— cell line was induced with 1 
g/ml tetracycline for 24 hours and Sf9 cells were infected for 72 hours. The western blot inserts are a 4 times 
longer exposure. (B) The amount of functional detergent-solubilised A1R-GL26 was determined by measuring 
specific binding of the antagonist [3H]-DPCPX. After the addition of ligand, membranes were solubilised in the 
detergent indicated and non-bound ligand was separated from receptor-ligand complex on gel filtration spin 
columns and measured by liquid scintillation counting: filled red bars, A1R-GL26 expressed in Sf9 cells; filled 
blue bars, A1R-GL26 expressed in iGnTI— cells. The amount of A1R-GL26 in membranes (non-solubilised) was 
determined by separation of receptor-bound and free radioligand by filtration through glass fibre plates: hatched 
red bars, A1R-GL26 expressed in Sf9 cells; hatched blue bars, A1R-GL26 expressed in iGnTI— cells. For ease of 
comparison, binding data have been normalised with respect to A1R-GL26 in membranes (100%), which is 
equivalent to 17,400 ± 800 dpm (n=3; 435 fmoles/million cells) for baculovirus-infected Sf9 cells and 2,000 ± 
350 (n=2; 48 fmoles/million cells) for iGnTI—(A1R-GL26-GFP-H10) cells. Absolute levels of A1R-GL26 therefore 
cannot be compared meaningfully between the two expression systems using this bar graph. Binding assays for 
A1R-GL26 contained 150,000 iGnTI— or Sf9 cells. Each data point was determined in duplicate or triplicate from 
a single experiment and was plotted as mean ± SEM. 
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 Differential solubility of 1AR and SERT 
 
To further verify the accuracy of the differential solubility assay, two additional membrane 
proteins were examined, the turkey 1 adrenergic receptor (1AR) and the rat serotonin 
transporter (SERT). 1AR was examined because its structure has been determined 
numerous times bound to several different ligands 25, 52, 71, 72, 73 and, in all cases, the 
recombinant protein was produced using the baculovirus system 114, 165. Therefore it was 
interesting to determine whether the baculovirus expression system produced misfolded 
1AR as it did with AT1R and A1R. A western blot of wild type 1AR with N-terminal and 
C-terminal deletions solubilised in different detergents showed that there was more peptide 
solubilised by the harsh detergents SDS and DDM in comparison to the more mild 
detergents DDM and digitonin (Figure 6.6). The [3H]-DHA binding assay showed that 1AR 
was functional when solubilised in the detergents digitonin, DDM and FC12 (Figure 6.6). 
When SDS was used no [3H]-DHA binding was observed (Figure 6.6). Combining the 
results of the binding assay with the strong signal seen on the western blot for the SDS 
condition indicated that there was misfolded 1AR present, but considerably less than 
observed for either AT1R or A1R. A thermostable version of 1AR fused to thioredoxin 
(ts1AR) also showed evidence of misfolded receptor with considerably more receptor 
solubilised by SDS and FC12 than either digitonin or DDM (Figure 6.6). Interestingly, 
receptor that contained an uncleaved leader sequence was solubilised only by SDS or FC12, 
suggesting that it was predominantly misfolded. 
 
The final membrane protein to be examined was SERT. It had previously been shown that 
the majority of SERT produced in the baculovirus system was misfolded and the most 
efficient system for producing it was inducible HEK293 cells 60. Therefore it was interesting 
to determine whether this result was replicated with the detergent assay. Indeed, the pattern 
of a strong western blot signal in SDS and FC12 with no [125I]-RTI-55 binding observed for 
the FC12 condition (SDS binding was not measured) was repeated for SERT produced in 
the baculovirus system (Figure 6.7). This was not the case for SERT produced in the 
mammalian system where an equal signal was seen on the western blot for all detergent 
conditions tested (Figure 6.7). Once more, the detergent assay described here detected the 
presence of unfolded SERT when produced using the baculovirus system but not the 
mammalian system.   
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Figure 6.6 Misfolded 1AR is poorly solubilised by either DDM or digitonin 
(A) Western blot of 1AR solubilised from whole cells using four different detergents (SDS, FC12, DDM or 
digitonin) and probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of 
total protein. 1AR was expressed by using the recombinant baculovirus bv1AR-H10 to infect Hi5 cells. ts1AR 
was expressed by using the recombinant baculovirus bvts1AR-H10 to infect Sf9 cells. Hi5 and Sf9 cells were 
infected for 48 hours. The dashed line indicates two separate blots. (B) The amount of functional detergent-
solubilised 1AR and ts1AR was determined by measuring specific binding of the antagonist [3H]-DHA. After 
the addition of ligand, membranes were solubilised in the detergent indicated and non-bound ligand was 
separated from receptor-ligand complex on gel filtration spin columns and measured by liquid scintillation 
counting: filled red bars, 1AR expressed in Hi5 cells; filled blue bars, ts1AR expressed in Sf9 cells. The 
amount of 1AR in membranes (non-solubilised) was determined by separation of receptor-bound and free 
radioligand by filtration through glass fibre plates: hatched red bars, 1AR expressed in Hi5 cells; hatched blue 
bars, ts1AR expressed in Sf9 cells. For ease of comparison, binding data have been normalised with respect to 
1AR in membranes (100%), which is equivalent to 11,000 ± 550 dpm (n=3; 6.1 pmoles/million cells) for 
baculovirus-infected Hi5 cells and 2,600 ± 190 (n=3; 1.4 pmoles /L) for bvts1AR-H10 infected Sf9 cells. Absolute 
levels of 1AR therefor cannot be compared meaningfully between the two constructs using this bar graph. All 
binding assays for 1AR and ts1AR contained 8,300 cells. Each data point was determined in duplicate or 
triplicate from a single experiment and was plotted as mean ± SEM. 
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Figure 6.7 Misfolded SERT produced by the baculovirus expression system is poorly solubilised by 
either DDM or digitonin 
(A) Western blot of SERT solubilised from whole cells using four different detergents (SDS, FC12, DDM or 
digitonin) and probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of 
total protein. SERT was expressed either in the stable mammalian cell line iGnTI—(SERT-SAH9-GFP-H10) or by 
using the recombinant baculovirus bvSERT-H10 to infect Sf9 cells. The iGnTI— cell line was induced with 1 g/ml 
tetracycline for 24 hours and Sf9 cells were infected for 48 hours. The dashed line indicates separate blots. (B) 
The amount of functional detergent-solubilised SERT was determined by measuring specific binding of the 
ligand [125I]-RTI-55. After the addition of ligand, membranes were solubilised in the detergent indicated and non-
bound ligand was separated from receptor-ligand complex on gel filtration spin columns and measured by liquid 
scintillation counting: filled red bars, SERT expressed in Sf9 cells; filled blue bars, SERT-SAH9 expressed in 
iGnTI— cells; *, not determined. The amount of SERT in membranes (non-solubilised) was determined by 
separation of receptor-bound and free radioligand by filtration through glass fibre plates: hatched red bars, 
SERT expressed in Sf9 cells; hatched blue bars, SERT-SAH9 expressed in iGnTI— cells. For ease of 
comparison, binding data have been normalised with respect to SERT in membranes (100%), which is 
equivalent to 10,200 ± 950 dpm (n=2; 75.7 fmoles/million cells) for baculovirus-infected Sf9 cells and 35,400 ± 
420 dpm (n=2; 730 fmoles/million cells) for iGnTI—(Sert-SAH9-GFP-H10) cells. Absolute levels of SERT 
therefore cannot be compared meaningfully between the two expression systems using this bar graph. Binding 
assays for SERT contained either 28,000 Sf9 cells or 10,000 iGnTI— cells. Each data point was determined in 
duplicate or triplicate from a single experiment and was plotted as mean ± SEM.   
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6.4 Discussion 
 
When considering the results of the differential solubility experiments, it is interesting to 
note that all of the membrane proteins produced using the baculovirus system suffered from 
a varying degree of misfolding. This was particularly notable for 1AR produced using the 
baculovirus system, a system which has been used to determine several structures of this 
protein with different ligands bound 25, 52, 71, 72, 73. However, the amount of misfolded 
material present was much less than for the other baculovirus-generated membranes proteins 
examined, which might account for the ability of 1AR to be crystallised. It is possible that 
aggregated material is removed during the purification process through the use of filters or 
size exclusion chromatography, or that the misfolded material might precipitate during 
crystallisation. In contrast, the mammalian system produced no detectable misfolded 
material for any of the membrane proteins examined. However, mammalian expression 
using stable cell lines is not suitable in all circumstances. For A1R, large scale growth using 
stable mammalian cell lines would potentially be hindered by the slow growth rate of the 
cells, presumably due to high basal activity of the receptor. One potential way around this 
would be to create an A1R-T4L fusion in intracellular loop three, which would prevent G 
protein coupling 41. Another possibility is to express A1R in a mammalian system but, 
instead of creating stable cell lines, a virus could be used to infect cells once they reach a 
high enough density. Recent success using the BacMam expression system 192 suggests that 
this could be useful for the expression of A1R. 
 
The technique of using detergents of different levels of harshness to solubilise a membrane 
protein prior to western blotting and examining the resulting signal intensity creates a rapid 
assay for detecting the presence of unfolded membrane proteins. Given that consistent 
results were obtained for four different membrane proteins there is no longer a need to 
couple the western blot with radioligand binding assays as it is indicated that the western 
blot assay alone would reliably predict the presence of misfolded protein in other cases. 
Therefore this assay could be of great benefit when dealing with proteins for which a ligand 
does not exist or where radioligand binding experiments are not possible. The western blot 
assay described here can be simplified further by using just two detergents, one harsh (SDS) 
and one mild (digitonin) which should provide a sufficient indication of the presence of 
misfolded material. There has been an emphasis on screening membrane proteins in a high-
throughput system to find a candidate suitable for structural studies 193. The method 
described here can be easily used with high-throughput screening of eukaryotic membrane 
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proteins. It also can be used to rapidly determine the best choice of expression system. 
Therefore, this simple and rapid assay should be of great value to the field. This assay would 
also be useful for people who are relatively new to the field of membrane proteins since it is 
a simple diagnostic tool to use. Finally, if the yield of a purification is significantly lower 
than what was expected then this could be due to the presence of unfolded material which 
precipitated over the course of the purification. This assay will help to avoid misleading 
conclusions being drawn in these circumstances. 
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CHAPTER 7 OVERALL DISCUSSION AND CONCLUSIONS 
 
For most GPCRs, the amount of protein that can be isolated from native sources is 
significantly less than would be necessary for structure determination 57, 58. For this reason, 
a necessary precursor to structural projects is the overexpression of the GPCR in a relevant 
system. To date, the most frequently used overexpression system for GPCRs has been the 
baculovirus-infected insect cell system 113. However, this system is not generally applicable 
to all GPCRs, which vary enormously in both their complexity and the number of their N-
linked glycosylation sites. The technique adopted in this project of creating mammalian cell 
lines that stably express AT1R was very successful, resulting in 26 million molecules of 
AT1R per cell or approximately 2 mg of AT1R per litre, assuming 1 million cells per ml. 
After further optimisation of the construct and through the use of a Wave Bioreactor system, 
the stable mammalian cell line iGNTI25 produced 6 mg of AT1R per litre of culture, at a cell 
density of 3.4 x 106 cells per ml. Inducible expression of AT1R in stable mammalian cell 
lines remained consistent despite being in culture for over twenty days and the expressed 
receptor was of high quality with virtually all of the AT1R produced being N-glycosylated 
and virtually no misfolded receptor present. This was in stark contrast to AT1R produced in 
the baculovirus system, which showed limited amounts of N-glycosylation, large amounts of 
misfolded material and only 1.8 million molecules of functional AT1R per cell (0.1 mg of 
AT1R per litre of culture, at a cell density of 1 million cells per ml). Given this, the 
mammalian system was shown to be superior to the baculovirus system for the 
overexpression of AT1R. 
 
Despite their advantages, there are a number of drawbacks to creating tetracycline-inducible 
stable mammalian cell lines to overexpress GPCRs for structural studies. There is a good 
probability that at least a few of the stable mammalian cell lines will result in favourable 
expression levels. However, out of fifteen cell lines created that stably expressed AT1R, only 
five showed levels of expression consistent with obtaining the milligram quantities of AT1R 
required for structural studies. Also, not all of the stable cell lines could be grown in large 
scale, for example the clonal cell line iHEK415 could not be grown efficiently in 
suspension. In addition, there is no reliable way to alter the protein once it has integrated 
into the genome, which makes it difficult to optimise a construct for crystallography. One 
possibility for overcoming this problem is to use the CRISPR / Cas9 system 186 to edit the 
genome of the stable cell line, although there are many potential problems in getting this 
system to work. Another major drawback is that inducible stable mammalian cell lines do 
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not work for some GPCRs such as A1R. Despite using an inducible system and an inverse 
agonist in the culture media, a cell line which stably expressed A1R did not grow rapidly 
enough to enable large-scale growth, i.e. it took over two weeks for the cells to reach 
confluency in a T-75 flask. The reason for the poor growth of the A1R cell line is unclear, 
but could be due to the basal activity of the receptor. A more general problem with using 
mammalian cells as an expression system is that the amount of time it takes to generate a 
stable cell line, approximately two months, presents a significant obstacle. One potential 
way to shorten the time frames is to use transient transfection. However, expression levels in 
transient transfection are often too low for purification purposes. Also, expression levels 
obtained using this method did not necessarily correlate with expression levels observed in 
stable cell lines. Testing multiple constructs in parallel is usually necessary before the 
optimum final construct for crystallisation is determined and this is particularly onerous if 
stable cell lines are used. For example, when inserting a small soluble protein such as T4L to 
increase the likelihood of crystal contacts forming, it would often be necessary to screen 
about a hundred constructs to obtain a highly expressed chimera with no flexible regions 41, 
62 and this would not be feasible using stable cell lines. Transient transfection can be used in 
a high-throughput mode, however the difficulties described above, such as low expression, 
can be problematic. Another possibility for screening hundreds of constructs is to use a viral 
delivery system that expresses the gene of interest. Unlike transient transfection, viral 
systems efficiently infect all of the cells in a population and thereby normally achieve high 
levels of expression. One such system is the baculovirus-mediated gene transduction of 
mammalian cells (BacMam) system 192. This system was used to overproduce an engineered 
dopamine transporter 121 and both the NMDA 123 and AMPA 124 receptors. This approach 
allowed the structures of these three proteins to be determined, thus proving the utility of the 
BacMam system for the expression of integral membrane proteins. Although the BacMam 
system is compatible with high-throughput methods, it can still take up to one month to 
generate a baculovirus. Another virus system that can be used to create high level 
recombinant protein expression in mammalian cells and which can also be used in a high-
throughput capacity is the lentivirus system 194, 195, 196. The drawbacks of the lentivirus 
system are that it has not yet been tested for high level expression of mammalian membrane 
proteins and that its use often requires working under biosafety level 2 conditions, which 
would be difficult with large-scale cultures. An issue common to several viral expression 
systems is that they may express predominantly unfolded material in the endoplasmic 
reticulum of the host 110, which would not be suitable for purification and crystallisation. 
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Nevertheless, viral delivery systems seem worth investigating given that the alternative of 
creating stable cell lines is far from ideal. 
From the data presented in this thesis, it is unclear whether N-linked glycosylation will 
prove to be an obstacle for crystallising AT1R. It is possible to obtain well diffracting 
crystals of some proteins with glycosylation intact. For example, the first crystal structure of 
rhodopsin was obtained from native sources and with its complex N-glycans intact 19. In 
addition, structure determination of constitutively active metarhodopsin-II relied on the 
presence of N-glycans as they formed crystal contacts 119. Glycosylation can be a source of 
heterogeneity for crystallisation, thus potentially preventing the formation of well-
diffracting crystals, but the N-glycans can be removed. Structures of the P2Y receptor 197, 
198, dopamine D3 receptor 
199 and CXCR4 chemokine receptor 200 were all obtained after the 
recombinant protein was fully deglycosylated using PNGase F. However AT1R might be 
unstable with all of its sugars removed. If this proved to be the case, an alternative approach 
would be to express the receptor in an iGNTI cell line, which only produces a high mannose 
core. These core N-glycans can then be removed using Endo H, which leaves one GlcNAc 
residue covalently bound, which could potentially improve the stability of the protein. It is 
not possible to predict which strategy would be the most beneficial and this would have to 
be determined empirically. N-glycosylation could be removed by mutating one or more of 
the N-linked glycosylation sites of AT1R to alanine, but it was not possible to remove all 
three N-glycosylation sites while maintaining expression levels. Another option would be to 
mutate the sites to an hydrophilic amino acid, such as Ser, Lys or Glu which might give very 
different results from using Ala. It might then be feasible to mutate all of the N-
glycosylation sites without significantly affecting both stability and expression. 
 
To assess the stability of AT1R, this project used two criteria, the apparent Tm assay and 
FSEC. Using the [Super +] format apparent Tm assay, detergent-solubilised AT1R was found 
to have a Tm of 47°C with the antagonist Sar
1 bound. This was deemed to be sufficiently 
stable to attempt crystallisation without further stabilisation. However, when Sar1 was 
incubated with AT1R overnight, the FSEC peak was dramatically reduced in signal in 
comparison to the receptor being incubated with no ligand overnight. This indicated that 
incubation of AT1R with Sar
1 for an extended period of time was somehow destabilising the 
receptor and, on account of this, crystallisation with antagonist present might be 
problematic. There are several approaches to dealing with this problem. Conformational 
thermostabilisation 17, 65, 66, 67, 68, 69, particularly in combination with FSEC, might prove 
beneficial at stabilising AT1R with ligand bound. It is interesting to note that the addition of 
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T4L into CL3 of AT1R increased the apparent Tm by 11°C when the [Super +] format assay 
was used in comparison to the wild type receptor. However when the apparent Tm was 
measured using the [-] format assay, T4L reduced the apparent Tm by 6°C in comparison to 
the wild type receptor. Therefore, in any future mutagenesis projects of AT1R, it would be 
advisable to measure thermostability using both [Super +] and [-] format assays. Another 
possibility for increasing the stability of AT1R with ligand bound is to perform a charge scan 
on the intracellular side of AT1R which might remove unfavourable charge-charge 
interactions and allow additional hydrogen bonds to form. An alanine scan of the turkey 
1AR revealed that R68A was stabilising and R68S was even more stabilising 69. The reason 
for this was subsequently revealed in the 1AR structure which showed that R68 was 
adjacent in three dimensional space to R355 on H8 and the mutant R68S enabled the 
formation of two hydrogen bonds between the intracellular domains of H1 and H8 52. In 
theory, E68 might have been even more stabilising, however this was not tested. Salt bridges 
could also be introduced to increase thermostability. 2AR was determined to be more 
thermostable than 1AR 108 possibly due to the presence of a salt bridge between Asp192 
and Lys305 23 which 1AR lacks 25. This was engineered into 1AR and shown to improve 
thermostability by 5°C 66. Another approach to stabilising AT1R is to bind either a G protein 
or arrestin to the receptor. However, this would be extremely difficult since no applicable 
generic methodology exists and AT1R couples most frequently to Gq, which is both difficult 
to express and unstable in detergent (Nehme and Tate, unpublished). Additionally, an 
antibody could be used to stabilise the intracellular face of AT1R (Section 1.3.2). 2AR was 
stabilised in the agonist conformation by a camelid antibody fragment (nanobody 80) 42 and 
the A2AR was locked into an inverse agonist position by the binding of a Fab fragment 
(Fab2838) to its cytoplasmic face 61. To produce an antibody that recognises AT1R, purified 
protein would need to be obtained and a ligand that locks the receptor into one conformation 
would need to be identified.  
 
The discrepancy between the apparent thermostability of AT1R, as measured using a 
radioligand, and the FSEC data raises the question of why AT1R is behaving so differently 
from receptors such as 1AR and A2AR. One possibility is that there is a time dependent 
dislocation between the ligand binding pocket and the intracellular side of the receptor. This 
behaviour might not be observed in membranes where transmembrane helices of the 
receptor are subjected to lateral pressure forces generated by the lipid bilayer. However, 
once the lateral pressure is removed by solubilisation with detergent, the receptor may 
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become more dynamic. One method for examining the dynamics of a receptor is double 
electron-electron resonance (DEER) and this could be used to study the differences in AT1R 
dynamics in detergent micelles compared to membranes. DEER has been used to map 
conformational changes in rhodopsin after binding visual arrestin 201. However, this method 
requires purified protein that contains a pair of spin labels. Another possibility for 
explaining the unusual behaviour of AT1R is that, in terms of -arrestin recruitment, it 
belongs to class B, which means that the receptor-arrestin binding interaction is strong and 
enduring, so that AT1R internalises with -arrestin still bound 82, 202. Whether class B 
receptors exhibit a different range or magnitude of conformational dynamics compared to 
class A receptors is unknown, but if they do then this could help to explain the unusual 
features of AT1R stability. Another possibility is that the high concentration of Arg/Lys 
residues on the intracellular face of AT1R makes this region less stable then the intracellular 
face of other receptors. 
 
In order for structure determination of AT1R to proceed, it is clear that the receptor needs to 
be stabilised either by mutagenesis or the inclusion of a binding protein as mentioned above. 
Once this is achieved, the work presented in this thesis demonstrates that the inducible 
mammalian system is the best for producing the milligram quantities of AT1R needed for 
structural studies.  
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APPENDIX 1 AT1R AMINO ACID SEQUENCE 
ALIGNMENTS 
 
 huADRB2         --------MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNV 52 
mgADRB1         MGDGWLPPDCGPHNRSGGGGATAAPTGSRQVSAELLSQQWEAGMSLLMALVVLLIVAGNV 60 
huDRD3          ------------MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNG 48 
huHRH1          --------------MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNL 46 
huADORA2A       -----------------------------------MPIMGSSVYITVELAIAVLAILGNV 25 
huAGTR1         -------------MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNS 47 
                                                                  : :  :  *  
 
huADRB2         LVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMK-MWTFGNFWCEFWTS 111 
mgADRB1         LVIAAIGRTQRLQTLTNLFITSLACADLVMGLLVVPFGATLVVRG-TWLWGSFLCECWTS 119 
huDRD3          LVCMAVLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVT 108 
huHRH1          LVLYAVRSERKLHTVGNLYIVSLSVADLIVGAVVMPMNILYLLMS-KWSLGRPLCLFWLS 105 
huADORA2A       LVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAIPFAITISTGFCA---ACHGCLFIAC 82 
huAGTR1         LVVIVIYFYMKLKTVASVFLLNLALADLCF-LLTLPLWAVYTAMEYRWPFGNYLCKIASA 106 
                **  .:     *:.  .  : .*: **: .   .:*              .   *      
 
huADRB2         IDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQM 171 
mgADRB1         LDVLCVTASIETLCVIAIDRYLAITSPFRYQSLMTRARAKVIICTVWAISALVSFLPIMM 179 
huDRD3          LDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPL 168 
huHRH1          MDYVASTASIFSVFILCIDRYRSVQQPLRYLKYRT---KTRASATILGAWFLSFLWVIPI 162 
huADORA2A       FVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLG 142 
huAGTR1         SVSFNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIH 166 
                   .   :*:  :  :.:*** ::  *.:         .         :            
 
huADRB2         HWYRATHQEAINCYANETCC-------DFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQ 224 
mgADRB1         HWWRDEDPQALKCYQDPGCC-------DFVTNRAYAIASSIISFYIPLLIMIFVYLRVYR 232 
huDRD3          LFGFNTTGDPTVCS---------------ISNPDFVIYSSVVSFYLPFGVTVLVYARIYV 213 
huHRH1          LGWNHFMQQTSVRREDKCET-------DFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYK 215 
huADORA2A       WNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYFNFFACVLVPLLLMLGVYLRIFL 202 
huAGTR1         RNVFFIENTNITVCAFHYESQ------NSTLPIGLGLTKNILGFLFPFLIILTSYTLIWK 220 
                                                      . .  . .*  : :  *  ::  
 
huADRB2         EAKRQLQKIDKSEGRFHVQN-------LSQVEQDGRTGHGLRR--SSKFCLKEHKALKTL 275 
mgADRB1         EAKEQIRKIDRCEGRFYGSQEQPQPPPLPQHQPILGNGRASKRKTSRVMAMREHKALKTL 292 
huDRD3          VLKQRRRK----------Truncation R222-R318---------GVPLREKKATQMV 331 
huHRH1          AVRQHC------------Truncation Q222-G404---------LHMNRERKAAKQL 417 
huADORA2A       AARRQLKQMESQPLPGE---------------------------RARSTLQKEVHAAKSL 235 
huAGTR1         ALKKAYEIQK--------------------------------------NKPRNDDIFKII 242 
                  :.                                               :: .  : : 
 
huADRB2         GIIMGTFTLCWLPFFIVNIVHVIQDNLIR---------KEVYILLNWIGYVNSGFNPLIY 326 
mgADRB1         GIIMGVFTLCWLPFFLVNIVNVFNRDLVP---------DWLFVFFNWLGYANSAFNPIIY 343 
huDRD3          AIVLGAFIVCWLPFFLTHVLNTHCQTCHVS--------PELYSATTWLGYVNSALNPVIY 383 
huHRH1          GFIMAAFILCWIPYFIFFMVIAFCKNCCN---------EHLHMFTIWLGYINSTLNPLIY 468 
huADORA2A       AIIVGLFALCWLPLHIINCFTFFCPDCSHA-------PLWLMYLAIVLSHTNSVVNPFIY 288 
huAGTR1         MAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPLFY 302 
                  ::  * ..*:*  :   .                           :.: *. .**.:* 
 
huADRB2         CRS-PDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTE 385 
mgADRB1         CRS-PDFRKAFKRLLCFPRKADRRLHAGGQPAPLPGGFISTLGSPEHSPGGTWSDCNGGT 402 
huDRD3          TTFNIEFRKAFLKILSC------------------------------------------- 400 
huHRH1          PLCNENFKKTFKRILHIRS----------------------------------------- 487 
huADORA2A       AYRIREFRQTFRKIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWAN 348 
huAGTR1         GFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE--- 359 
                     .*:  * .::    
                                           
huADRB2         DFVGHQGTVPSDNIDSQGRNCSTNDSLL-------------------------------- 413 
mgADRB1         RGGSESSLEERHSKTSRSESKMEREKNILATTRFYCTFLGNGDKAVFCTVLRIVKLFEDA 462 
huDRD3          ------------------------------------------------------------ 
huHRH1          ------------------------------------------------------------ 
huADORA2A       GSAPHPERRPNGYALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDG 408 
huAGTR1         ------------------------------------------------------------ 
                                                                             
 
huADRB2         ---------------------- 
mgADRB1         TCTCPHTHKLKMKWRFKQHQA- 483 
huDRD3          ---------------------- 
huHRH1          ---------------------- 
huADORA2A       AGVS------------------ 412 
huAGTR1         ---------------------- 
 
Appendix Figure 1 Alignment of AT1R with GPCRs of known structure 
ClustalW alignment 191 of the amino acid sequence of the human 2AR (huADRB2), turkey 1AR (mgADRB1), 
human dopamine D3 receptor (huDRD3), human histamine H1 receptor (huHRH1) and A2AR (huADORA2A) 
with the human AT1R (huAGTR1). Transmembrane domains are shown in alternating highlighted colours and 
H8 is shown in red text. Truncations for alignment purposes are indicated in grey boxes. * denotes the 
conserved D[E]RY, CWXP and NPXXY motifs.  
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Appendix Figure 2 Alignment of vertebrate AT1Rs shows a high level of conservation 
ClustalW alignment 191 of human, rat, mouse, chicken, anole lizard, fugu, zebrafish and Xenopus laevis AT1R 
amino acid sequences. Putative N-linked glycosylation sites are shown in solid black boxes, cysteine residues 
which may form disulphide bridges are shown in dashed black boxes. Putative TMs are shown in solid black 
boxes above the sequence and were determined by aligning AT1R with GPCRs of known structure (Appendix 
Figure 1). Conserved residue properties are grouped by colour, e.g. blue represents a hydrophobic residue.   
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 huCHRM2         -------------------------------------------MNNSTNSSNNSLALTSP 17 
rnChrm3         -MTLHSNSTTSPLFPNISSSWVHSPSEAGLPLGTVTQLGSYNISQETGNFSSNDTSSDPL 59 
huHRH1          ---------------------------------------MSLPNSSCLLEDKMCEGNKTT 21 
huAGTR1         -------------------------------------MILNSSTEDGIKRIQDDCPKAGR 23 
huCXCR4         ----------------------------MEGISIYTSDNYTEEMGSGDYDSMKEPCFREE 32 
mmOprd1         -------------------MELVPSARAELQSSPLVNLSDAFPSAFPSAGANASGSPGAR 41 
mmOprm1         MDSSAGPGNISDCSDPLAPASCSPAPGSWLNLSHVDGNQSDPCGPNRTGLGGSHSLCPQT 60 
huOPRK1         ---------MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEP 51 
huDRD3          ------------------------------------MASLSQLSGHLNYTCGAENSTGAS 24 
huADRB2         ---------------------------------MGQPGNGSAFLLAPNGSHAPDHDVTQE 27 
huS1PR1         -----------------------MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNI 37 
rnNtsr1         ----MHLNSSVPQGTPGEPDAQPFSGPQSEMEATFLALSLSNGSGNTSESDTAGPNSDLD 56 
                                                                             
 
huCHRM2         --YKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNR---HLQTVNNYFLFSLACADLII 72 
rnChrm3         GGHTIWQVVFIAFLTGFLALVTIIGNILVIVAFKVNK---QLKTVNNYFLLSLACADLII 116 
huHRH1          --MASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSER---KLHTVGNLYIVSLSVADLIV 76 
huAGTR1         ---HNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYM---KLKTVASVFLLNLALADLCF 77 
huCXCR4         --NANFNKIFLPTIYSIIFLTGIVGNGLVILVMGYQK---KLRSMTDKYRLHLSVADLLF 87 
mmOprd1         SASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYT---KLKTATNIYIFNLALADALA 98 
mmOprm1         GSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYT---KMKTATNIYIFNLALADALA 117 
huOPRK1         AHISPAIPVIITAVYSVVFVVGLVGNSLVMFVIIRYT---KMKTATNIYIFNLALADALV 108 
huDRD3          ---QARPHAYYALSYCALILAIVFGNGLVCMAVLKER---ALQTTTNYLVVSLAVADLLV 78 
huADRB2         --RDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFE---RLQTVTNYFITSLACADLVM 82 
huS1PR1         SADKENSIKLTSVVFILICCFIILENIFVLLTIWKTK---KFHRPMYYFIGNLALSDLLA 94 
rnNtsr1         VNTDIYSKVLVTAIYLALFVVGTVGNSVTAFTLARKKSLQSLQSTVHYHLGSLALSDLLI 116 
                                 :       * ..   .        ::         *: :*    
 
huCHRM2         GVFSMNLYTLYTVIG--YWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLT 130 
rnChrm3         GVISMNLFTTYIIMN--RWALGNLACDLWLSIDYVASNASVMNLLVISFDRYFSITRPLT 174 
huHRH1          GAVVMPMNILYLLMS--KWSLGRPLCLFWLSMDYVASTASIFSVFILCIDRYRSVQQPLR 134 
huAGTR1         LLTLPLWAVYTAMEY--RWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHPMK 135 
huCXCR4         VITLPFWAVDAVAN----WYFGNFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATN 143 
mmOprd1         TSTLPFQSAKYLME---TWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVK 155 
mmOprm1         TSTLPFQSVNYLMG---TWPFGNILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVK 174 
huOPRK1         TTTMPFQSTVYLMN---SWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVK 165 
huDRD3          ATLVMPWVVYLEVTGG-VWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVH 137 
huADRB2         GLAVVPFGAAHILMK--MWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFK 140 
huS1PR1         GVAYTANLLLSGATT---YKLTPAQWFLREGSMFVALSASVFSLLAIAIERYITMLKMKL 151 
rnNtsr1         LLLAMPVELYNFIWVHHPWAFGDAGCRGYYFLRDACTYATALNVASLSVERYLAICHPFK 176 
                                  : :                 ::   :  :..:**  :      
 
huCHRM2         YPV---KRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQFFSNA--- 184 
rnChrm3         YRA---KRTTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSE---- 227 
huHRH1          YLK---YRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKCETDFYDV---- 187 
huAGTR1         SRL---RRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNI--TVCAFHYESQNST 190 
huCXCR4         ---SQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANVSEADDR---YICDRFYP---NDL 194 
mmOprd1         ALD---FRTPAKAKLINICIWVLASGVGVPIMVMAVTQPRDGA---VVCMLQFPS-PSWY 208 
mmOprm1         ALD---FRTPRNAKIVNVCNWILSSAIGLPVMFMATTKYRQGS---IDCTLTFSH-PTWY 227 
huOPRK1         ALD---FRTPLKAKIINICIWLLSSSVGISAIVLGGTKVREDVDV-IECSLQFPDDDYSW 221 
huDRD3          YQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNT-----TGDPTVCSISNP------ 186 
huADRB2         YQS---LLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFT-- 195 
huS1PR1         HNG----SNNFRLFLLISACWVISLILGGLPIMGWNCISALSS-----CSTVLPLY---- 208 
rnNtsr1         AKT---LMSRSRTKKFISAIWLASALLAIPMLFTMGLQNRSGDGTHPGGLVCTPIVD-TA 232 
                        .           *. :       :                             
 
huCHRM2         ---AVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQ│KKKPPPSREKKV 385 
rnChrm3         --PTITFGTAIAAFYMPVTIMTILYWRIYKETEKRTKELAGLQASGT│RMSLIKEKKAAQ 490 
huHRH1          --TWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHR│VSGLHMNRERKAAKQLGF-- 419 
huAGTR1         LPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFKIIMA------ 244 
huCXCR4         WVVVFQFQHIMVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKTTVI----------- 243 
mmOprd1         WDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLV--- 265 
mmOprm1         WENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLV--- 284 
huOPRK1         WDLFMKICVFIFAFVIPVLIIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLV--- 278 
huDRD3          ----DFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTR│LQPRGVPLREKKATQ 329 
huADRB2         NQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF│RTGHGLRRSSKFCL 266 
huS1PR1         --HKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKNISKASRSSEKSLALLK 256 
rnNtsr1         TVKVVIQVNTFMSFLFPMLVISILNTVIANKLTVMVHQAAEQGRVC│HSTFNMTIEPGRV 300 
                             : .           :                            
 
huCHRM2         -----TRTILAILLAFIITWAPYNVMVLINTFCAPC----------IPNTVWTIGYWLCY 430 
rnChrm3         -------TLSAILLAFIITWTPYNIMVLVNTFCDSC----------IPKTYWNLGYWLCY 533 
huHRH1          -----------IMAAFILCWIPYFIFFMVIAFCKNC----------CNEHLHMFTIWLGY 458 
huAGTR1         -----------IVLFFFFSWIPHQIFTFLDVLIQLGIIRD-CRIADIVDTAMPITICIAY 292 
huCXCR4         -----------LILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAF 292 
mmOprd1         -----------VVGAFVVCWAPIHIFVIVWTLV------DINRRDPLVVAALHLCIALGY 308 
mmOprm1         -----------VVAVFIVCWTPIHIYVIIKALI------TIP-ETTFQTVSWHFCIALGY 326 
huOPRK1         -----------VVAVFVVCWTPIHIFILVEALGSTS-------HSTAALSSYYFCIALGY 320 
huDRD3          -------MVAIVLGAFIVCWLPFFLTHVLNTH---------CQTCHVSPELYSATTWLGY 285 
huADRB2         KEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNL----------IRKEVYILLNWIGY 316 
huS1PR1         -------TVIIVLSVFIACWAPLFILLLLDV--------GCKVKTCDILFRAEYFLVLAV 301 
rnNtsr1         QALRHGVLVLRAVVIAFVVCWLPYHVRRLMFCYIS-DEQWTTFLFDFYHYFYMLTNALFY 359 
                           ::  *   * *                                   :   
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huCHRM2         INSTINPACYALCNATFKKTFKHLLMCHYKNIGATR------------------------ 466 
rnChrm3         INSTVNPVCYALCNKTFRTTFKTLLLCQCDKRKRRKQQYQQRQSVIFHKRVPEQAL---- 589 
huHRH1          INSTLNPLIYPLCNENFKKTFKRILHIRS------------------------------- 487 
huAGTR1         FNNCLNPLFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSS----- 347 
huCXCR4         FHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESS----- 347 
mmOprd1         ANSSLNPVLYAFLDENFKRCFRQLCRTPCGRQEPGSLRRPRQATTRERVTACTPS----- 363 
mmOprm1         TNSCLNPVLYAFLDENFKRCFREFCIPTSSTIEQQNSARIRQNTREHPSTANTVDRTNHQ 386 
huOPRK1         TNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRVR-NTVQDPAYLRDID----- 374 
huDRD3          VNSALNPVIYTTFNIEFRKAFLKILSC--------------------------------- 312 
huADRB2         VNSGFNPLIYCRS-PDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENK 375 
huS1PR1         LNSGTNPIIYTLTNKEMRRAFIRIMSCCKCPSGDSAGKFKRPIIAGMEFSRSKSDNSSHP 361 
rnNtsr1         VSSAINPILYNLVSANFRQVFLSTLACLCPGWRHRRKKRPTFSRKPNSMSSNHAFSTSAT 419 
                     **  *      ::                                           
 
huCHRM2         -------------------------------------- 
rnChrm3         -------------------------------------- 
huHRH1          -------------------------------------- 
huAGTR1         STKKPAPCFEVE-------------------------- 359 
huCXCR4         SFHSS--------------------------------- 352 
mmOprd1         DGPGGGAAA----------------------------- 372 
mmOprm1         LENLEAETAPLP-------------------------- 398 
huOPRK1         GMNKPV-------------------------------- 380 
huDRD3          -------------------------------------- 
huADRB2         LLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL 413 
huS1PR1         QKDEGDNPETIMSSGNVNSSS----------------- 382 
rnNtsr1         RETLY--------------------------------- 424 
 
Appendix Figure 3 Alignment of AT1R with GPCR-T4L fusions 
ClustalW alignment 191 of the human muscarinic acetylcholine receptor M2 (Del. D229-A373) (huCHRM2), 
Rattus norvegicus muscarinic acetylcholine receptor M3 (Del. E273-K478) (rnChrm3), human histamine 
receptor H1 (Del. E225 – Y401) (huHRH1), human angiotensin II receptor type 1(huAGTR1), human C-X-C 
chemokine receptor type 4 (huCXCR4), Mus musculus opioid receptor 1 (mmOprd1), Mus musculus opioid 
receptor 1 (mmOprm1), Mus musculus -type opioid receptor (mmOprk1), human dopamine receptor D3 (Del. 
Q227–P314) (huDRD3), human β2 adrenergic receptor (Del. H241-G252) (huADRB2), Rattus norvegicus 
neurotensin receptor type 1 (Del. T279 to E287) (rnNtsr1). Truncations for alignment purposes are indicated 
with │. Transmembrane domains are highlighted in alternating colours. Residues replaced by T4 lysozyme 
(T4L) are indicated in red text. huCXCR4 receptor has an additional linker sequence of GS on either end of the 
T4L insertion. Placement of T4L into CL3 of AT1R is highlighted in grey. 
 
 
AGTR1_Human      MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLK 60 
Agtr1_Rat        MALNSSAEDGIKRIQDDCPKAGRHSYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLK 60 
                 * ****:*****************.*********************************** 
 
AGTR1_Human      TVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLT 120 
Agtr1_Rat        TVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNHLCKIASASVSFNLYASVFLLT 120 
                 **************************************:********************* 
 
AGTR1_Human      CLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVC 180 
Agtr1_Rat        CLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLMAGLASLPAVIHRNVYFIENTNITVC 180 
                 **********************************:********:*****:********** 
 
AGTR1_Human      AFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFK 240 
Agtr1_Rat        AFHYESRNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFR 240 
                 ******:****************************************************: 
 
AGTR1_Human      IIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPL 300 
Agtr1_Rat        IIMAIVLFFFFSWVPHQIFTFLDVLIQLGVIHDCKISDIVDTAMPITICIAYFNNCLNPL 300 
                 *************:***************:*:**:*:*********************** 
 
AGTR1_Human      FYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE 359 
Agtr1_Rat        FYGFLGKKFKKYFLQLLKYIPPKAKSHSSLSTKMSTLSYRPSDNMSSSAKKPASCFEVE 359 
                 **********:*****************.***************:***:****.***** 
Appendix Figure 4 Alignment of human and rat AT1R 
ClustalW alignment 191 of the human angiotensin II receptor type 1a (AGTR1_Human) with the Rattus 
norvegicus angiotensin II receptor type 1a (Agtr1_Rat). 
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APPENDIX 2 INSECT CELL EXPRESSION TEST DATA 
 
A 
 
 SF21 + bvAT1R-H10 and bvAT1R-LS-H10 
B 
 
 Hi5 + bvAT1R-H10 
C 
 
 Hi5 + bvAT1R-LS-H10 
Appendix Figure 5 Optimisation of bvAT1R-H10 and bvAT1R-LS-H10 expressed in Sf21 or Hi5 cells 
Western blot of proteins from whole cells. The blot was probed with an anti-pentaHis-HRP conjugated antibody. 
(A) Sf21 cells infected with either bvAT1R-H10 or bvAT1R-LS-H10 as indicated. The dashed line indicates two 
separate blots. (B) Hi5 cells infected with bvAT1R-H10. (C) Hi5 cells infected with bvAT1R-LS-H10. N-linked 
glycosylation was removed using Endo H where indicated (+). The high manose form of AT1R (HM), 
unglycosylated (UG) and putative degradation products (D) are indicated. Bands corresponding to HM and UG 
forms of AT1R were quantified using Image J (Figure 2.8). 
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Appendix Figure 6 Size exclusion chromatography of AT1R expressed in insect cells 
Western blot of detergent-solubilised AT1R-H10 from Sf9 cells analysed by SEC. The blot was probed with an 
anti-pentaHis-HRP conjugated antibody. The retention volume (RV) of the sample is indicated in ml. Bands 
corresponding to AT1R were quantified using Image J (Figure 2.16). 
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APPENDIX 3 FLUORESCENCE ACTIVATED CELL 
SORTING DATA 
 
Appendix Table 1 FACS analysis of monoclonal cell lines from the polyclonal cell line iHEK(AT1R-GFP-
H10) 
FACS analysis of iHEK cells. Cells were harvested in PBS and analysed on the FACSCalibur II for GFP 
fluorescence using the FL-1 detector. Monoclonal cell lines derived from the population with moderate basal 
expression were named iHEK3XX. Monoclonal cell lines derived from the population with high basal expression 
were named iHEK4XX. Green indicates cell lines that are significantly better than the polyclonal cell line 
iHEK(AT1R-GFP-H10) for the respective population from which it was derived (i.e. high or moderate basal 
expression). 
  
Induced Uninduced 
Cell line 
FACS Fluorescence 
intensity 
Cells 
expressing 
GFP (%) 
FACS Fluorescence 
intensity 
Cells 
expressing 
GFP (%) 
Mean  Median  Mean Median 
iHEK301 376 205 96.1 14 8 15.4 
iHEK302 446 237 97.4 19 8 17.8 
iHEK303 440 235 96.9 23 10 22.2 
iHEK304 422 284 97.3 16 8 16.6 
iHEK305 458 271 97.6 15 9 17.6 
iHEK306 445 237 96.4 15 8 16.6 
iHEK307 428 229 97.4 15 8 16.0 
iHEK308 495 227 97.5 18 9 20.4 
iHEK309 523 305 98.0 17 9 16.5 
iHEK310 392 176 96.4 13 6 12.6 
iHEK311 410 204 96.6 17 8 17.7 
iHEK312 423 221 97.5 22 9 21.7 
iHEK313 407 237 97.3 17 9 17.4 
iHEK314 436 213 97.5 16 8 16.5 
iHEK315 415 213 97.5 20 8 19.0 
iHEK316 418 211 97.2 14 8 15.2 
iHEK317 401 184 96.8 22 8 21.6 
iHEK318 439 221 97.3 17 9 19.7 
iHEK319 619 365 97.7 14 9 14.4 
iHEK320 360 184 95.3 18 8 19.4 
iHEK321 414 223 97.5 17 9 21.2 
iHEK322 414 229 96.5 17 9 20.8 
iHEK323 375 213 96.4 15 8 16.4 
iHEK324 420 213 96.1 18 10 23.2 
iHEK401 334 235 93.7 14 9 14.2 
iHEK402 581 368 98.5 17 10 19.4 
iHEK403 457 264 98.0 17 10 19.2 
iHEK404 345 204 96.9 14 8 15.2 
iHEK405 487 316 97.9 14 9 14.2 
iHEK406 504 331 98.2 14 9 13.6 
iHEK407 591 334 98.4 18 10 20.4 
iHEK408 409 259 98.0 13 8 12.5 
iHEK409 452 297 97.8 22 10 20.6 
iHEK410 373 255 97.5 18 9 16.9 
iHEK411 365 204 97.6 13 8 13.3 
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Induced Uninduced 
Cell line 
FACS Fluorescence 
intensity 
Cells 
expressing 
GFP (%) 
FACS Fluorescence 
intensity 
Cells 
expressing 
GFP (%) 
Mean  Median  Mean Median 
iHEK412 336 186 97.0 16 8 15.4 
iHEK413 358 191 97.5 15 9 15.9 
iHEK414 362 213 97.6 17 8 15.9 
iHEK415 748 429 98.8 20 12 26.3 
iHEK416 520 308 98.0 13 8 12.7 
iHEK417 352 241 96.3 12 7 10.1 
iHEK418 354 233 97.8 12 7 10.6 
iHEK419 507 289 98.4 26 10 20.2 
iHEK420 671 437 98.8 21 14 28.1 
iHEK421 363 209 97.3 14 8 15.0 
iHEK422 400 235 97.9 17 9 18.3 
iHEK423 486 302 97.0 — — — 
iHEK424 390 189 96.3 15 8 15.2 
iHEK425 625 379 98.7 26 9 19.3 
iHEK426 527 359 98.2 18 10 18.1 
iHEK427 381 219 97.0 18 12 24.9 
iHEK428 430 271 96.9 16 9 17.1 
iHEK429 489 325 98.3 12 8 10.4 
iHEK430 377 213 96.5 14 8 14.0 
iHEK431 528 239 97.2 21 10 21.6 
iHEK432 445 284 97.7 12 8 11.4 
iHEK433 311 161 93.1 11 6 10.6 
iHEK434 584 302 97.8 25 9 24.2 
iHEK435 497 305 97.7 15 10 19.4 
iHEK436 423 246 97.1 14 9 17.4 
iHEK437 477 267 97.9 16 9 18.7 
iHEK438 409 207 96.5 14 8 15.5 
iHEK439 449 279 96.9 22 11 23.8 
iHEK440 481 308 97.4 15 9 16.7 
iHEK441 535 313 96.9 25 11 26.0 
iHEK442 454 120 73.0 23 10 24.3 
iHEK443 510 337 97.3 16 10 17.0 
iHEK444 367 202 96.8 15 8 16.7 
iHEK445 500 328 97.5 14 10 16.5 
iHEK446 452 284 95.4 14 10 17.4 
iHEK447 513 328 96.9 28 12 26.8 
iHEK448 438 217 97.4 23 9 23.8 
iHEK(AT1R-GFP-H10) 310 276 91.7 10 8 5.7 
iHEK parental — — — 8 6 5.6 
 
APPENDIX 4 Submitted Journal Article 
 Page 160  
 
APPENDIX 4 SUBMITTED JOURNAL ARTICLE 
 
 
 
ArticleJennifer A. Tho0022-2836/© 2014 MRC
license (http://creativecomQuality Control in Eukaryotic Membrane
Protein Overproductionmas and Christopher G. Tate
MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge CB2 0QH, UKCorrespondence to Christopher G. Tate: cgt@mrc-lmb.cam.ac.uk.
http://dx.doi.org/10.1016/j.jmb.2014.10.012
Edited by B. PoolmanAbstract
The overexpression of authentically folded eukaryotic membrane proteins in milligramme quantities is a
fundamental prerequisite for structural studies. One of the most commonly used expression systems for the
production of mammalian membrane proteins is the baculovirus expression system in insect cells. However, a
detailed analysis by radioligand binding and comparative Western blotting of G protein-coupled receptors and
a transporter produced in insect cells showed that a considerable proportion of the expressed protein was
misfolded and incapable of ligand binding. In contrast, production of the same membrane proteins in stable
inducible mammalian cell lines suggested that the majority was folded correctly. It was noted that detergent
solubilisation of the misfolded membrane proteins using either digitonin or dodecylmaltoside was considerably
less efficient than using sodium dodecyl sulfate or foscholine-12, whilst these detergents were equally efficient
at solubilising correctly folded membrane proteins. This provides a simple and rapid test to suggest whether
heterologously expressed mammalian membrane proteins are indeed correctly folded, without requiring
radioligand binding assays. This will greatly facilitate the high-throughput production of fully functional
membrane proteins for structural studies.
© 2014 MRC Laboratory of Molecular Biology. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).Introduction
Structure determination of integral membrane
proteins requires the production of milligrammes of
pure, authentically folded protein for crystallisation
[1]. As a natural prerequisite, the protein needs to be
expressed in one of a number of heterologous
expression systems, such as Escherichia coli,
yeasts, insect cells or mammalian cells [2]. A number
of expression strategies have been developed for
each host system and many are now efficient for
expression trials of hundreds of proteins in parallel
[3]. A popular strategy for the expression of
membrane proteins in E. coli is to generate fusion
proteins with green fluorescent protein (GFP), which
can be used as an indicator for both the quantity of
protein expressed [4] and its relative stability upon
detergent solubilisation by fluorescence-detection
size-exclusion chromatography (FSEC) [5]. The
utility of this strategy is that fluorescence of the
fusion protein expressed in bacteria discriminatesLaboratory of Molecular Biology. Published
mons.org/licenses/by/3.0/).between correctly folded membrane protein (the
GFP tag is fluorescent) and misfolded, aggregated
membrane protein (the GFP tag is not fluorescent)
[6,7]. In E. coli, it appears that the misfolded
membrane protein promotes the formation of inclu-
sion bodies and, once in an aggregate, the GFP is
unable to fold and attain fluorescence. However, in
eukaryotic cells, such as yeasts, insect cells used in
the baculovirus expression system and in mamma-
lian cells, GFP tagged to a membrane protein
remains fluorescent regardless of whether the
membrane protein is misfolded in the endoplasmic
reticulum or correctly folded in the plasma mem-
brane [8–11]. Higher eukaryotes have an efficient
quality control system in the endoplasmic reticulum
so that only folded proteins exit the endoplasmic
reticulum, whilst misfolded proteins are retained for
degradation [12]. Thus, GFP is not an appropriate
marker for the folding status of membrane proteins
produced using either mammalian cells or the
baculovirus expression system, although it is stillby Elsevier Ltd. This is an open access article under the CC BY
J. Mol. Biol. (2014) 426, 4139–4154
4140 Quality of overexpressed membrane proteinsuseful in analysing the stability of a membrane
protein in different detergents by FSEC.
The baculovirus expression system has proven
efficient for the production of many eukaryotic
membrane proteins, such as G protein-coupled
receptors (GPCRs) [13], some of which have been
crystallised and their structures determined [14].
However, recombinant baculovirus is not a panacea
and there are many proteins that are poorly
expressed and there have also been reports that
some membrane proteins are expressed predomi-
nantly in a misfolded state [2,15]. This is a serious
problem for structural biology, as it is not obvious
from current methodology whether an overex-
pressed membrane protein is predominantly folded
or misfolded. If misfolded material is inadvertently
purified, then this will likely have a detrimental effect
on the ability of the sample to crystallise and may
also adversely affect the quality of any crystals
obtained. The best way to determine whether
misfolded material is present is to perform quantita-
tive Western blotting to assess the total amount of
membrane protein expressed in conjunction with
radioligand binding assays to determine how much
is functional [16,17]. However, this is expensive,
difficult to perform and is also impossible for the
majority of membrane proteins that do not possess
high-affinity radioligands. It is also unclear whether
the presence of misfolded overexpressed mem-
brane protein is a rare event or whether it is
commonly observed. We have therefore studied a
number of membrane proteins produced both in
stable mammalian cell lines and using the baculo-
virus expression system. The data show that all the
four membrane proteins analysed are expressed in
the baculovirus system as a mixture of folded and
misfolded proteins, whereas mammalian cell lines
are much more efficient at producing only correctly
folded membrane proteins. A simple comparative
detergent solubilisation assay is described, which is
an excellent indicator for the presence of misfolded
membrane proteins.Results
Comparative expression of the angiotensin II type
1 receptor in insect cells and stable mammalian
cell lines
The human angiotensin II type 1 receptor (AT1R) is
a GPCR with the typical predicted architecture of
seven transmembrane regions with the N-terminus
on the extracellular surface of the cell. The receptor
contains three N-linked glycosylation sites with one
in the N terminal region (Asn4) and two in extracel-
lular loop 2 (Asn176 and Asn188). Two expression
systems were used for the production of AT1R, thebaculovirus expression system and stable tetracy-
cline-inducible mammalian cell lines (the T-Rex
system). AT1R was expressed with a C-terminal
decahistidine tag (H10) from the polyhedrin promoter
in the recombinant baculovirus bvAT1R-H10. In
inducible mammalian HEK293 cells (iHEK), AT1R
was expressed with a C-terminal GFP-H10 tag from
the CMV promoter after induction with tetracycline;
the stable cell line iHEK(AT1R-GFP-H10) was gen-
erated through random integration of the plasmid in
the genome followed by fluorescence-activated cell
sorting to isolate a high-expressing clonal cell line.
Initial analysis of expression was performed by
Western blotting using an anti-penta-His horseradish
peroxidase (HRP) conjugated antibody for detection
(Fig. 1). AT1R was extensively N-glycosylated in
mammalian cells, which could be removed by
treatment with PNGase F to yield a major product
AT1R-GFP-H10 of apparent molecular mass of
60 kDa; no unglycosylated AT1R-GFP-H10 was
visible in untreated cells. In Sf9 cells, AT1R-H10
was expressed as a mixture of glycosylated and
unglycosylated receptor, which yielded a single
major product (apparent molecular mass of
36 kDa) after treatment with PNGase F. The blot in
Fig. 1 contained the same number of cells per lane;
thus, an assessment of band intensities by eye
suggested that there were similar levels of AT1R
expressed from the baculovirus expression system
and from the stable mammalian cell line. However,
despite the apparently similar levels of AT1R
polypeptide expressed in Sf9 and iHEK cells,
radioligand binding assays showed that there was
20× more functional AT1R expressed per cell in
mammalian cells compared to the best baculoviral
expression observed (Fig. 1). This implied that a
large proportion of AT1R expressed in insect cells
was misfolded and incapable of binding antagonist.
Detergent solubilisation is the first step in the
purification of a membrane protein; thus, the ability of
AT1R expressed stably in the iHEK cell line
iHEK(AT1R-GFP-H10) to be solubilised by four
different detergents was tested. The four detergents
used in order of decreasing “harshness” [18] were
sodium dodecyl sulfate (SDS), foscholine-12
(FC12), dodecylmaltoside (DDM) and digitonin.
Digitonin was the mildest detergent used and it is
very effective in maintaining membrane proteins in a
functional state. DDM is one of the most popular mild
detergents used for membrane protein purification,
but it is a little harsher than digitonin. Only very few
bacterial membrane proteins are sufficiently stable
to maintain their integrity in either FC12 or SDS;
thus, no ligand binding would be expected for AT1R
solubilised in either SDS or FC12. All four detergents
were equally effective at solubilising AT1R polypep-
tide expressed in iHEK cells (Fig. 2). However, as
expected from the differing “harshness” of the
detergents, only DDM and digitonin maintained the
4141Quality of overexpressed membrane proteinsintegrity of 125I-Sar1-bound AT1R so that receptor-
bound radioligand could be detected (Fig. 2). In
contrast, bound radioligand was not detected when
SDS was used to solubilise 125I-Sar1-bound AT1R,
and only a small amount was detected when FC12
was used. Assays on DDM-solubilised AT1R mea-
sured nearly twice as much receptor as detected in
membranes (Fig. 2), which could be due to freeze–
thawed membranes being a mixture of both right-
side-out vesicles and inside-out vesicles, and the
membrane-impermeant peptide 125I-Sar1 could bind
only to AT1R in the rightside-out vesicles.
Detergent solubilisation of 125I-Sar1-bound AT1R
from Sf9 cell membranes after expression from the
recombinant baculovirus bvAT1R-H10 followed a
similar pattern to that observed from the stable
mammalian iHEK cell line; that is, double the amount
of radioligand was observed in DDM-solubilised
receptor compared to membranes and no binding
was detected when SDS was used. Note that the
binding data in Fig. 2 are normalised for ease of
comparison, whereas in actuality, there is 20-fold
less functional AT1R per cell in Sf9 cells compared to
the stable mammalian cell line. However, the
Western blotting data of AT1R produced in Sf9kDa
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s)cells are different from the analogous data from the
iHEK cell line. Orders of magnitude more AT1R
polypeptide was solubilised from Sf9 cell mem-
branes by SDS or FC12 compared to either DDM or
digitonin (Fig. 2). It is reasonable to assume from the
125I-Sar1 binding data that DDM solubilised all the
functional AT1R and therefore the difference be-
tween the signal on the Western blot for DDM-solu-
bilised AT1R and SDS-solubilised AT1R represents
misfolded AT1R.
There is a significant difference between the
Western blotting signal for SDS-solubilised AT1R
and DDM-solubilised AT1R from Sf9 cells and that
difference represents an amount of misfolded AT1R
that can be solubilised by SDS but not by DDM.
However, there may be more misfolded AT1R
present in Sf9 cell membranes than suggested
from the differential solubility in SDS versus DDM
because it is plausible that DDM can also solubilise
some AT1R that cannot bind antagonist. To assess
this possibility, we diluted membranes from the
stable mammalian cell line iHEK(AT1R-GFP-H10)
and insect cell membranes expressing AT1R-H10 to
give the same amount of functional AT1R per
millilitre, solubilised in DDM and then analysed by
Western blotting. The data (Fig. 3) showed clearly
that there was considerably more AT1R polypeptide
solubilised from Sf9 cells than from the mammalian
cell line and that this difference is due to misfolded
receptor given that there was the same amount of
functional receptor per lane. Efforts to decrease the
amount of misfolded AT1R in the baculovirusFig. 1. Functional expression of AT1R in mammalian
cells that is 5-fold higher compared to insect cells. (a)Western
blot of whole cells expressing AT1R solubilised in SDS.
Lanes 1 and 3, iHEK parental cells; lanes 2 and 4,
iHEK(AT1R-GFP-H10) stable clonal cell line; lanes 5 and 7,
uninfected Sf9 cells; lanes 6 and 8, bvAT1R-H10 infected Sf9
cells. N-Linked glycosylation was removed using PNGase F
where indicated (+). Bands corresponding to AT1R-GFP-H10
in mammalian cells are indicated with a yellow asterisk (*).
iHEK cell lineswere inducedwith 1 μg/ml tetracycline for 24 h
and insect cells were infected with recombinant baculovirus
for 48 h. The blot was probed with an anti-pentaHis-HRP
conjugated antibody. (b) The amount of functional AT1R in
each expression system was determined by measuring
specific binding of the antagonist [125I]Sar1. Baculoviral
expression was performed in Sf9, Sf21 or Hi5 cells. After
the addition of ligand, membranes were solubilised in DDM
and non-bound ligand was separated from receptor–ligand
complex on gel-filtration spin columns andmeasured by liquid
scintillation counting. [125I]Sar1-boundAT1R is stable inDDM,
but not in SDS. The amount of functional AT1R was most
accurately determined after solubilisation with DDM to ensure
that all the receptor was accessible to ligand (see Fig. 2,
where twice as much receptor could be measured upon
solubilisation in DDMcompared to inmembranes). Each data
point was determined in triplicate from two independent
experiments andwas plotted asmean ± SEM (standard error
of the mean).
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Fig. 2. Misfolded AT1R produced by the baculovirus expression system is poorly solubilised either by DDM or digitonin.
(a) Western blot of AT1R solubilised from whole cells using four different detergents (SDS, FC12, DDM or digitonin) and
probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of total protein and N-linked
glycosylation was removed from all samples using PNGase F prior to SDS-PAGE. AT1R was expressed either in the stable
mammalian cell line iHEK(AT1R-GFP-H10) or by using the recombinant baculovirus bvAT1R-H10 to infect Sf9 cells. The
iHEK cell line was induced with 1 μg/ml tetracycline for 24 h and Sf9 cells were infected for 48 h. TheWestern blot insert is
a 7× longer exposure. (b) The amount of functional detergent-solubilised AT1R was determined by measuring specific
binding of the antagonist [125I]Sar1. After the addition of ligand, membranes were solubilised in the detergent indicated and
non-bound ligand was separated from receptor–ligand complex on gel-filtration spin columns and measured by liquid
scintillation counting: red-filled bars, AT1R expressed in Sf9 cells; blue-filled bars, AT1R expressed in iHEK cells. The
amount of AT1R in membranes (non-solubilised) was determined by separation of receptor-bound and free radioligand
by filtration through glass fibre plates: red hatched bars, AT1R expressed in Sf9 cells; blue hatched bars, AT1R expressed
in iHEK cells. For ease of comparison, binding data have been normalised with respect to AT1R in membranes
(100%), which is equivalent to 1400 ± 240 dpm (n = 2; 380 fmol per million cells) for baculovirus-infected Sf9 cells and
12,000 ± 300 dpm (n = 2; 8.8 pmol per million cells) for iHEK(AT1R-GFP-H10) cells. Absolute levels of AT1R therefore
cannot be compared meaningfully between the two expression systems using this bar graph (see Fig. 1). Binding assays
for AT1R contained either 150,000 Sf9 cells or 55,000 iHEK cells. Each data point was determined in duplicate or triplicate
from a single experiment and was plotted as mean ± SEM.
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Fig. 3. DDM solubilises considerable amounts of
inactive AT1R produced in the baculovirus expression
system. (a) Western blot of DDM-solubilised AT1R, with
equal amounts of active receptor per sample (lanes 2, 3
and 5–10). The blot was probed with an anti-penta-
His-HRP conjugated antibody. Lane 1, iHEK parental
cells; lanes 2 and 3, iHEK(AT1R-GFP-H10) stable
clonal cell line; lane 4, uninfected Sf9 cells; lanes 5–10,
bvAT1R-H10 infected insect cells. N-Linked glycosylation
was removed using PNGase F where indicated (+). AT1R
was expressed either in the stable mammalian cell line
iHEK(AT1R-GFP-H10) or by using the recombinant bacu-
loviruses bvAT1R-H10 and bvAT1R-LS-H10 to infect Sf9,
Sf21 and Hi5 cells as indicated. iHEK cell lines were
induced with 1 μg/ml tetracycline for 24 h and insect cells
were infected with recombinant baculovirus for 48 h. The
amount of functional AT1R was determined by measuring
specific binding of the antagonist [125I]Sar1.
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Fig. 4. Comparison of AT1R expressed in mammalian
cells and insect cells. (a) Stability of DDM-solubilised AT1R
bound to the antagonist [125I]Sar1. AT1R was expressed
using three different expression systems: blue circles,
baculovirus bvAT1R in Sf9 cells; red diamonds, stable
clonal cell line iHEK(AT1R-GFP-H10). The apparent Tm
values of AT1R expressed in each system are as follows:
Sf9 cells, 46 ± 0.8 °C; iHEK(AT1R-GFP-H10), 46 ± 0.7 °C.
Each data point was determined in triplicate and was
plotted as a mean value ± SEM. (b) SEC was carried out
using a Superdex 200 10/300 (24 ml) column. The elution
of iHEK(AT1R-GFP-H10) was detected using GFP fluores-
cence (mV). The elution of bvAT1R-H10 was detected by
Western blotting and band quantification (ImageJ value).
iHEK(AT1R-GFP-H10) shows a symmetrical peak whereas
bvAT1R-H10 shows two peaks; however, both systems
show elution of a protein of a similar size. The void (Vo) and
total (VT) column volumes are indicated.
4143Quality of overexpressed membrane proteinsexpression system either by using different cell lines
(Sf21, Hi5) or by including an N-terminal signal
sequence on AT1R were ineffective (Fig. 3).
In order to ascertain the quality of AT1R expressed
in either mammalian cells or insect cells, we
analysed two biophysical parameters of the deter-
gent-solubilised receptor. Firstly, the thermostability
of DDM-solubilised AT1R was determined and the
apparent Tm values of
125I-Sar1-bound AT1R
expressed in either Sf9 cells or mammalian cells
were found to be identical (Sf9 cells, 46 ± 0.8 °C;
iHEK(AT1R-GFP-H10), 46 ± 0.7 °C). Secondly, the
mobility on size-exclusion chromatography (SEC) of
AT1R expressed using the baculovirus expression
system in Sf9 cells or from the stable mammalian cell
line was compared and also found to be very similar
(Fig. 4). These data, coupled with the similarity in
pharmacology between AT1R expressed in the two
cell types [19], suggest that there is no significant
difference between correctly folded AT1R produced
in the baculovirus expression system and AT1R
produced in the stable mammalian cell line.The presence of misfolded protein upon
overexpression from recombinant baculovirus
is not uncommon
The presence of substantial amounts of misfolded
AT1R upon production in the baculovirus expression
system raised thequestion ofwhether this is specific for
AT1R or whether other membrane proteins also
exhibited this property. As it is not possible to test
rigorously all membrane proteins, a careful selection
was made of interesting test cases. The avian β1-
adrenergic receptor (β1AR) is a well-characterised
GPCR and its structure has been determined bound
to many different ligands of different efficacy [20–23].
All of the β1AR crystals were grown from protein
expressed in either Sf9 or Hi5 cells using recombinant
4144 Quality of overexpressed membrane proteinsbaculoviruses [24,25]. The assays described for AT1R
were therefore repeated using wild-type β1AR with
truncations at the N-terminus and at the C-terminus
(bvβ1AR-H10), which facilitates expression of a homog-
enous protein. Comparison of the amount of β1AR-H10
solubilised by the different detergents clearly indicates
that a large proportion of the receptor is indeed
misfolded, as suggested by the higher proportion of
receptor solubilised by either SDS or FC12 comparedkDa
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Fig. 5. Misfolded β1AR is poorly solubilised either by DDM o
cells using four different detergents (SDS, FC12, DDM or dig
antibody. Each lane contains an equal amount of total protein. β
bvβ1AR-H10 to infect Hi5 cells. tsβ1AR was expressed by usin
cells. Hi5 and Sf9 cells were infected for 48 h. The broken line
detergent-solubilised β1AR and tsβ1AR was determined bymea
addition of ligand, membranes were solubilised in the deterg
receptor–ligand complex on gel-filtration spin columns and me
expressed in Hi5 cells; blue-filled bars, tsβ1AR expresse
(non-solubilised) was determined by separation of receptor-b
plates: red hatched bars, β1AR expressed in Hi5 cells; blue h
comparison, binding data have been normalised with respec
11,000 ± 550 dpm (n = 3; 6.1 pmol per million cells) for baculo
for bvtsβ1AR-H10 infected Sf9 cells. All binding assays for
comparison on absolute levels of receptor can be directly co
triplicate from a single experiment and was plotted as mean ±to eitherDDMor digitonin (Fig. 5). Efforts to improve the
proportion of folded protein by using a thermostable
β1AR mutant fused at the N-terminus to a leader
sequence and a well-folded soluble protein (thiore-
doxin) did not increase the proportion of correctly folded
β1AR (Fig. 5). However, it is interesting to note that
receptor containing an uncleaved leader sequence
was only extracted by SDS or FC12, suggesting that
this sub-population of receptor was probably mainlykDa
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4145Quality of overexpressed membrane proteinsmisfolded. In addition, it is unlikely that the fusion
proteinwas efficiently trafficked to the cell surface given
that FC12 extraction resulted in a 3-fold increase in the
amount of receptor binding obtained compared towhen
membranes were used.
In a second example, we compared the expres-
sion of the adenosine A1 receptor (A1R) in both the
stable mammalian cell line iGnTI−(A1R-GFP-H10)PNGaseF
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Fig. 6. Expression of A1R in mammalian cells com-
pared to insect cells. (a) Western blot of whole cells
expressing A1R solubilised in SDS. Lanes 1 and 3, iGnTI
−
parental cells; lanes 2 and 4, iGnTI−(A1R-GFP-H10) stable
cell line; lanes 5 and 7, uninfected Sf9 cells; lanes 6 and 8,
bvA1R-H10 infected Sf9 cells. N-Linked glycosylation was
removed using PNGase F where indicated (+). Bands
corresponding to A1R-GFP-H10 in mammalian cells are
indicated with a red asterisk (*). The iGnTI− cell line was
induced with 1 μg/ml tetracycline for 24 h and insect cells
were infected with recombinant baculovirus for 72 h. The
blot was probed with an anti-pentaHis-HRP conjugated
antibody. (b) The amount of functional A1R in each
expression system was determined by measuring specific
binding of the antagonist [3H]DPCPX. After the addition
of ligand, membranes were solubilised in DDM and
non-bound ligand was separated from receptor–ligand
complex on gel-filtration spin columns and measured by
liquid scintillation counting. Each data point was deter-
mined in duplicate and was plotted as mean ± SEM.and the insect cells using the baculovirus expression
system (bvA1R-H10). N-Linked glycosylated sites are
found in extracellular regions of A1R (extracellular
loop 2; Asn148 and Asn159), which produces a
glycosylated form in mammalian cells that can be
reduced in molecular weight by treatment with
PNGase F, whereas the majority of the receptor is
unglycosylated in Sf9 cells (Fig. 6). Expression of
A1R-H10 in insect cells gave comparative Western
blots analogous to those observed for AT1R-H10,
with SDS and FC12 extracting orders of magnitude
more polypeptide from insect cell membranes
compared to either DDM or digitonin, consistent
with a large excess of misfolded receptor produced
in the baculovirus expression system (Fig. 7). In
contrast, all the detergents used to solubilise
A1R-GFP-H10 from a stable mammalian cell line
were equally efficacious, indicating that there is
minimal misfolded receptor in these cells (Fig. 7).
The low levels of antagonist binding activity ob-
served for A1R is a consequence of the poor stability
of this receptor in detergent solutions. A1R also
provided a nice example of the usefulness of
confocal microscopy in defining whether a receptor
is likely to be correctly folded. A1R-GFP-H10 is
expressed in the stable cell line predominantly at the
cell surface whereas a mutant of A1R that contained
multiple changes introduced to try and facilitate
crystallisation (A1R-GL26-GFP-H10; see Methods)
was expressed predominantly in intracellular mem-
branes (Fig. 8). The confocal data correlated well
with the Western blotting data. The misfolded mutant
A1R-GL26-GFP-H10 was only efficiently extracted
from mammalian cells with SDS (Fig. 9), whereas
the wild-type receptor was extracted equally effi-
ciently using either digitonin or SDS (Fig. 7).
The final example we tested was the serotonin
transporter (SERT). The expression of SERT has
been studied intensively [16,17,26] and was the first
example along with rhodopsin that showed the
utility of mammalian cells for the overexpression of
functional membrane protein using the tetracycli-
ne-inducible HEK293 cell line [27,28]. Here we
demonstrated that the Western blot data show an
identical pattern of results with constructs based on
wild-type A1R and AT1R, namely, similar amounts
of extractable SERT-SAH9-GFP-H10 from the
mammalian cell line, regardless of the detergent
used, whereas there are orders of magnitude more
SDS-extractable SERT-H10 in Sf9 cells compared
to the amount solubilised by digitonin or DDM
(Fig. 10).
A simplified assay for the detection of misfolded
membrane proteins
Analysis of the data in Figs. 1–10 suggests that the
salient conclusions of this paper, that is, that the
majority of AT1R, A1R and SERT constructs
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4147Quality of overexpressed membrane proteinsexpressed in insect cells were misfolded, whereas
expression in mammalian cells produced correctly
folded protein, could be deduced with a fraction of
the work. Comparison of two lanes in each Western
blot, namely, SDS-extracted protein and digitoni-
n-extracted protein, is sufficient to draw the relevant
conclusions. Importantly, this obviates the need for
radioligand binding assays and a stable mammalian
cell line for each membrane protein to be studied.
Radioligands have been developed for only a small
fraction of membrane proteins and not all radioli-
gands are of sufficiently high affinity (100 nM or
better) to make them suitable for assays on
detergent-solubilised membrane proteins. In addi-
tion, construction of stable mammalian cell lines can
take many months and sometimes the cell lines grow
very poorly due to basal activity of the membrane
protein. This was noticeable for the stable A1R cell
line iGnTI−(A1R-GFP-H10) developed here, which
grew very poorly compared to the stable cell line
iGnTI−(A1R-GL26-GFP-H10) expressing the inactive
A1R mutant, despite the use of an inducible
promoter.
Using the methodology described in this paper, it
would be relatively simple to test 50 or so different
membrane protein expression trials in a day. Howev-
er, if hundreds of samples are to be tested in 96-well
plates, then the ultracentrifugation step will become
limiting and will need to be replaced using filtration
through low-protein-binding 0.2-μm filters. The use of
a dot-blot apparatus and semi-quantification of the
resulting signals in relation to a known standard would
be sufficient to define howmuch functional membrane
protein could be extracted and whether or not extraFig. 7. Misfolded A1R produced by the baculovirus express
(a) Western blot of A1R solubilised from whole cells using fou
probed with an anti-pentaHis-HRP conjugated antibody. Each
glycosylation was removed from all samples using PNGase F p
mammalian cell line iGnTI−(A1R-GFP-H10) or by using the re
iGnTI− cell line was induced with 1 μg/ml tetracycline for 24
functional detergent-solubilised A1R was determined bymeasu
addition of ligand, membranes were solubilised in the deterg
receptor–ligand complex on gel-filtration spin columns and me
expressed in Sf9 cells; blue-filled bars, A1R expressed in iGnTI
was determined by separation of receptor-bound and free radi
bars, A1R expressed in Sf9 cells; blue hatched bars, A1R expre
have been normalised with respect to A1R in membranes (10
2.9 pmol per million cells) for baculovirus-infected Sf9 cells a
iGnTI−(A1R-GFP-H10) cells. Absolute levels of A1R therefo
expression systems using this bar graph. Binding assays for A
Each data point was determined in duplicate or triplicate from
Western blot of DDM-solubilised A1R, with equal amounts of ac
probed with an anti-pentaHis-HRP conjugated antibody. L
(A1R-GFP-H10) stable cell line; lane 4, uninfected Sf9 cells;
glycosylation was removed using PNGase F where indicated (
line iGnTI−(A1R-GFP-H10) or by using the recombinant baculov
A1R-GFP-H10 in mammalian cells are indicated with a yellow
tetracycline for 24 h and insect cells were infected with recom
was determined by measuring specific binding of the antagonprecautions may be required to remove potential
misfolded protein during purification. It would also be
possible to measure the fluorescence of a
GFP-tagged membrane protein, rather than perform-
ing a Western blot, to improve further the high--
throughput capabilities of this assay.Discussion
A commonly held misconception, particularly
amongst investigators new to the membrane protein
field, is that if a membrane protein can be expressed
into a membrane within a cell and can be extracted
with detergent, then that membrane protein is folded
authentically. Over the last 30 years, there have
been sporadic reports of overexpressed membrane
proteins in E. coli, yeast or the baculovirus expres-
sion system being predominantly misfolded and
inactive [2]. The work presented here demonstrates
that the baculovirus expression system is particularly
prone to producing misfolded membrane proteins,
even of apparently uncomplex GPCRs that were
expressed over 20 years ago. However, the simple
assay proposed here will rapidly demonstrate
whether misfolded membrane protein is indeed
present. A few words of caution are warranted with
regard to the differential solubility assay. Firstly, we
have tested the assay on membrane proteins
expected to be expressed in the plasma membrane
of mammalian cells, which is efficiently solubilised by
DDM. This is evident from the similar levels of
solubilisation between DDM and SDS of correctly
folded membrane proteins in the plasma membrane.ion system is poorly solubilised either by DDM or digitonin.
r different detergents (SDS, FC12, DDM or digitonin) and
lane contains an equal amount of total protein and N-linked
rior to SDS-PAGE. A1R was expressed either in the stable
combinant baculovirus bvA1R-H10 to infect Sf9 cells. The
h and Sf9 cells were infected for 72 h. (b) The amount of
ring specific binding of the antagonist [3H]DPCPX. After the
ent indicated and non-bound ligand was separated from
asured by liquid scintillation counting: red-filled bars, A1R
− cells. The amount of A1R in membranes (non-solubilised)
oligand by filtration through glass fibre plates: red hatched
ssed in iGnTI− cells. For ease of comparison, binding data
0%), which is equivalent to 120,000 ± 2000 dpm (n = 3;
nd 7500 ± 250 dpm (n = 3; 3.8 pmol per million cells) for
re cannot be compared meaningfully between the two
1R contained either 150,000 Sf9 cells or 7500 iGnTI
− cells.
a single experiment and was plotted as mean ± SEM. (c)
tive receptor per sample (lanes 2, 3, 5 and 6). The blot was
ane 1, iGnTI− parental cells; lanes 2 and 3, iGnTI−
lanes 5 and 6, bvAT1R-H10 infected Sf9 cells. N-Linked
+). A1R was expressed either in the stable mammalian cell
irus bvA1R-H10 to infect Sf9 cells. Bands corresponding to
asterisk (*). The iGnTI− cell line was induced with 1 μg/ml
binant baculovirus for 72 h. The amount of functional A1R
ist [3H]DPCPX binding.
Fig. 8. A1R-GL26 ismisfoldedwhenexpressed inmammalian cells. (a–c)Confocalmicrographsof the iGnTI
−(A1R-GFP-H10)
cell line after 24 hof inductionwith tetracycline. Cellswere fixed using paraformaldehyde and the plasmamembranewasdefined
by stainingwith Alexa Fluor 647-conjugated conAprior to visualisation. Unlabelled iGnTI− parental cells showed no fluorescence
(data not shown). The scale bar represents 10 μm. (d–f) Confocal micrographs of the iGnTI−(A1R-GL26-GFP-H10) cell line after
24 h of induction with tetracycline. Cells were fixed using paraformaldehyde and the plasmamembrane was defined by staining
with Alexa Fluor 647-conjugated conA prior to visualisation. Unlabelled iGnTI− parental cells showed no fluorescence (data not
shown). The scale bar represents 10 μm.
4148 Quality of overexpressed membrane proteinsSecondly, we are using the assay as a guide rather
than as an exact measure for determining the
number of molecules of the target membrane protein
that are correctly folded compared to the number of
molecules that are misfolded.
Knowing that a proportion of an expressed mem-
brane protein is misfolded is important. Many efforts
have been made to parallelise expression of
membrane proteins to facilitate high-throughput post-
genomic approaches to determine rapidly membrane
protein structures [3]. Although it has proven possibleto do this for bacterial membrane proteins, it has
proven harder to replicate these strategies for mam-
malian membrane proteins, partly because yields of
membrane protein suggested from thequantification of
polypeptide expressed have not reflected the yield of
purified membrane protein. There are two factors that
could explain this. Firstly, as described here, most of
the membrane protein could be expressed in a
misfolded state and therefore cannot be purified in
mild detergents. Secondly, membrane proteins are
often unstable in detergent and therefore they become
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Fig. 9. Misfolded A1R-GL26 is poorly solubilised either by DDM or digitonin. (a) Western blot of A1R solubilised from
whole cells using four different detergents (SDS, FC12, DDM or digitonin) and probed with an anti-pentaHis-HRP
conjugated antibody. Each lane contains an equal amount of total protein. A1R was expressed either in the stable
mammalian cell line [iGnTI−(A1R-GL26-GFP-H10)] or by using the recombinant baculovirus bvA1R-GL26-H10 to infect Sf9
cells. The iGnTI− cell line was induced with 1 μg/ml tetracycline for 24 h and Sf9 cells were infected for 72 h. The Western
blot inserts are a 4× longer exposure. (b) The amount of functional detergent-solubilised A1R-GL26 was determined by
measuring specific binding of the antagonist [3H]DPCPX. After the addition of ligand, membranes were solubilised in the
detergent indicated and non-bound ligand was separated from receptor–ligand complex on gel-filtration spin columns and
measured by liquid scintillation counting: red-filled bars, A1R-GL26 expressed in Sf9 cells; blue-filled bars, A1R-GL26
expressed in iGnTI− cells. The amount of A1R-GL26 in membranes (non-solubilised) was determined by separation of
receptor-bound and free radioligand by filtration through glass fibre plates: red hatched bars, A1R-GL26 expressed in Sf9
cells; blue hatched bars, A1R-GL26 expressed in iGnTI
− cells. For ease of comparison, binding data have been normalised
with respect to A1R-GL26 in membranes (100%), which is equivalent to 17,400 ± 800 dpm (n = 3; 435 fmol per million
cells) for baculovirus-infected Sf9 cells and 2000 ± 350 (n = 2; 48 fmol per million cells) for iGnTI−(A1R-GL26-GFP-H10)
cells. Absolute levels of A1R therefore cannot be compared meaningfully between the two expression systems using this
bar graph. Binding assays for A1R-GL26 contained 150,000 cells. Each data point was determined in duplicate or triplicate
from a single experiment and was plotted as mean ± SEM.
4149Quality of overexpressed membrane proteinsinactive and aggregate during solubilisation and
purification. The assay described here will define
which is the problematic step, thus directing resourcesto solving the relevant problem. For example, knowing
that the majority of membrane protein is misfolded in
the baculovirus expression systemsuggests that using
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Fig. 10. Misfolded SERT produced by the baculovirus expression system is poorly solubilised by either DDM or
digitonin. (a) Western blot of SERT solubilised from whole cells using four different detergents (SDS, FC12, DDM or
digitonin) and probed with an anti-pentaHis-HRP conjugated antibody. Each lane contains an equal amount of total
protein. SERT was expressed either in the stable mammalian cell line iGnTI−(SERT-SAH9-GFP-H10) or by using the
recombinant baculovirus bvSERT-H10 to infect Sf9 cells. The iGnTI
− cell line was induced with 1 μg/ml tetracycline for 24 h
and Sf9 cells were infected for 48 h. The broken line indicates separate blots. (b) The amount of functional
detergent-solubilised SERT was determined by measuring specific binding of the ligand [125I]RTI-55. After the addition of
ligand, membranes were solubilised in the detergent indicated and non-bound ligand was separated from receptor–ligand
complex on gel-filtration spin columns and measured by liquid scintillation counting: red-filled bars, SERT expressed in Sf9
cells; blue-filled bars, SERT-SAH9 expressed in iGnTI− cells; *, not determined. The amount of SERT in membranes
(non-solubilised) was determined by separation of receptor-bound and free radioligand by filtration through glass fibre
plates: red hatched bars, SERT expressed in Sf9 cells; blue hatched bars, SERT-SAH9 expressed in iGnTI− cells. For
ease of comparison, binding data have been normalised with respect to SERT in membranes (100%), which is equivalent
to 10,200 ± 950 dpm (n = 2; 75.7 fmol per million cells) for baculovirus-infected Sf9 cells and 35,400 ± 420 dpm (n = 2;
730 fmol per million cells) for iGnTI−(Sert-SAH9-GFP-H10) cells. Therefore, absolute levels of SERT cannot be compared
meaningfully between the two expression systems using this bar graph. Binding assays for SERT contained either 28,000
Sf9 cells or 10,000 iGnTI− cells. Each data point was determined in duplicate or triplicate from a single experiment and was
plotted as mean ± SEM.
4150 Quality of overexpressed membrane proteinsstable inducible mammalian cell lines could improve
yields [29]. In the work described here, the AT1R
expressed in the baculovirus expression systemwould
yield only 0.1 mg/l of functional receptor, whereas the
stable clonal cell line iHEK(AT1R-GFP-H10) would
yield 0.5 mg/l. However, the major advantage of usingthe mammalian expression system is that there is little
or no misfolded AT1R expressed.
Is the misfolded membrane protein expressed in
insect cells a potential problem for downstream
purification and crystallisation? Even though DDM is
a mild detergent and cannot solubilise misfolded
4151Quality of overexpressed membrane proteinsprotein as well as SDS or FC12, misfolded AT1R is
the major component of DDM-solubilised insect cell
membranes. In the initial stages of a project, this
could be highly misleading, as it would appear that
major losses were being incurred on, for example,
the first Ni2+-affinity column, when in actual fact, it
may be the case that the only protein lost was the
misfolded material and that the yields of the correctly
folded protein were around 80–90%. In the worst
instance, researchers may note that FC12 extracts
more of the target protein than DDM and then waste
many years trying to purify and crystallise this
material, not knowing that the target protein was
likely to be totally inactive. Interestingly, the work
here shows that β1AR is expressed as a mixture of
both folded and misfolded receptors, but β1AR was
purified and crystallised and its structure was
determined without knowing this. Two effects may
help in reducing the impact of misfolded membrane
proteins on crystallisation trials. Firstly, SEC is a
frequently used step in protein purification and will
effectively remove any misfolded protein. Secondly,
misfolded membrane proteins have a tendency to
aggregate; thus, this portion may just “disappear”,
either through retention on columns by non-specific
effects or by being unable to pass through pre-filters
that are normally present upstream of columns run
on automated protein purification equipment. Third-
ly, during crystallisation, any remaining inactive
protein will precipitate more readily than the folded
protein, hopefully allowing crystals to form later on.
Why are misfolded membrane proteins produced in
the baculovirus expression system? Although there
are many potential differences between insect cells
andmammalian cells thatmay reduce the efficiency of
membrane protein folding (e.g., potential specificity
and amounts of molecular chaperones, different lipid
composition, etc.), there are twooverriding factors that
have tobeconsidered. Baculoviruses are lytic viruses,
and one of the first effects of the virus is to impair the
cells' secretory pathway, which is precisely where
membrane proteins are folded. Thus, during the
infection cycle, the rate of secretion decreases and it
is also observed that post-translational modifications
such as N-glycosylation also decrease [30]. In
addition, the polyhedrin promoter is one of the
strongest known eukaryotic promoters, resulting in
the polyhedron mRNA transcript representing over
20% of the cellular polyadeylated RNA [31,32] and
polyhedrin representing over 50% of the total cellular
protein upon infection of a wild-type baculovirus [33].
Thus, it is highly likely that production of too much
mRNA of a target membrane protein, which could well
overwhelm the secretory pathway due to insufficient
folding factors, in combination with an impairment in
the secretory pathway caused by the baculovirus,
combines to facilitate the production of misfolded
membrane proteins. It is interesting to note that where
careful comparisons have been made with mamma-lian expression systems that utilise viruseswith strong
promoters, such as the semiliki forest virus expression
system,misfolded and inactivemembrane protein has
also been observed [19,34,35]. Thus, the current
successes with the production of authentically folded
membrane proteins in mammalian cells for structural
studies are all about ensuring that there is a balance
between the amount of mRNA produced and the
ability of themembrane protein to fold [29]. This will be
different for each membrane protein and will have to
be optimised empirically on a case-by-case basis.
However, the differential solubility assay described
here will ensure that expression of only the correctly
folded membrane protein will be optimised.Materials and Methods
Materials
All radiolabelled ligandswere purchased fromPerkinElmer:
[125I]sar1-Ile8-angiotensin II ([125I]Sar1), [3H]dihydroalprenolol
([3H]DHA), [3H]dipropylcyclopentylxanthine ([3H]DPCPX)
and [125I]2β-carbomethoxy-3β-(4-iodophenyl)tropane ([125I]
RTI-55). The detergents n-dodecyl β-D-maltopyranoside
(DDM) and fos-choline-12 (FC12) were purchased from
Anatrace; SDS was purchased from Sigma and digitonin
was purchased from Calbiochem. Anti-penta-histidine anti-
body conjugated toHRP (anti-pentaHis-HRP)was purchased
fromQiagen. A tetracycline-inducible HEK293 cell line, T-Rex
™-293 (iHEK), was purchased from Invitrogen. A tetracycli-
ne-inducible HEK293S cell line lacking N-acetylglucosami-
nyltransferase I (iGnTI−) was kindly provided by Philip J.
Reeves (Massachusetts Institute of Technology) [36].
Methods
Constructs
Expression in mammalian cells was performed using
derivatives of pcDNA4/TO (Invitrogen). The serotonin
transporter cDNA was inserted into the EcoRV/NotI
restriction sites in pcDNA4/TO, for expression from the
tetracycline-inducible CMV promoter, and then a cassette
encoding enhancedGFP, theStrepII tag andadecahistidine
(H10) tag was inserted after SERT in the NotI/ApaI sites
(plasmid pJMA111, kindly provided by J. Andréll, MRC
Laboratory of Molecular Biology). The cDNA clone for
human angiotensin II type 1 receptor (AT1R) was obtained
from the Missouri S&T cDNA Resource Center†, amplified
by polymerase chain reaction, flanked with EcoRV and NotI
sites and cloned into the corresponding sites of pJMA111 to
create plasmid pJAP2, which expressed AT1R-GFP-H10.
Additionally, the cDNA for the human adenosine A1R
(Missouri S&T cDNAResourceCenter) was cloned similarly
into the EcoRV/NotI sites to create plasmid pJAP34, which
expressed A1R-GFP-H10. In an effort to create a thermo-
stable A1R receptor, four mutations that stabilised the
adenosine A2A receptor in the active state (L48A, A54L,
T65A, Q89A) [37] were transferred to A1R (mutations L51A,
A57L, L68A, Q92A). In addition, the mutations N148G and
N159G were included to remove the putative N-linked
4152 Quality of overexpressed membrane proteinsglycosylation sites. To remove flexible regions, we truncated
the N-terminus between Pro2 and Ile5, truncated the
C-terminus at Phe307 and also added the sequence
VLRQQEPFKAA to the C-terminus, thus generating
A1R-GL26. A synthetic cDNA encoding A1R-GL26
(Life Technologies) was cloned into the EcoRV/NotI
sites in pJMA111 creating pJAP37, which expressed
A1R-GL26-GFP-H10. For generating baculoviruses, AT1R
was cloned into the BamHI/EcoRI sites of the transfer vector
pBacPAK8 (Clonetech), A1R was cloned into the XhoI/
EcoRI sites and A1R-GL26 was cloned into the EcoRI/EagI
sites, creating plasmids pJAP15, pJAP44 and pJAP33,
respectively. Additionally, AT1R was cloned into the BamHI/
EcoRI sites in plasmid pAcGP67-B (BD Biosciences) in
order to utilise the acidic glycoprotein gp67 signal sequence
(LS) preceding the N-terminus of AT1R, creating
plasmid pJAP16, which expressed AT1R-LS-H10. All bacu-
lovirus sequences were engineered to contain a C-terminal
tobacco etch virus cleavage site and H10 tag. All constructs
were verified by DNA sequencing (Source Biosciences,
UK).
Transient transfection, generation of stable cell lines and
protein expression
Mammalian expression plasmids for the expression of
AT1R (pJAP2), A1R (pJAP34) and A1R-GL26 (pJAP37)
were amplified in E. coli strain DH5α, purified using a
Maxi-prep kit (Qiagen) and transiently transfected (Gene-
Juice, Novagen) into adherent mammalian iHEK cells or
iGnTI− cells following the manufacturer's protocol. Cells
were grown in Dulbecco's modified Eagle's media supple-
mented with 10% tetracycline-free foetal bovine serum
(Invitrogen) and 5 μg/ml blasticidin (Invitrogen) and incu-
bated at 37 °C in an atmosphere containing 5% CO2.
Expression of plasmids was induced by addition of 1 μg/ml
tetracycline and incubated at 37 °C for 24 h. Stable cell
lines were generated by selection with media containing
200 μg/ml Zeocin (Invitrogen). An iGnTI− stable cell line
expressing a thermostable mutant of SERT, SERT-SAH9
(J. Andréll and C. Tate, unpublished results; Ref. [38]) and
(iGnTI− SERT-SAH9-GFP-H10) was kindly provided by J.
Andréll. A highly expressing clonal AT1R-GFP-H10 cell line
was selected from a polyclonal cell line using fluorescen-
ce-activated cell sorting. After expression, cells were
washed twice in phosphate-buffered saline (PBS), count-
ed using the Countess Automated Cell Counter (Invitro-
gen), pelleted (1200g for 5 min) and resuspended at 10
million cells per millilitre in ice-cold cell buffer [50 mM Tris
(pH 7.4) and 150 mM NaCl supplemented with Complete
EDTA (ethylenediaminetetraacetic acid)-Free Protease
Inhibitor Cocktail (Roche)]. Cell suspensions were flash
frozen in liquid nitrogen and stored at −80 °C.
Recombinant baculovirus generation and protein expression
Recombinant baculoviruses that expressed AT1R, A1R
or A1R-GL26 were generated using the BaculoGold
Baculovirus Expression System according to manufac-
turer's protocol (BD Bioscience). Viruses were isolated by
plaque purification and screened for expression by
Western blotting using an anti-pentaHis-HRP antibody.
Recombinant baculovirus that expressed SERT with a H10
tag at its C-terminus was previously described [16,26].
Recombinant baculovirus that expressed β1AR with a H10tag at its C-terminus [24] was kindly provided by R. Nehme
(MRC Laboratory of Molecular Biology) and a thermosta-
ble β1AR fused to thioredoxin (tsβ1AR) was kindly provided
by T. Warne (MRC Laboratory of Molecular Biology).
Recombinant baculoviruses were passaged twice in Sf9
cells to obtain high titre stocks. Viruses were used to infect
Sf9, Sf21 or Hi5 cells for 48 or 72 h as indicated. After
protein expression, cells were counted using the Countess
Automated Cell Counter (Invitrogen), pelleted (1200g for
5 min) and washed twice in PBS, and the cell pellet was
resuspended at 10 million cells per millilitre in ice-cold cell
buffer [50 mM Tris (pH 7.4) and 150 mM NaCl supple-
mented with Complete EDTA-Free Protease Inhibitor
Cocktail (Roche)]. Cell suspensions were flash frozen in
liquid nitrogen and stored at −80 °C.
Western blotting
Cell suspensions were sonicated briefly and the total
protein concentration was determined using the Bradford
assay [39]. Samples were then solubilised in the detergent
indicated [SDS, FC12, DDM or digitonin; all at 1% (w/v) final
concentration] at either 4 °C (FC12, DDM, digitonin) or
20 °C (SDS) for 1 h. For blots corresponding to the
differential solubility assay, the solubilisate was centrifuged
at 280,000g for 30 min at 4 °C to remove the insoluble
fraction. SDS-loading buffer was added to the supernatant
(corresponding to approximately 150,000 cells), and sam-
ples were separated on a 4–20% Tris glycine gel and
transferred to nitrocellulose using standard techniques.
Membranes were probed with anti-pentaHis-HRP at a
dilution of 1:1000 and developed using enhanced chemilu-
minescence (GE Healthcare). Where indicated, 2 μl of
PNGase F (New England Biolabs) was added to 15 μl of
the supernatant and incubated at 37 °C for 1 h prior to
SDS-PAGE to remove N-linked glycosylation.
Thermostability assay of detergent-solubilised AT1R
The cell suspension containing unpurified AT1R was
sonicated briefly and diluted into buffer [50 mM Tris
(pH 7.4), 5 mM MgCl2, 1 mM EDTA, 0.1% (w/v) bovine
serum albumin, 150 mM NaCl and 40 μg/ml bacitracin].
[125I]Sar1 and unlabelled Sar1 were added to give final
concentrations of 0.5 nM and 100 nM, respectively, and
incubated for 1 h at room temperature before chilling on
ice and solubilising in 1% DDM (w/v, final concentration).
The samples were then heated at varying temperatures
for 30 min and the [125I]Sar1-bound receptor was sepa-
rated from the free radioligand by gel-filtration spin
columns as described previously [40–43]. Background
was determined by adding radioligand to non-transfected
parental mammalian cells or uninfected insect cells. Each
reaction was performed in triplicate. Results were
evaluated by nonlinear regression using GraphPad
Prism.Detergent-solubilised and membrane-bound radioligand
binding assays
Cell suspensions were sonicated briefly and the total
protein concentration was determined using the Bradford
assay [39]. Cells were then diluted into buffer [150 mM
NaCl and 50 mM Tris (pH 7.4)], incubated with the
4153Quality of overexpressed membrane proteinsrespective radioligand (1 h, 4 °C) and solubilised in a final
concentration of 1% detergent (DDM, FC12, digitonin,
SDS) for 1 h at 4 °C. [ 3H]DHA was used at a
final concentration of 200 nM and [3H]DPCPX was used
at a final concentration of 39 nM in 150 mM NaCl and
50 mM Tris (pH 7.4). [125I]RTI-55 was used at a concen-
tration of 1 nM in PBS. [125I]Sar1 was used as per the
thermostability assay mentioned above. Bound and free
radioligands were separated on gel-filtration spin columns
as above.
To determine the amount of SERT, AT1R, β1AR or A1R
present in cell membranes, we performed binding assays
as mentioned above but without the samples being
solubilised with detergent. Separation of receptor-bound
and free radioligands was achieved by filtration through a
96-well glass fibre filter plates (Millipore) pre-treated
with 0.1% polyethyleneimine [38] except for [125I]Sar1
where no polyethyleneimine was used. Background for
both assays was determined by adding radioligand to
non-transfected parental mammalian cells or uninfected
insect cells.FSEC and SEC analysed by Western blotting
The void volume (8.16 ml) of the Superdex 200 10/300
(24 ml) (GE healthcare) was determined by running
blue dextran through the column and observing where it
eluted using A280. For FSEC, approximately 5 million
iHEK(AT1R-GFP-H10) cells were thawed on ice and
sonicated briefly. Cells were incubated at room temper-
ature for 1 h with 40 nM Sar1 before chilling on ice
and solubilising in 1% DDM (w/v, final concentration).
Followed by centrifugation at 280,000g for 30 min at 4 °C.
The supernatant was then passed through a 0.22-μm filter
and injected onto a Superdex 200 10/300 column
pre-equilibrated with running buffer [0.03% (w/v) DDM,
50 mM Tris (pH 7.4), 150 mM NaCl and 1 μM Sar1]. The
fluorescence of eluent was detected by a Hitachi
fluorometer (mV) set to an excitation of 488 nm and an
emission of 525 nm. Approximately 5 million cells were
sonicated, incubated with ligand, solubilised and centri-
fuged as described above, in order to detect bvAT1R-H10
produced in Sf9 cells. The eluent was detected by
Western blotting as described above and bands corre-
sponding to bvAT1R-H10 were quantified by densitometry
using ImageJ.Fixing and staining cells for analysis by confocal laser-
scanning microscopy
Cells were grown on 35-mm glass bottom culture
dishes, induced for 24 h under standard conditions and
fixed using 2% paraformaldehyde [28]. After washing with
PBS, we selectively stained membranes using a solution
(10 μg/ml) of concanavalin A (ConA)–Alexa Fluor 647
conjugate (Invitrogen) in PBS for 10 min at room temper-
ature. After washing with PBS, we stored icells n fresh PBS
with 0.02% Na azide at 4 °C protected from light. Cells
were visualised on a Leica TCS SP8 STED inverted
laser-scanning microscope with 63× oil-immersion objec-
tive and a 1.4 numerical aperture. The white light laser was
set to a wavelength of 488 nm to excite GFP and to
633 nm for Alexa Fluor 647 with the pinhole emission
wavelength set to 580 nm.Acknowledgements
J.A.T. was the recipient of an MRC-funded
studentship and research in the laboratory of C.G.T.
is funded by a core grant from the Medical Research
Council (MRC U105197215).
Received 15 August 2014;
Received in revised form 12 October 2014;
Accepted 13 October 2014
Available online 28 October 2014
Keywords:
eukaryotic membrane proteins;
overexpression;
G protein-coupled receptors;
transporters
www.cdna.org
Abbreviations used:
FSEC, fluorescence-detection size-exclusion
chromatography; GPCR, G protein-coupled receptor;
A1R, A1 receptor; GFP, green fluorescent protein; PBS,
phosphate-buffered saline.References
[1] Bill RM, Henderson PJ, Iwata S, Kunji ER, Michel H, Neutze
R, et al. Overcoming barriers to membrane protein structure
determination. Nat Biotechnol 2011;29:335–40.
[2] Grisshammer R, Tate CG. Overexpression of integral
membrane proteins for structural studies. Q Rev Biophys
1995;28:315–422.
[3] Mancia F, Love J. High throughput platforms for structural
genomics of integral membrane proteins. Curr Opin Struct
Biol 2011;21:517–22.
[4] Drew D, Lerch M, Kunji E, Slotboom DJ, de Gier JW.
Optimization of membrane protein overexpression and
purification using GFP fusions. Nat Methods 2006;3:303–13.
[5] Kawate T, Gouaux E. Fluorescence-detection size-exclusion
chromatography for precrystallization screening of integral
membrane proteins. Structure 2006;14:673–81.
[6] Drew DE, von Heijne G, Nordlund P, de Gier JW. Green
fluorescent protein as an indicator to monitor membrane protein
overexpression in Escherichia coli. FEBS Lett 2001;507:220–4.
[7] Geertsma ER, Groeneveld M, Slotboom DJ, Poolman B.
Quality control of overexpressed membrane proteins. Proc
Natl Acad Sci USA 2008;105:5722–7.
[8] Newstead S, Kim H, von Heijne G, Iwata S, Drew D. High-
throughput fluorescent-based optimization of eukaryotic
membrane protein overexpression and purification in Sac-
charomyces cerevisiae. Proc Natl Acad Sci USA 2007;104:
13936–41.
[9] Haggie PM, Stanton BA, Verkman AS. Diffusional mobility of
the cystic fibrosis transmembrane conductance regulator
mutant, delta F508-CFTR, in the endoplasmic reticulum
4154 Quality of overexpressed membrane proteinsmeasured by photobleaching of GFP-CFTR chimeras. J Biol
Chem 2002;277:16419–25.
[10] Illing ME, Rajan RS, Bence NF, Kopito RR. A rhodopsin
mutant linked to autosomal dominant retinitis pigmentosa is
prone to aggregate and interacts with the ubiquitin protea-
some system. J Biol Chem 2002;277:34150–60.
[11] Saliba RS, Munro PM, Luthert PJ, Cheetham ME. The
cellular fate of mutant rhodopsin: quality control, degradation
and aggresome formation. J Cell Sci 2002;115:2907–18.
[12] Ellgaard L, Helenius A. Quality control in the endoplasmic
reticulum. Nat Rev Mol Cell Biol 2003;4:181–91.
[13] Akermoun M, Koglin M, Zvalova-Iooss D, Folschweiller N,
Dowell SJ, Gearing KL. Characterization of 16 human G
protein-coupled receptors expressed in baculovirus-infected
insect cells. Protein Expression Purif 2005;44:65–74.
[14] Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler
GF, Babu MM. Molecular signatures of G-protein-coupled
receptors. Nature 2013;494:185–94.
[15] Tate CG. Overexpression of mammalian integral membrane
proteins for structural studies. FEBS Lett 2001;504:94–8.
[16] Tate CG, Blakely RD. The effect of N-linked glycosylation on
activity of the Na(+)- and Cl(−)-dependent serotonin trans-
porter expressed using recombinant baculovirus in insect
cells. J Biol Chem 1994;269:26303–10.
[17] Tate CG,Whiteley E, Betenbaugh MJ. Molecular chaperones
stimulate the functional expression of the cocaine-sensitive
serotonin transporter. J Biol Chem 1999;274:17551–8.
[18] Tate CG. Practical considerations of membrane protein
instability during purification and crystallisation. Methods
Mol Biol 2010;601:187–203.
[19] Shukla AK, Reinhart C, Michel H. Comparative analysis of
the human angiotensin II type 1a receptor heterologously
produced in insect cells and mammalian cells. Biochem
Biophys Res Commun 2006;349:6–14.
[20] MoukhametzianovR,Warne T, Edwards PC, Serrano-VegaMJ,
Leslie AG, Tate CG, et al. Two distinct conformations of helix 6
observed in antagonist-bound structures of a beta1-adrenergic
receptor. Proc Natl Acad Sci USA 2011;108:8228–32.
[21] Warne T, Moukhametzianov R, Baker JG, Nehme R,
Edwards PC, Leslie AG, et al. The structural basis for
agonist and partial agonist action on a beta(1)-adrenergic
receptor. Nature 2011;469:241–4.
[22] Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R,
EdwardsPC,HendersonR, et al. Structureof abeta1-adrenergic
G-protein-coupled receptor. Nature 2008;454:486–91.
[23] Miller-Gallacher JL, Nehme R, Warne T, Edwards PC,
Schertler GF, Leslie AG, et al. The 2.1 Å resolution structure
of cyanopindolol-bound beta1-adrenoceptor identifies an
intramembrane Na+ ion that stabilises the ligand-free recep-
tor. PLoS One 2014;9:e92727.
[24] Warne T, Serrano-Vega MJ, Tate CG, Schertler GF. Develop-
ment and crystallization of a minimal thermostabilised G protein-
coupled receptor. Protein Expression Purif 2009;65:204–13.
[25] Warne T, Chirnside J, Schertler GF. Expression and purification
of truncated, non-glycosylated turkey beta-adrenergic receptors
for crystallization. Biochim Biophys Acta 2003;1610:133–40.
[26] Tate CG. Baculovirus-mediated expression of neurotrans-
mitter transporters. Methods Enzymol 1998;296:443–55.
[27] Reeves PJ, Kim JM, Khorana HG. Structure and function
in rhodopsin: a tetracycline-inducible system in stable
mammalian cell lines for high-level expression of opsin
mutants. Proc Natl Acad Sci USA 2002;99:13413–8.[28] Tate CG, Haase J, Baker C, BoorsmaM, Magnani F, Vallis Y,
et al. Comparison of seven different heterologous protein
expression systems for the production of the serotonin
transporter. Biochim Biophys Acta 2003;1610:141–53.
[29] Andrell J, Tate CG. Overexpression of membrane proteins in
mammalian cells for structural studies. Mol Membr Biol 2013;
30:52–63.
[30] Jarvis DL, Summers MD. Glycosylation and secretion of
human tissue plasminogen activator in recombinant baculo-
virus-infected insect cells. Mol Cell Biol 1989;9:214–23.
[31] Rohel DZ, Cochran MA, Faulkner P. Characterization of
two abundant mRNAs of Autographa californica nuclear
polyhedrosis virus present late in infection. Virology 1983;
124:357–65.
[32] AdangMJ,Miller LK.Molecular cloning ofDNA complementary
to mRNA of the baculovirus Autographa californica nuclear
polyhedrosis virus: location and gene products of RNA
transcripts found late in infection. J Virol 1982;44:782–93.
[33] Miyamoto C, Smith GE, Farrell-Towt J, Chizzonite R,
Summers MD, Ju G. Production of human c-myc protein in
insect cells infected with a baculovirus expression vector.
Mol Cell Biol 1985;5:2860–5.
[34] SenS, JaakolaVP,HeimoH,EngstromM,LarjomaaP,Scheinin
M, et al. Functional expression and direct visualization of the
human alpha 2B-adrenergic receptor and alpha 2B-AR-green
fluorescent fusion protein inmammalian cell usingSemliki Forest
virus vectors. Protein Expression Purif 2003;32:265–75.
[35] Shukla AK, HaaseW, Reinhart C, Michel H. Biochemical and
pharmacological characterization of the human bradykinin
subtype 2 receptor produced in mammalian cells using the
Semliki Forest virus system. Biol Chem 2006;387:569–76.
[36] Reeves PJ, Callewaert N, Contreras R, Khorana HG.
Structure and function in rhodopsin: high-level expression
of rhodopsin with restricted and homogeneous N-glycosyla-
tion by a tetracycline-inducible N-acetylglucosaminyltrans-
ferase I-negative HEK293S stable mammalian cell line. Proc
Natl Acad Sci USA 2002;99:13419–24.
[37] Lebon G, Bennett K, Jazayeri A, Tate CG. Thermostabilisa-
tion of an agonist-bound conformation of the human
adenosine A(2A) receptor. J Mol Biol 2011;409:298–310.
[38] Abdul-Hussein S, Andrell J, Tate CG. Thermostabilisation of
the serotonin transporter in a cocaine-bound conformation. J
Mol Biol 2013;425:2198–207.
[39] BradfordMM. A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of
protein-dye binding. Anal Biochem 1976;72:248–54.
[40] Serrano-Vega MJ, Magnani F, Shibata Y, Tate CG.
Conformational thermostabilization of the beta1-adrenergic
receptor in a detergent-resistant form. Proc Natl Acad Sci
USA 2008;105:877–82.
[41] Shibata Y, Gvozdenovic-Jeremic J, Love J, Kloss B, White JF,
Grisshammer R, et al. Optimising the combination of thermo-
stabilising mutations in the neurotensin receptor for structure
determination. Biochim Biophys Acta 2013;1828:1293–301.
[42] Magnani F, Shibata Y, Serrano-Vega MJ, Tate CG.
Co-evolving stability and conformational homogeneity of
the human adenosine A2a receptor. Proc Natl Acad Sci USA
2008;105:10744–9.
[43] Shibata Y, White JF, Serrano-Vega MJ, Magnani F, Aloia AL,
Grisshammer R, et al. Thermostabilization of the neurotensin
receptor NTS1. J Mol Biol 2009;390:262–77.
